WO2011145718A1 - Novel pyrrolo[2,3-d]pyrimidine compound - Google Patents

Abstract

Provided is a novel pyrrolo[2,3-d]pyrimidine compound which has GPR119 receptor agonistic activity and is useful as a drug. Specifically provided is a compound represented by formula [I] or a pharmacologically acceptable salt thereof. In formula [I], E is -NH- or the like; A is a substituted benzene ring represented by formula (A-i), or the like; R^01A and R^01B may be the same or different and are each hydrogen, halogen, or the like; R⁰² is alkylthio or the like; R⁰³ is hydrogen or alkyl; R⁰⁴ is alkyl or the like; R⁰⁵ is alkylsulfonyl; Q is a single bond or alkylene; R⁰ is a cyclic group represented by formula (R-iii), or the like; R¹ is acyl represented by formula: R¹¹OCO- [wherein R¹¹ is alkyl which may be substituted by one to three halogen atoms], or the like; R² is halogen; and R³ is hydrogen or the like.

Description

Novel pyrrolo [2,3-d] pyrimidine compounds

The present invention relates to a novel pyrrolo [2,3-d] pyrimidine compound or a pharmacologically acceptable salt thereof which has an excellent GPR119 receptor agonistic activity and is useful as a medicine.

GPR119, a G protein-coupled receptor (GPCR), is a receptor that is highly expressed in pancreatic insulin-producing β-cells and intestinal cells, and is a natural long-chain fatty acid amide that is a natural long-chain fatty acid amide. It was activated by compounds such as oil ethanolamide (OEA) and low molecular weight synthetic ligand PSN632408, and activation of the receptor was observed to suppress feeding and weight gain in high-fat diet rats. (Non-Patent Document 1).

Furthermore, a recent study on the physiological role of GPR119 using a selective small molecule agonist (AR231453) represented by the following formula revealed that pancreatic pancreatic pancreatic pancreatic pancreas was mediated by increased cAMP (adenylate cyclase activation) by activation of the receptor. It has been clarified that glucose-dependent insulin release in β-cells is enhanced, and that glucose homeostasis can be improved (Non-Patent Document 2).

In addition, this receptor regulates glucose homeostasis through enhanced release of incretins (glucagon-like peptide-1 / GLP-1 and glucose-dependent insulin peptide / GIP), which may be referred to as endogenous antidiabetic hormones. (Non-patent Document 3). Furthermore, the low molecular weight GPR119 agonist can be expected to have an effect of directly and / or indirectly protecting the pancreas via an incretin hormone (an anti-apoptotic action and / or a proliferation promoting action on islet cells). From the above findings, GPR119 has attracted attention as an attractive therapeutic target in metabolic related diseases including diabetes and obesity.

Currently, as GPR119 agonists, in addition to the aforementioned OEA, PSN632408, and AR231453, bipiperidinyl compounds (Patent Document 1), 1H-pyrazolo [3,4-d] pyrimidin-4-yloxypiperidine compounds (Patent Document 2), 6, 7-dihydro-5H-pyrrolo [2,3-d] pyrimidin-4-yloxy-1-piperidine compound, 2,3-dihydro-1-indol-4-yloxy-1-piperidine compound (Patent Document 3), 4 -(Benzo [b] [1,4] oxazin4 (3H) -yl) piperidine compounds (Patent Document 4), [1,2,3] triazolo [4,5-c] pyrimidine (Patent Document 5), etc. It is known that a pyrrolo [2,3-d] pyrimidine compound as in the present invention has an agonistic effect on GPR119. , It has not been reported so far.

International Publication No. 2008/076243 Pamphlet International Publication No. 2005/007658 Pamphlet International Publication No. 2008/008895 Pamphlet International Publication No. 2008/137435 Pamphlet International Publication No. 2008/137436 Pamphlet

An object of the present invention is to provide a novel pyrrolo [2,3-d] pyrimidine compound having an excellent GPR119 receptor agonistic activity and useful as a medicine.

The present invention
The following general formula [I]:

[Where,
E represents a group represented by the formula: —NH— or —O—;
Ring A has the following formula:

A substituted benzene ring, a substituted pyridine ring or a substituted piperidine ring represented by
R ^01A and R ^01B are the same or different and are a hydrogen atom, a halogen atom, an alkyl group or a trihalogenoalkyl group,
R ⁰² is A) an alkylthio group,
B) an alkylsulfinyl group,
C) an alkylsulfonyl group,
D) a saturated or unsaturated nitrogen-containing 5-membered heterocyclic group which may be substituted with 1 to 2 groups selected from an alkyl group, an alkoxycarbonyl group, a hydroxyalkyl group, an amino group, an oxo group and a carbamoyl group ( Here, the heterocyclic group may contain an oxygen atom as a hetero atom other than a nitrogen atom),
E) a group represented by the formula: —CONR ^a R ^b (where R ^a is a hydrogen atom or an alkyl group, R ^b is a) an alkyl group, b) a mono- or dihydroxyalkyl group, c) an alkoxy group, d) alkoxy An alkyl group substituted with a carbonyl group (the alkyl group portion may be further substituted with a hydroxyl group), e) a carboxyalkyl group, f) an alkylsulfonylalkyl group, g) an aminoalkyl group, h) a carbamoylalkyl group ( The alkyl portion of the group may be further substituted with an amino group), i) a morpholinoalkyl group, j) a 5- to 6-membered aliphatic sulfur-containing heterocyclic group (the heterocyclic group is a hydroxyl group, an oxo group, and Optionally substituted with 1 to 3 groups selected from hydroxyalkyl groups) or k) an alkyl group substituted with a hydroxyl group and a carbamoyl group), or F) the following formula (B-iii):

Wherein G is a group represented by the formula: —C (═O) — or —CH ₂ —, and ring B further contains a heteroatom selected from a nitrogen atom, a sulfur atom and an oxygen atom. A 4- to 6-membered hetero ring, wherein R ^A1 and R ^A2 are the same or different and are a hydrogen atom or a halogen atom, R ^A3 and R ^A4 are the same or different and are a) a hydrogen atom, b) a halogen atom, c) Cyano group, d) hydroxyl group, e) oxo group, f) alkyl group, g) hydroxyalkyl group, h) alkoxyalkyl group, i) alkoxycarbonyl group, j) carboxyl group, k) 1-2 alkyl groups An optionally substituted amino group or l) a carbamoyl group optionally substituted by 1 to 2 alkyl groups),
R ⁰³ is a hydrogen atom, an alkyl group or an alkoxy group,
R ⁰⁴ represents a hydrogen atom, an alkyl group, an alkoxy group, an alkylsulfonyl group, a carbamoyl group (this group may be substituted with 1 or 2 groups selected from an alkyl group and a hydroxyalkyl group), or 1 to 4 A 5-membered aromatic heterocyclic group containing the nitrogen atom of
R ⁰⁵ is an alkylsulfonyl group,
Q is a single bond or an alkylene group,
R ⁰ is (a) the following formula:

Or (b) a group represented by the formula: R ⁰⁰¹ -N (R ^k )-(wherein R ⁰⁰¹ is a 6-membered heteroaryl group or alkoxycarbonyl group optionally substituted with an alkyl group, R ^k represents a hydrogen atom or an alkyl group),
R ¹ is a) an acyl group represented by R ¹¹ OCO— (where R ¹¹ represents an alkyl group which may be substituted with 1 to 3 halogen atoms), or b) a nitrogen atom, an oxygen atom and 5- to 6-membered heteroaryl group containing the same or different 1 to 4 heteroatoms selected from the group consisting of sulfur atoms (the heteroaryl group is substituted with 1 to 3 halogen atoms). Optionally substituted with 1 to 3 groups selected from an alkyl group, a cycloalkyl group and an alkoxy group),
R ² is a halogen atom,
R ³ represents a hydrogen atom, a hydroxyl group, a halogen atom or an alkyl group.
(However,
Ring A is a substituted benzene ring represented by the formula (Ai), Q is a single bond, R ⁰ is a group represented by the formula (R-iii), R ³ is a hydrogen atom, and (a) R ⁰² is a group represented by the formula (B-iii), G is a group represented by the formula: —C (═O) —, and R ^A1 , R ^A2 , R ^A3 and R ^A4 are all hydrogen atoms. Or (b) when R ⁰² is a group represented by the formula: —CONR ^a R ^b and R ^b is an alkyl group or a monohydroxyalkyl group; or (c) R ⁰² is an alkylsulfonyl group If there is;
(D) R ⁰² is an unsubstituted nitrogen-containing 5-membered heterocyclic group; or
(E) When R ⁰² is a group represented by the formula (B-iii), G is a group represented by the formula: —C (═O) —, and R ^A3 and / or R ^A4 is a hydroxyl group Represents the group R ^01A on the substituted benzene ring ( ^Ai ) is an alkyl group). ]
Or a pharmaceutically acceptable salt thereof.

The present invention also relates to a pharmaceutical composition comprising the compound [I] or a pharmacologically acceptable salt thereof as an active ingredient. Furthermore, the present invention relates to a GPR119 modulator, particularly a GPR119 agonist (agonist) comprising the above compound [I] or a pharmaceutically acceptable salt thereof as an active ingredient.

The compound of the present invention is a compound that exerts an excellent regulatory action (agonist action, etc.) on GPR119 activity, has few side effects, and has high medicinal safety. For example, as shown in the experimental examples described below, the compound of the present invention was useful as a GPR119 agonist because it exhibited an excellent cAMP production enhancing action against the same cells in an assay system using human GPR119-expressing CHO cells. is there. In addition, the compound of the present invention which is a low molecular weight GPR119 agonist can be expected to have a pancreatic protective action (anti-apoptotic action and / or proliferation promoting action on islet cells) directly and / or indirectly through incretin hormone. .

The present invention, as one embodiment, in the general formula [I]
(1) Ring A is represented by the following formula (Aia):

[Wherein the symbols have the same meaning as described above. ]
A compound having a substituted benzene ring represented by:
(2) Ring A is the following formula:

[Wherein the symbols have the same meaning as described above. ]
(3) ring A is represented by the following formula (A-iii-a):

[Wherein the symbols have the same meaning as described above. ]
The compound which is a substituted piperidine ring shown by these is included.

Further, the present invention provides a more specific embodiment in the general formula [I]:
(A) Ring A is represented by the following formula (Aib):

[Wherein the symbols have the same meaning as described above. ]
And (B) ring A is represented by the following formula:

[Wherein the symbols have the same meaning as described above. ]
The compound which is a substituted pyridine ring shown by these is included.

In each of the above embodiments, the substituent (R ⁰² ) on ring A may be substituted with 1 to 2 groups selected from an alkyl group, an alkoxycarbonyl group, a hydroxyalkyl group, an amino group, and a carbamoyl group. In the case of a saturated or unsaturated nitrogen-containing 5-membered heterocyclic group (wherein the heterocyclic group may contain an oxygen atom as a heteroatom other than a nitrogen atom), the nitrogen-containing 5-membered heterocyclic group Examples of the group moiety include an oxazolyl group, a dihydrooxazolyl group, an oxadiazolyl group, a triazolyl group, and a tetrazolyl group. Preferred examples of the optionally substituted nitrogen-containing 5-membered heterocyclic group (R ⁰² ) include the following formula:

[In the formula, R ^X represents a hydroxyalkyl group, an alkoxycarbonyl group or a carbamoyl group, R ^Y represents an alkyl group, R ^Z represents a hydroxyalkyl group, R ^W represents an amino group, and a dotted line represents the presence or absence of a bond.]
The group shown by these is mention | raise | lifted.

Among the above, as a preferable embodiment, the substituent (R ⁰² ) on the ring A is represented by the formula (B-iii):

[Wherein the symbols have the same meaning as described above. ]
A compound represented by the formula: Specific examples of the substituent (B-iii) in the compound include, for example, the following formula:

[Where,
R ^A20 represents a hydrogen atom or a halogen atom,
R ^A30 is a hydrogen atom, a halogen atom or a hydroxyl group,
R ^A40 represents a hydrogen atom, a halogen atom, a cyano group, an amino group, a hydroxyl group, a hydroxyalkyl group, an alkoxyalkyl group, a carboxyl group, an alkoxycarbonyl group, or a carbamoyl group (the amino moiety of the carbamoyl group is 1 to 2 alkyl groups). May be substituted),
R ^A11 , R ^A21 , R ^A32 and R ^A42 are the same or different halogen atoms,
R ^A33 is a hydrogen atom or a hydroxyl group,
R ^A43 represents an alkyl group, a hydroxyalkyl group, an alkoxycarbonyl group or a carbamoyl group,
Z is an oxygen atom or a sulfur atom,
R ^A44 represents a hydrogen atom or a hydroxyalkyl group,
R ^A35 and R ^A45 are the same or different halogen atoms,
R ^A36 represents a hydrogen atom, an alkyl group or a hydroxyalkyl group (provided that when the above substituents R ^A20 , R ^A30 and R ^A40 are both hydrogen atoms, they are on the substituted benzene ring represented by the formula (Ai)). The group R ^01A is an alkyl group). ]
A cyclic group having a substituent represented by:
And groups in which G is a group represented by the formula: —C (═O) — or —CH ₂ —.

Of the substituents (B-iii) as described above, it is more preferable that G is a group represented by the formula: —C (═O) —.

In the above embodiment, when the substituent (R ⁰² ) on ring A is a group represented by the formula: —CONR ^a R ^b and R ^b is a 5- to 6-membered aliphatic sulfur-containing heterocyclic group Examples of the 5- to 6-membered aliphatic sulfur-containing heterocyclic group include a tetrahydrothienyl group and a tetrahydrothiopyranyl group. The 5- to 6-membered aliphatic sulfur-containing heterocyclic group may be substituted with the same or different 1 to 3 groups selected from a hydroxyl group, an oxo group and a hydroxyalkyl group. More specific examples of the substituted 5- to 6-membered aliphatic sulfur-containing heterocyclic group include a tetrahydrothienyl group substituted with 1 or 2 oxo groups (this group may be further substituted with a hydroxyl group). And a dioxotetrahydrothiopyranyl group substituted with one or two oxo groups, a tetrahydrothiopyranyl group substituted with a hydroxyalkyl group, and the like. Preferred examples of the substituted 5- to 6-membered aliphatic sulfur-containing heterocyclic group include 1,1-dioxotetrahydrothienyl group, 3-hydroxy-1,1-dioxotetrahydrothienyl group, 1,1-dioxotetrahydro group. Examples thereof include a thiopyranyl group and a 4-hydroxymethyltetrahydrothiopyranyl group.

In the above embodiment, when R ¹ is a 5- to 6-membered heteroaryl group containing the same or different 1 to 4 heteroatoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, the heteroaryl group As, for example, pyrrolyl group, imidazolyl group, pyrazolyl group, triazolyl group, tetrazolyl group, isothiazolyl group, isoxazolyl group, thiazolyl group, oxadiazolyl group, furazanyl group, thiadiazolyl group, thienyl group, furyl group, pyridyl group, pyrimidinyl group, A pyrazinyl group, a pyridazinyl group, a triazinyl group, etc. are mention | raise | lifted. Of these, a 5- or 6-membered heteroaryl group (such as an oxadiazolyl group, a pyridyl group, or a pyrimidinyl group) containing 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom and an oxygen atom is preferable. Further, the heteroaryl group may be substituted with 1 to 3 groups selected from a halogen atom, an alkyl group optionally substituted with 1 to 3 halogen atoms, a cycloalkyl group and an alkoxy group. Preferred examples of the substituted 5- to 6-membered heteroaryl group include (1) a pyrimidinyl group substituted with a halogen atom, an alkyl group, a cycloalkyl group, or a trihalogenoalkyl group, or (2) an alkyl group or And an oxadiazolyl group substituted with a trihalogenoalkyl group.

Among the compounds of the present invention, as preferred compounds, for example, in the general formula [I]:
Ring A is a substituted benzene ring represented by the above formula (Ai),
R ^01A is a hydrogen atom or a halogen atom,
R ^01B is a hydrogen atom or a halogen atom R ⁰² is (a) an alkylsulfinyl group;
(B) an alkylsulfonyl group;
(C) a group represented by the formula: —CONR ^a R ^b , wherein R ^a is a hydrogen atom or an alkyl group, R ^b is an alkyl group, a monohydroxyalkyl group, a dihydroxyalkyl group, an aminoalkyl group, or a carbamoylalkyl group;
(D) The following formula:

R ^A20 is a hydrogen atom or a halogen atom, R ^A30 is a hydrogen atom, a hydroxyl group or a halogen atom, R ^A40 is a hydrogen atom, a halogen atom, a cyano group, a hydroxyalkyl group or a carbamoyl group, R ^A11 , R ^A21 , R ^A32 and R ^A42 are the same or different halogen atoms, and R ^A35 and R ^A45 are the same or different halogen atoms; or (e) 5-membered unsaturation containing 1 to 4 nitrogen atoms as heteroatoms A heterocyclic group,
Examples thereof include compounds in which R ² is a halogen atom, and R ³ is a hydrogen atom or an alkyl group (provided that R ^A20 , R ^A30 and R ^A40 are all hydrogen atoms and Q is a single bond, R ⁰ is a group represented by the formula (R-vii)).

Among the above compounds, more preferable compounds are
(1) Ring A is a substituted benzene ring represented by the formula (Aia), and R ¹ is a) an alkoxycarbonyl group or b) 1 to 3 selected from a nitrogen atom and an oxygen atom A compound containing a heteroatom and a 5- to 6-membered heteroaryl group substituted with a halogen atom, an alkyl group, a trihalogenoalkyl group or a cycloalkyl group, or (2) ring A is represented by formula (A-ii) The substituted pyridine ring shown, R ⁰³ is an alkyl group, R ⁰⁴ is an alkylsulfonyl group, Q is an alkylene group, and R ⁰ is the following formula:

And a compound in which R ¹ is a nitrogen-containing 6-membered heteroaryl group substituted with a trihalogenoalkyl group.

Among the compounds of the present invention, more preferred compounds include, for example, the following formula [I-AA]:

[Wherein, R ^A represents 2- (hydroxyC _1-4 alkyl) -1-pyrrolidinyl group, 2-cyano-1-pyrrolidinyl group, 2-carbamoyl-1-pyrrolidinyl group, 4-hydroxy-2- (hydroxyC _1-4 alkyl) -1-pyrrolidinyl group, 3-halogeno-1-pyrrolidinyl group, 1,1-dioxothiomorpholino group, N- (dihydroxy C _1-4 alkyl) amino group, N—C _1-4 alkyl -N- (dihydroxy C _1-4 alkyl) amino group, N- (amino C _1-4 alkyl) amino group or N-C _1-4 alkyl-N- (carbamoyl-C _1-4 alkyl) amino group, R ^01C is a halogen ^{atom, R 01D} is hydrogen atom or halogen ^{atom, R 10} is _{C 1-4} alkoxycarbonyl group, 5-halogeno-2-yl group, _{5-C 1-4} A Kill pyrimidin-2-yl group, or 5- (trihalogeno _{C 1-4} alkyl) -1,2,4-oxadiazol-3-yl ^{group, R 20} is a halogen atom, and ^{R 31} is a hydrogen atom or an alkyl group Represents. ]
Or a pharmacologically acceptable salt thereof.

Among the compounds of the present invention, particularly preferred compounds include, for example,
[4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl] ((R) -2-hydroxymethylpyrrolidin-1-yl) methanone;
[4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl] (1,1-dioxo-1λ ⁶ -thiomorpholin-4-yl) methanone;
[4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl] ((S) -2-cyanopyrrolidin-1-yl) methanone;
[4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl] ((S) -2-carbamoylpyrrolidin-1-yl) methanone;
3-Fluoro-4- [5-fluoro-7- [1- (5-propylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- N- [2-hydroxy-1- (hydroxymethyl) ethyl] benzamide;
[4- [7- [1- (5-Isopropylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl] ((S) -2-carbamoylpyrrolidin-1-yl) methanone;
[4- [7- [1- (5-Isopropylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl] ((R) -2-hydroxymethylpyrrolidin-1-yl) methanone;
[4- [7- [1- (5-Isopropylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl] ((R) -2-carbamoylpyrrolidin-1-yl) methanone;
[4- [7- [1- (5-Chloropyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl] ((S) -2-carbamoylpyrrolidin-1-yl) methanone;
3-Fluoro-4- [5-fluoro-7- [1- (5-propylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- N- [2-hydroxy-1- (hydroxymethyl) ethyl] -N-methylbenzamide;
3-Fluoro-4- [5-fluoro-7- [1- (5-propylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- N- (2,3-dihydroxypropyl) -N-methylbenzamide;
3-Fluoro-4- [5-fluoro-7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- N- (2,3-dihydroxypropyl) -N-methylbenzamide;
[4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl] ((2R, 4R) -4-hydroxy-2-hydroxymethylpyrrolidin-1-yl) methanone;
4- [4- [4-((R) -3-fluoropyrrolidine-1-carbonyl) -2-fluorophenylamino] -5-fluoropyrrolo [2,3-d] pyrimidin-7-yl] piperidine-1 -Carboxylic acid isopropyl ester;
[4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -2,5 -Difluorophenyl] ((2R, 4R) -4-hydroxy-2-hydroxymethylpyrrolidin-1-yl) methanone;
3-Fluoro-4- [5-fluoro-7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- N- (2-aminoethyl) benzamide;
[4- [7- [1- (5-trifluoromethyl-1,2,4-oxadiazol-3-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d ] Pyrimidin-4-ylamino] -3-fluorophenyl] ((2R, 4R) -4-hydroxy-2-hydroxymethylpyrrolidin-1-yl) methanone;
[4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-chlorophenyl ] ((R) -2-hydroxymethylpyrrolidin-1-yl) methanone;
3-Fluoro-4- [5-fluoro-7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- N-methyl-N-((R) -2,3-dihydroxy) propyl] benzamide;
3-Fluoro-4- [5-fluoro-7- [1- (5-propylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- N-methyl-N-((S) -2,3-dihydroxy) propyl] benzamide;
3-Fluoro-4- [5-fluoro-7- [1- (5-chloropyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- N-methyl-N-((S) -2,3-dihydroxy) propyl] benzamide;
3-Fluoro-4- [5-fluoro-7- [1- (5-isopropylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- N-methyl-N-((S) -2,3-dihydroxy) propyl] benzamide;
2,5-difluoro-4- [5-fluoro-7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino ] -N-methyl-N-((S) -2,3-dihydroxy) propyl] benzamide;
[4- [7-cis- [1- (5-Ethylpyrimidin-2-yl) -3-methylpiperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidine-4- Ylamino] -3-fluorophenyl] ((S) -2-carbamoylpyrrolidin-1-yl) methanone; and 3-fluoro- [4- [7- [1- (5-trifluoromethyl-1,2,4] -Oxadiazol-3-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -N- (carbamoylmethyl) -N-methylbenzamide Examples thereof include a compound selected from the group or a pharmacologically acceptable salt thereof.

When the compound [I] of the present invention has an asymmetric carbon atom in the molecule, it can exist as a plurality of stereoisomers (diastereoisomers, optical isomers) based on the asymmetric carbon atom. The invention includes any one of these stereoisomers or mixtures thereof.

Since the compound [I] of the present invention has an excellent agonistic effect on the GPR119 receptor, various diseases or conditions that can be expected to be improved by regulating the receptor activity, such as obesity, hyperglycemia, diabetes (Including insulin-dependent diabetes, non-insulin-dependent type 2 diabetes, or their intermediate type diabetes) and complications thereof, metabolic syndrome, impaired glucose tolerance, hyperinsulinemia, hyperlipidemia, hypercholesterolemia, It is useful for the prevention and treatment of metabolic diseases including diseases such as hypertriglyceridemia and abnormal lipid metabolism, or cardiovascular diseases such as arteriosclerosis, hypertension, coronary disease, and myocardial infarction.

The compound [I] of the present invention or a pharmacologically acceptable salt thereof has a feature of low toxicity and high safety as a medicine.

The compound [I] of the present invention can be used for pharmaceutical use either in a free form or in the form of a pharmacologically acceptable salt thereof. Examples of pharmaceutically acceptable salts include inorganic acid salts such as hydrochloride, sulfate, phosphate or hydrobromide, acetate, trifluoroacetate, fumarate, oxalate, citric acid, and the like. And organic acid salts such as acid salts, methanesulfonate, benzenesulfonate, tosylate, and maleate.

The compound [I] of the present invention or a pharmacologically acceptable salt thereof includes any of its intramolecular salts and adducts, solvates or hydrates thereof.

The compound [I] of the present invention or a pharmacologically acceptable salt thereof can be administered orally or parenterally, and tablets, granules, capsules, powders, injections, inhalants, etc. It can be used as a conventional pharmaceutical preparation.

The dose of the compound [I] of the present invention or a pharmacologically acceptable salt thereof varies depending on the administration method, the age, body weight and condition of the patient. 100 mg / kg, especially about 0.01 to 10 mg / kg, and in the case of an oral preparation, it is usually preferably about 0.01 to 1000 mg / kg, especially about 0.1 to 100 mg / kg per day.

The compound [I] of the present invention or a pharmacologically acceptable salt thereof can be used alone or in combination with one or more other drugs depending on the disease to be treated. Examples of such drugs include the following.

(A) Antihypertensive drugs: angiotensin converting enzyme inhibitors (enalapril maleate, imidapril hydrochloride, etc.), angiotensin II receptor antagonists (losartan potassium, candesartan cilexetil, etc.), β-blockers (atenolol, bisoprolol fumarate, etc.), α / β blockers (such as carvedilol and labetalol hydrochloride), calcium antagonists (such as amlodipine besylate and diltiazem hydrochloride), α ₁ blockers (such as doxazosin mesylate and prazosin hydrochloride), central α ₂ agonists, and other central effects Drugs (clonidine hydrochloride, reserpine, etc.), vasodilators (hydralazine hydrochloride, minoxidil, etc.), etc .;
(B) Diuretics: thiazide diuretics (chlorothiazide, hydrochlorothiazide, etc.), loop diuretics (bumetanide, furosemide, etc.), potassium-sparing diuretics (amiloride hydrochloride, triamterene, etc.);
(C) Heart failure treatment drugs: nitrate drugs (nitroglycerin, etc.), digitalis preparations (digoxin, digitoxin, etc.), catecholamines (dobutamine hydrochloride, denopamine, etc.), endothelin antagonists (bosentan, etc.), phosphodiesterase inhibitors (milrinone lactate, amrinone) Etc.), neutral endopeptidase inhibitors (such as fascytril), atrial diuretic peptide, etc .;
(D) Antiarrhythmic drugs: Na channel blockers (procainamide hydrochloride, flecainide acetate, etc.), K channel blockers (amiodarone hydrochloride, etc.), Ca channel blockers (verapamil hydrochloride, etc.) and the like;
(E) Hyperlipidemic drugs: HMG-CoA reductase inhibitors (pravastatin sodium, atorvastatin calcium, fluvastatin sodium, etc.), fibrate derivatives (bezafibrate, clofibrate, etc.), squalene synthase inhibitors, etc .;
(F) Antithrombotic drugs: blood coagulation inhibitors (warfarin sodium, heparin sodium, etc.), thrombolytic drugs (urokinase, t-PA, etc.), antiplatelet drugs (aspirin, ticlopidine hydrochloride, etc.);
(G) Drugs for treating diabetes / diabetic complications: insulin, DPP4 inhibitors (such as vildagliptin, sitagliptin), α-glucosidase inhibitors (such as voglibose, acarbose, miglitol, emiglitate), biguanides (such as metformin hydrochloride, buformin, phenformin) , Insulin resistance improvers (pioglitazone, troglitazone, rosiglitazone, etc.), insulin secretagogues (tolbutamide, glibenclamide, gliclazide, glyclopyramide, chlorpropamide, glimepiride, glybide, sulfonylurea compounds such as glybazole, tolazamide, acetohexamide ), Amylin antagonists (pramlintide, etc.), aldose reductase inhibitors (epalrestat, tolrestat, zenarestat, fidarestat, Naruresutatto, zopolrestat, etc.), neurotrophic factors (NGF, etc.), AGE inhibitors (pimagedine, pyratoxathine, etc.), neurotrophic factor production promoter agent, and the like;
(H) Anti-obesity drugs: Central anti-obesity drugs (such as mazindol, fenfluramine, sibutramine), pancreatic lipase inhibitors (such as orlistat), β ₃ agonists (such as SB-226552, BMS-196085), peptidic appetite Inhibitors (such as leptin), cholecystokinin receptor agonists (such as lynchtrypto), etc .;
(I) Non-steroidal anti-inflammatory drugs: acetaminophen, ibuprofen, etc. (j) Chemotherapeutic agents: antimetabolites (5-fluorouracil, methotrexate, etc.), anticancer drugs (vincristine, taxol, cisplatin, etc.);
(K) Immunomodulators: immunosuppressants (cyclosporine, tacrolimus, etc.), immune enhancers (crestin, lentinan, etc.), cytokines (interleukin 1, interferon, etc.), cyclooxygenase inhibitors (indomethacin, celecoxib, etc.), anti-TNFα Antibodies (such as infliximab).

When the compound [I] of the present invention is used in combination with another drug, the administration form includes (1) administration of a single preparation (mixture) containing the compound [I] and another drug, and (2) The combined administration of a preparation containing compound [I] and a preparation containing other drugs can be mentioned. In the case of the combined administration of (2), the administration route and administration time of each preparation may be different.
(Synthesis method 1)
Among the compounds [I] of the present invention, the following general formula [Ia]:

[Wherein the symbols have the same meaning as described above. ]
For example, the compound represented by the following formula [II-a]:

[Wherein, X ¹ represents a halogen atom, and other symbols have the same meaning as described above. ]
And a compound of the following formula [III-a]:

[Wherein the symbols have the same meaning as described above. ]
It can be made by reacting the amine compound shown by the following, and then removing the hydroxyl protecting group from the reaction product if necessary.

The reaction between the compound [II-a] and the amine compound [III-a] can be carried out in a solvent in the presence of a palladium catalyst and a base, and if necessary, in the presence of a ligand. The solvent may be any inert solvent that does not interfere with the reaction. Examples of such solvents include ethers such as dioxane and dimethoxyethane, aromatic hydrocarbons such as toluene, and N, N-dimethylformamide. Such amides, water and the like. Examples of the palladium catalyst include palladium acetate, tris (dibenzylideneacetone) dipalladium, dichlorobis (triphenylphosphine) palladium, tetrakis (triphenylphosphine) palladium, [1,1′-bis (diphenylphosphino) ferrocene] palladium dichloride. Etc. Examples of the ligand include 2- (ditert-butylphosphino) biphenyl, triphenylphosphine, 2- (ditert-butylphosphino) -1,1′-binaphthyl, and 2-dicyclohexylphosphino-2 ′. -(N, N-dimethylamino) biphenyl, 2,2'-bis (diphenylphosphino) -1,1'-binaphthyl, 1,1'-bis (diphenylphosphino) ferrocene and the like. Examples of the base include sodium tert-butoxide, potassium tert-butoxide, sodium phenoxide, potassium carbonate, cesium carbonate, potassium phosphate, sodium hydrogen carbonate, lithium chloride, diisopropylethylamine, triethylamine and the like. The amount of compound [III-a] to be used is 0.9 to 3.0 equivalents, preferably 1.0 to 1.2 equivalents, relative to compound [II-a]. The amount of the palladium catalyst to be used is 0.01 to 0.3 equivalent, preferably 0.01 to 0.1 equivalent, relative to compound [II-a] or compound [III-a]. The amount of the base used is 1.0 to 5.0 equivalents, preferably 2.0 to 3.0 equivalents, relative to compound [II-a] or compound [III-a]. The amount of the ligand used is 0.01 to 0.3 equivalent, preferably 0.01 to 0.1 equivalent, relative to compound [II-a] or compound [III-a]. This reaction can be carried out at 0 to 200 ° C., preferably 60 to 150 ° C.

The reaction of the compound [II-a] and the amine compound [III-a] can also be carried out by reacting in a solvent (alcohol such as isopropanol) in the presence of an acid catalyst (hydrochloric acid or the like). The amount of the acid catalyst used can be 0.01 to 1.0 equivalent relative to compound [II-a].

Furthermore, the reaction between the compound [II-a] and the amine compound [III-a] is carried out by using a base (an alkali metal alkoxide such as sodium tert-butoxide) in a solvent (an ether such as dioxane, an alcohol such as ethanol), The reaction can also be carried out in the presence of a tertiary amine such as diisopropylethylamine. The amount of the base used can be 1.0 to 3.0 equivalents relative to compound [II-a].
(Synthesis method 2)
Among the compounds [I] of the present invention, the following formula [Ib]:

[Wherein ring A ² represents the following formula:

The other symbols have the same meaning as described above. ]
[Wherein the symbols have the same meaning as described above. ]
For example, the compound represented by the following formula [II-b]:

[Wherein the symbols have the same meaning as described above. ]
And a compound of the following formula [III-b]:

[Wherein W ¹ represents a halogen atom, and other symbols have the same meaning as described above. ]
It can also manufacture by making the compound shown by react.

The reaction of compound [II-b] and compound [III-b] can be carried out in the same manner as the reaction of compound [II-a] and amine compound [III-a].
(Synthesis method 3)
Among the compounds [I] of the present invention, the following general formula [I-b1]:

[Wherein the symbols have the same meaning as described above. ]
For example, the compound represented by the following formula [II-a]:

[Wherein the symbols have the same meaning as described above. ]
And a compound of the following formula [III-c]:

[Wherein the symbols have the same meaning as described above. ]
It can manufacture by making the compound shown by react.

The reaction of compound [II-a] and compound [III-c] can be carried out in a solvent in the presence of a base. The solvent may be any inert solvent that does not interfere with the reaction. Examples of such solvents include ethers such as dimethyl sulfoxide and tetrahydrofuran, amides such as N, N-dimethylformamide, and ketones such as acetone. Etc. Examples of the base include potassium carbonate, cesium carbonate, sodium carbonate, sodium hydride and the like. The amount of compound [III-c] to be used is 0.9 to 3.0 equivalents, preferably 1.0 to 1.5 equivalents, relative to compound [II-a]. The amount of the base to be used is 1.0 to 5.0 equivalents, preferably 1.5 to 3.0 equivalents, relative to compound [II-a] or compound [III-c]. This reaction can be carried out at 0 ° C. to 200 ° C., preferably 60 ° C. to 100 ° C.
(Synthesis Method 4)
Among the compounds [I] of the present invention, compounds in which R ¹ is an acyl group represented by the formula: R ¹¹ OCO—, that is, the following general formula [Ie]:

[Wherein the symbols have the same meaning as described above. ]
For example, the compound represented by the following formula [II-c]:

[Wherein the symbols have the same meaning as described above. ]
And a compound of the following formula [III-e] or [III-f]:
R ¹¹ OCOX ² [III-e]
R ¹¹ OCOOX ³ [III-f]
[Wherein, X ² represents a halogen atom, X ³ represents a p-nitrophenyl group, and other symbols have the same meaning as described above. ]
It can also be made by reacting the compound represented by the following, and then removing the hydroxyl protecting group from the reaction product if necessary.

The reaction of compound [II-c] or a salt thereof (such as a mineral salt such as hydrochloride) and compound [III-e] can be carried out in a solvent in the presence of a base. The solvent may be any inert solvent that does not interfere with the reaction. Examples of such solvents include halogenated aliphatic hydrocarbons such as dichloromethane, ethers such as tetrahydrofuran, and aromatic hydrocarbons such as toluene. And the like. Examples of the base include triethylamine, diisopropylethylamine, pyridine and the like. The amount of compound [III-e] to be used is 0.9 to 3.0 equivalents, preferably 1.0 to 1.5 equivalents, relative to compound [II-c]. The amount of the base used is 1.0 to 5.0 equivalents, preferably 1.5 to 2.0 equivalents, relative to compound [II-c] or compound [III-e]. This reaction can be carried out at 0 ° C. to 100 ° C., preferably 0 ° C. to room temperature. In this reaction product, when R ³¹ is a protected hydroxyl group, the protecting group can be removed in the same manner as described in Synthesis Method 1.

The reaction of compound [II-c] or a salt thereof (such as a mineral salt such as hydrochloride) and compound [III-f] is the same as the reaction of compound [II-c] and compound [III-e] described above. Can be implemented.
(Synthesis Method 5)
Among the compounds [I] of the present invention, R ¹ is represented by the following formula:

(Wherein ring B ¹ represents a 5- to 6-membered heteroaryl group containing 1 to 4 heteroatoms which are the same or different and are selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom) And the heteroaryl group may be substituted with 1 to 3 groups selected from a halogen atom, an alkyl group optionally substituted with 1 to 3 halogen atoms, and an alkoxy group), That is, the following general formula [If]:

[Wherein the symbols have the same meaning as described above. ]
For example, the compound represented by the following formula [II-c]:

[Wherein the symbols have the same meaning as described above. ]
And a compound of the following formula [III-g]:

[In the above scheme, X ⁴ represents a halogen atom or a methanesulfonyl group, and other symbols have the same meaning as described above. ]
It can manufacture by making the compound shown by react.

The reaction of compound [II-c] or a salt thereof (mineral salt such as hydrochloride) and compound [III-g] can be carried out in a solvent in the presence or absence of a base. The solvent may be any inert solvent that does not interfere with the reaction. Examples of the solvent include amides such as dimethylformamide, ethers such as tetrahydrofuran, and the like. Examples of the base include diisopropylethylamine, triethylamine, pyridine, potassium carbonate and the like. The amount of compound [III-g] to be used is 1.0 to 10 equivalents, preferably 1.5 to 3.0 equivalents, relative to compound [II-c]. The amount of the base to be used is 1.0 to 5.0 equivalents, preferably 1.5 to 3.0 equivalents, relative to compound [II-c] or compound [III-g]. This reaction can be carried out at 0 ° C. to 150 ° C., preferably at room temperature to 80 ° C.

The reaction of compound [II-c] or a salt thereof and compound [III-g] can also be carried out in a solvent in the presence of a palladium catalyst and a base and in the presence or absence of an activator. As the solvent, palladium catalyst and base, those exemplified in Synthesis Scheme 1 (reaction of compound [II-a] with amine compound [III-a]) can be used. Examples of the activator include 1,3-bis (2,6-diisopropylphenyl) -4,5-dihydroimidazolium tetrafluoroboric acid. The amount of compound [III-g] to be used is 1.0 to 3.0 equivalents, preferably 1.0 to 1.5 equivalents, relative to compound [II-c]. The amount of the palladium catalyst to be used is 0.01 to 0.3 equivalent, preferably 0.01 to 0.1 equivalent, relative to compound [II-c] or compound [III-g]. The amount of the base used is 1.0 to 5.0 equivalents, preferably 2.0 to 4.0 equivalents, relative to compound [II-c] or compound [III-g]. This reaction can be carried out at 0 to 200 ° C., preferably 100 to 150 ° C.
(Synthesis Method 6)
Among the compounds [I] of the present invention, ring A is represented by the following formula:

(Wherein the 6-membered aromatic ring A ¹ is one or two groups selected from a halogen atom, an alkyl group and a cyano group in addition to the group represented by the formula: —CONR ^a R ^b ) Represents a benzene ring which may be substituted with a compound represented by the following general formula [Ih]:

[Wherein the symbols have the same meaning as described above. ]
For example, the compound represented by the following formula [II-d]:

[Wherein the symbols have the same meaning as described above. ]
And a compound of the following formula [III-i]:
R ^a R ^b NH [III-i]
It can be made by reacting the amine compound shown by the following, and then removing the hydroxyl protecting group from the reaction product if necessary.

The reaction of compound [II-d] or a salt thereof (such as a mineral salt such as hydrochloride) and amine compound [III-i] or a salt thereof (such as a mineral salt such as hydrochloride) It can be carried out in the presence, in the presence or absence of a base and an activator. The solvent may be an inert solvent that does not interfere with the reaction. Examples of such a solvent include halogenated aliphatic hydrocarbons such as dichloromethane. Examples of the condensing agent include 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (WSC · HCl). Examples of the activator include N-hydroxybenzotriazole monohydrate. Examples of the base include triethylamine, diisopropylethylamine and the like. The amount of compound [III-i] to be used is 1.0 to 5.0 equivalents, preferably 1.0 to 1.5 equivalents, relative to compound [II-d]. The amount of the condensing agent to be used is 1.0 to 5.0 equivalents, preferably 1.0 to 1.5 equivalents, relative to compound [II-d] or compound [III-i]. The amount of the activator used is 1.0 to 5.0 equivalents, preferably 1.0 to 1.5 equivalents, relative to compound [II-d] or compound [III-i]. The amount of the base used is 1.0 to 5.0 equivalents, preferably 1.0 to 2.0 equivalents, relative to compound [II-d] or compound [III-i]. This reaction can be carried out at 0 to 100 ° C., preferably 0 to 40 ° C.
(Synthesis Method 7)
Among the compounds [I] of the present invention, the following formula [Il]:

[Wherein, R ^a1 represents an alkyl group or a trihalogenoalkyl group, and other symbols have the same meaning as described above. ]
The compound represented by the following formula [II-m]:

[Wherein the symbols have the same meaning as described above. ]
And a compound represented by the following formula:
R ^a1 —COOH [a]
[Wherein the symbols have the same meaning as described above. ]
Or a reactive derivative thereof (corresponding acid halide or corresponding acid anhydride) in a solvent (aromatic hydrocarbons such as toluene, halogenated aliphatic hydrocarbons such as dichloromethane, etc.) in a base (triethylamine) In the presence of an organic amine or the like.

The group R ⁰ in the intermediate compound (compound [II-a], compound [Ib1], compound [Ih] or compound [II-d]) in the above synthesis methods 1 to 7 is represented by the following formula:

In the case of a group represented by the formula, an appropriate protecting group may be introduced into the hydroxyl group prior to carrying out the above reactions. Examples of the hydroxyl-protecting group include a benzoyl group. The removal of the protecting group can be carried out according to a conventional method. For example, in the case of a compound having a hydroxyl group protected with a benzoyl group, the removal of the protecting group can be carried out by a base treatment such as sodium tert-butoxide.

Similarly, when ring A in the intermediate compounds in the above synthesis methods 1 to 7 is a benzene ring substituted with a group containing a hydroxyl group (for example, a hydroxyalkyl group), the hydroxyl group is converted to an appropriate protecting group (for example, tert- It may be protected with a butyldimethylsilyl group or the like, and the protecting group can be removed by a conventional method (tetrabutylammonium fluoride treatment or the like).
(Synthesis Method 8)
Of the compounds [I] of the present invention, [Ir]:

[Wherein, R ^m represents an alkyl group or a cycloalkyl group which may be substituted with 1 to 3 halogen atoms, and other symbols have the same meaning as described above. ]
For example, the compound represented by the formula [II-r]:

[Wherein the symbols have the same meaning as described above. ]
And a compound of the following formula [III-r]:

[Wherein the symbols have the same meaning as described above. ]
In a solvent (an amide such as dimethylformamide, a nitrile such as acetonitrile, an aromatic hydrocarbon such as toluene), an acid catalyst (a protonic acid such as p-toluenesulfonic acid, Lewis such as zinc chloride) It can also be produced by reacting in the presence of an acid or a mixture thereof. The amount of the acid catalyst to be used can be 0.001 to 1.0 equivalent relative to compound [II-r].
(Synthesis Method 9)
Among the compounds [I] of the present invention, a compound having a substituent containing a formula: alkylsulfinyl group on ring A is a solvent (such as dichloromethane) having a corresponding compound having a substituent containing formula: alkylthio group on ring A. Treated with an oxidizing agent (m-chloroperbenzoic acid, etc.) in the presence or absence of acid (methanesulfonic acid, trifluoroacetic acid, etc.) in halogenated aliphatic hydrocarbons, alcohols such as methanol, etc. Can also be manufactured.
(Synthesis Method 10)
Among the compounds [I] of the present invention, the compound (R ^a R ^b NC (═O) —) on the ring A is a group containing a carboxyalkyl group, the corresponding substituent is an alkoxycarbonylalkyl group. It can be prepared by treating the compound as the containing group with a base (such as sodium hydroxide) or an acid (such as hydrochloric acid-dioxane) in a solvent (such as ethers such as tetrahydrofuran).
(Synthesis Method 11)
Among the compounds [I] of the present invention, a compound in which the substituent on ring A is an amino group or a group containing an amino group is an amino group in which the corresponding substituent is substituted with an alkoxycarbonyl group (protecting group) or It can also be prepared by treating a compound which is a group containing a substituted amino group with hydrochloric acid or the like to remove the protecting group.
(Synthesis Method 12)
Among the compounds [I] of the present invention, R ¹ is a group containing a group represented by the formula: —CONR ^c R ^d , and both R ^c and R ^d are bonded to each other to form 1 to 2 halogen atoms The compound which forms a 3- to 7-membered nitrogen-containing aliphatic heterocyclic group which may be substituted with a corresponding compound in which R ¹ is a group containing —COOH and the following formula:
HNR ^c R ^d [b]
[Wherein the symbols have the same meaning as described above. ]
In the presence of a condensing agent (such as water-soluble carbodiimide) and a base in a solvent (such as halogenated aliphatic hydrocarbons such as dichloromethane) and activation thereof It can also be produced by reacting in the presence or absence of an agent (such as 1-hydroxybenzotriazole).
(Synthesis Method 13)
Among the compounds [I] of the present invention, the compound in which the substituent on the ring A is a hydroxymethyl group or a group containing a hydroxymethyl group is, for example, a group in which the substituent on A contains an alkoxycarbonyl group or an alkoxycarbonyl group. The corresponding compound can be prepared by treating with a reducing agent (such as lithium aluminum hydride) in a solvent (such as ethers such as tetrahydrofuran). Further, according to the synthesis method, in general formula [I], ring A is represented by the following formula:

In a substituted benzene ring ^{represented, R 02} is formula (iii):

A compound represented by the formula (G represents the formula: —CH ₂ —) can also be produced.
(Synthesis Method 14)
Among the compounds [I] of the present invention, the following formula [In]:

[Wherein the symbols have the same meaning as described above. ]
For example, the compound represented by the formula [II-n]:

[Wherein, R ⁿ represents an alkyl group, an alkoxycarbonyl group, a hydroxyalkyl group, or a carbamoyl group, and other symbols have the same meaning as described above. ]
Can be produced by treating with a dehydrating agent (such as N, N-diethylaminosulfur trifluoride (DAST)) in a solvent (such as halogenated aliphatic hydrocarbons such as dichloromethane).
(Synthesis Method 15)
Among the compounds [I] of the present invention, the following formula [Ip]:

[Wherein the symbols have the same meaning as described above. ]
In the compound represented by the above, the compound [In] in a solvent (halogenated aliphatic hydrocarbons such as dichloromethane) in a base (1,8-diazabicyclo [5.4.0] undec-7-ene etc. ) In the presence of an oxidizing agent (such as chlorotrichloromethane bromide).
(Synthesis Method 16)
Among the compounds [I] of the present invention, the compound in which the substituent on the ring A is a group containing a carbamoyl group includes, for example, a corresponding compound in which the substituent on A is a group containing an alkoxycarbonyl group in a solvent (tetrahydrofuran In such ethers), the reaction product and ammonia can be treated in the same manner as in Synthesis Method 6 after treatment with a base (sodium hydroxide, etc.).
(Synthesis Method 17)
Among the compounds [I] of the present invention, the following formula [Iq]:

[Wherein the symbols have the same meaning as described above. ]
For example, the compound represented by the formula [II-q]:

[Wherein the symbols have the same meaning as described above. ]
And a hydrazine (H ₂ N—NH ₂ ) in a solvent (halogenated aliphatic hydrocarbons such as dichloromethane) in a condensing agent (1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (WSC / HCl) etc.) in the presence of a base (triethylamine, diisopropylethylamine, etc.) and an activator (N-hydroxybenzotriazole monohydrate, etc.), then the reaction Product and the following formula [III-q]:
(R ^r O) ₃ CR ^s [III-q]
[Wherein, R ^r represents an alkyl group, and R ^s represents an alkyl group. ]
It can manufacture by making the compound shown by react.

Compound [II-a], compound [II-b], compound [II-c] and compound [II-d], which are synthetic intermediates in the present invention, can be produced, for example, according to the following synthesis method.

Among compounds [II-a], a compound wherein R ² is a halogen atom (compound [II-a1]) can be produced according to the following synthesis method 18.

Synthesis method 18:

[In the above scheme, R ²¹ represents a halogen atom, X ¹ represents a halogen atom, and other symbols have the same meaning as described above. ]
The reaction of compound [1a] and a halogenating agent can be carried out in a solvent in the presence or absence of an acid. The solvent may be any inert solvent that does not interfere with the reaction. Examples of such a solvent include nitriles such as acetonitrile, halogenated aliphatic hydrocarbons such as dichloromethane, and the like. Examples of the halogenating agent include N-fluoro-N ′-(chloromethyl) triethylenediamine bis (tetrafluoroborate), N-chlorosuccinimide, N-bromosuccinimide, N-iodosuccinimide and the like. Examples of the acid include acetic acid and the like.

The reaction of compound [2a] and compound [3a] can be carried out in a solvent in the presence of a trisubstituted phosphine such as triphenylphosphine and an additive such as diethyl azodicarboxylate. The solvent may be any inert solvent that does not interfere with the reaction. Examples of such a solvent include ethers such as tetrahydrofuran, aromatic hydrocarbons such as toluene, and the like.

Compound [II-b] can be produced, for example, according to the following reaction synthesis method 19.

Synthesis method 19:

[In the above scheme, the symbols have the same meaning as described above. ]
The reaction of compound [1b] or a salt thereof (hydrochloride, etc.) and compound [2b] can be carried out in a solvent such as dichloromethane in the presence of a base such as triethylamine.

The reaction of compound [3b] and aminoacetaldehyde diethyl acetal can be carried out in a solvent such as dichloromethane in the presence of an acid catalyst such as acetic acid, a base such as triethylamine and a borohydride compound such as sodium triacetoxyborohydride. .

The reaction of compound [4b] and malononitrile can be carried out in a solvent such as dichloromethane in the presence of an additive such as p-toluenesulfonic acid.

The reaction of compound [5b] and triethyl orthoformate can be carried out in a solvent such as acetonitrile in the presence of an acid catalyst such as acetic acid.

Conversion of compound [6b] to compound [7b] can be carried out by treating compound [6b] with ammonia in a solvent such as methanol.

The reaction of compound [7b] and the halogenating agent can be carried out in a solvent such as acetonitrile. Examples of the halogenating agent include N-chlorosuccinimide, N-bromosuccinimide, N-iodosuccinimide, bromine and the like.

Compound [II-c] can be produced, for example, according to the following reaction synthesis method 20.

Synthesis method 20:

[In the above scheme, the symbols have the same meaning as described above. ]
The deacylation reaction of compound [Ie] can be carried out according to a conventional method depending on the kind of acyl group. For example, the removal of the acyl group from the compound [Ie] in which R ¹¹ is a tert-butoxycarbonyl group can be carried out by treating the compound with hydrochloric acid / dioxane.

Compound [II-d] can be produced, for example, according to Synthesis Method 21 below.

Synthesis method 21:

[In the above scheme, Z ¹ represents a protecting group for a carboxyl group, and other symbols have the same meaning as described above. ]
Examples of Z ¹ in the compound [II-y] include an alkyl group such as a tert-butyl group and an aralkyl group such as a benzyl group. Removal of the protecting group from compound [II-y] can be carried out by a conventional method. For example, removal of the protecting group from the compound [II-y] having a tert-butyl group as Z ¹ can be carried out by treating the compound with hydrochloric acid / dioxane or the like in a solvent or without a solvent.
(Synthesis Method 22)
Among the intermediate compounds in the present invention, the following formula:

[Wherein the symbols have the same meaning as described above. ]
For example, the compound represented by the formula [2a] and the following formula [3aa]:

[Wherein the symbols have the same meaning as described above. ]
The compound represented by formula (II-m-2) is treated in the same manner as in the reaction of the compound [2a] and the compound [3a] described in Synthesis Method 18.

[Wherein the symbols have the same meaning as described above. ]
Then, the compound [II-m-2] is present in a solvent (methylene chloride or the like) in a base (1,8-diazabicyclo [5.4.0] undec-7-ene or the like). Treatment with ethyl phosphorodichloridate under the following formula [II-m-3]:

[Wherein the symbols have the same meaning as described above. ]
The compound [II-m-3] and hydroxylamine can be further reacted in a solvent (alcohol such as isopropanol).
(Synthesis Method 23)
Among the intermediate compounds in the present invention, the following formula [II-p]:

[Wherein the symbols have the same meaning as described above. ]
The compound represented by the formula [II-c]:

[Wherein the symbols have the same meaning as described above. ]
Is reacted with a cyanogen halide (for example, cyanogen bromide) in a solvent (an alcohol such as ethanol, an ether such as tetrahydrofuran) in the presence of a base (such as sodium bicarbonate). The following formula [II-r]:

[Wherein the symbols have the same meaning as described above. ]
And then reacting the compound [II-r] with hydroxylamine in a solvent (alcohol such as isopropanol).
(Synthesis Method 24)
Of the synthetic intermediates in the present invention, the following formula [3A]:

[Wherein, OZ ² represents a protected hydroxyl group, and other symbols have the same meaning as described above. ]
For example, the compound represented by the formula [III-t]:

And a tetrahydropyridine compound represented by the following formula [III-u]:
R ¹ -X ^u [III-u]
[Wherein, X ^u represents a halogen atom, and other symbols have the same meaning as described above. ]
Is reacted in a solvent (such as an alcohol such as ethanol) to give the following formula [II-u]:

[Wherein the symbols have the same meaning as described above. ]
Then, the compound is treated with osmium tetroxide and N-methylmorpholine oxide in a solvent (such as a mixture of nitriles such as acetonitrile and water) in the following formula [II-v]:

[Wherein the symbols have the same meaning as described above. ]
And a protective group (Z ² ) is further introduced into the hydroxyl group at the 3-position of the compound according to a conventional method.

In the present invention, “halogen atom” means a fluorine atom, chlorine atom, iodine atom or bromine atom, and “alkyl” or “alkoxy” means 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms. It means straight-chain or branched alkyl or alkoxy, and “cycloalkyl” means cycloalkyl having 3 to 8 carbon atoms, preferably 3 to 6 carbon atoms. “Alkylene” means linear or branched alkylene having 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms, and “alkanoyl” means 2 to 8 carbon atoms, preferably 2 carbon atoms. Means up to 6 linear or branched alkanoyl.

The abbreviations used in this specification have the following meanings unless otherwise defined.

Ac: Acetyl Boc: tert-Butoxycarbonyl DMF: Dimethylformamide DMSO: Dimethyl sulfoxide Me: Methyl Et: Ethyl i-Pr: Isopropyl i-Bu: Isobutyl t-Bu or tert-Bu: tert-Butyl MOMO: Methoxymethoxy Ph Phenyl Bzl: benzyl TFA: trifluoroacetic acid CDI: 1,1′-carbonyldiimidazole HOBt: 1-hydroxybenzotriazole DIAD: diisopropyl azodicarboxylate dppf: diphenylphosphinoferrocene PPh ₃ : triphenylphosphine HPLC: high performance liquid chromatography BINAP: 2,2′-bis (diphenylphosphino) -1,1′-binaphthyl JohnPhos: 2- (dite t- butylphosphino) biphenyl TBDS (or TBDMS): tert-butyldimethylsilyl

Example 1
[7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-yl]-[3-methylpyridine- 4-Il] amine production

4-chloro-7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidine (the compound obtained in Reference Example 17) ) 108 mg, 4-amino-3-methylpyridine 32 mg, 2- (ditert-butylphosphino) biphenyl (JohnPhos) 9 mg, palladium acetate 7 mg and sodium tert-butoxide 72 mg 3 mL of a dimethylformamide solution 3 mL was stirred at 100 ° C. for 3 hours. did. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by NH silica gel chromatography (Chromatorex; Fuji Silysia Chemical, solvent; hexane / ethyl acetate = 90/10 to 50/50) to give 24 mg of the title compound as a powder. Obtained (yield 18%).
MS (APCI) m / z; 433 [M + H] ^< +>.

Example 2
4- [4- [4- (1,1-Dioxo-1λ ⁶ -thiazolidine-3-carbonyl) -2-fluorophenylamino] -5-fluoro-pyrrolo [2,3-d] pyrimidin-7-yl] Production of piperidine-1-carboxylic acid isopropyl ester

102 mg of 4- (4-chloro-5-fluoro-pyrrolo [2,3-d] pyrimidin-7-yl) piperidine-1-carboxylic acid isopropyl ester (the compound obtained in Reference Example 37), (4-amino- 3-fluoro-phenyl) (1,1-dioxo-1λ ⁶ -thiazolidin-3-yl) methanone (compound obtained in Reference Example 36) 77 mg, racemic-2,2′-bis (diphenylphosphino) -1 , 1′-binaphthyl (rac-BINAP) 37 mg, palladium acetate 13 mg and potassium carbonate 124 mg 3 mL of a dimethoxyethane solution was stirred in a microwave reactor at 100 ° C. for 10 minutes. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was concentrated, and the obtained residue was purified by silica gel chromatography (solvent; hexane / ethyl acetate = 70/30 to 20/80) to give 69 mg of the title compound as a powder (yield 41%). .
MS (APCI) m / z; 563 [M + H] ^< +>.

Example 3
[7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-yl]-[4- (5- Preparation of methyl- [1,3,4] oxadiazol-2-yl) phenyl] amine

4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] benzoic acid / hydrochloride (Compound obtained in Reference Example 24) 221 mg of hydrazine-hydrate (80%) and 279 μL of triethylamine were added to 4 mL of a dichloromethane solution of 221 mg of EDC · HCl 100 mg and HOBt · H ₂ O 80 mg, and the mixture was stirred at room temperature for 20 hours. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the organic layer obtained by extraction with chloroform-methanol (9: 1) was concentrated under reduced pressure. To the obtained residue, 3 mL of triethyl orthoacetate was added and heated under reflux for 2 hours. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was concentrated, and the obtained residue was purified by NH silica gel chromatography (Chromatorex; Fuji Silysia Chemical, solvent; hexane / ethyl acetate = 95/5 to 60/40) to obtain 56 mg of the title compound ( Yield 27%).
MS (APCI) m / z; 518 [M + H] ^< +>.

Example 4
[7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-4- (2-methylpyridin-3-yloxy) -7H-pyrrolo [2,3-d] Pyrimidine production

4-chloro-7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidine (the compound obtained in Reference Example 17) ) 108 mL, 3-hydroxy-2-methylpyridine 39 mg, and potassium carbonate 124 mg in 3 mL of a dimethyl sulfoxide solution were stirred at 100 ° C. for 18 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (solvent; hexane / ethyl acetate = 70 / 30-30 / 70) to give 96 mg of the title compound as a powder (yield 74%). ).
MS (APCI) m / z; 434 [M + H] ^< +>.

Example 5
[4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl] ((2R, 4R) -4-hydroxy-2-hydroxymethylpyrrolidin-1-yl) methanone

4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluorobenzoic acid 40 mg of (3R, 5R) -5-hydroxymethylpyrrolidin-3-ol hydrochloride (compound obtained in Reference Example 63) in a solution of 110 mg of acid · dihydrochloride (compound obtained in Reference Example 24) in 4 mL of dichloromethane N-hydroxybenzotriazole monohydrate (HOBt · H ₂ O) 46 mg, triethylamine 139 μL and 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (WSC · HCl) 58 mg were added, and the mixture was added. Was stirred at room temperature for 18 hours. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was concentrated, and the obtained residue was purified by NH silica gel chromatography (Chromatorex; Fuji Silysia Chemical, solvent; hexane / ethyl acetate = 50/50 to 0/100) to give 51 mg of the title compound as a colorless powder. Obtained (44% yield).
MS (APCI) m / z; 579 [M + H] ^< +>.

Examples 6 to 133
The corresponding starting materials were treated in the same manner as in Example 5 to obtain the compounds shown in Tables 1 to 17 below.

Example 134
7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-4- (5-methyl-1,3,4-oxadiazol-2-yl) phenyloxy- Production of 7H-pyrrolo [2,3-d] pyrimidine

The corresponding starting material compound was treated in the same manner as in Example 4 to obtain the title compound as a powder (yield: 59%).
MS (APCI) m / z; 519 [M + H] ^< +>.

Example 135
2- [4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] 3- Preparation of fluorophenyl] -4,5-dihydrooxazole-4-carboxylic acid methyl ester

2- [4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3 -Fluorobenzoylamino] -3-hydroxy-propionic acid methyl ester (compound obtained in Example 78) 1.05 g of a solution of 18 ml of dichloromethane in an ice-cooled solution was added 311 μL of N, N-diethylaminosulfur trifluoride (DAST) under ice cooling. In addition, the mixture was stirred at the same temperature for 1 hour. After adding saturated aqueous sodium hydrogen carbonate solution to the reaction mixture, the organic layer is concentrated, and the resulting residue is purified by silica gel chromatography (solvent; chloroform / methanol = 95/5 to 90/10) to give the title compound. 622 mg was obtained as a colorless powder (yield 61%).
MS (APCI) m / z; 563 [M + H] ^< +>.

Example 136
2- [4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3 -Fluorophenyl] oxazole-4-carboxylic acid methyl ester

2- [4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3 -Fluorophenyl] -4,5-dihydrooxazole-4-carboxylic acid methyl ester (compound obtained in Example 135) in a solution of 580 mg of dichloromethane in 10 mL of ice-cooled 1,8-diazabicyclo [5.4.0] 231 μL of undec-7-ene (DBU) and 152 μL of trichlorobromide methane were added. The mixture was warmed to room temperature and stirred for 1 hour. To the reaction mixture, 231 μL of DBU and 152 μL of chlorotrichloromethane were further added, and the mixture was stirred at room temperature for 23 hours. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, the organic layer was concentrated, and the obtained residue was purified by silica gel chromatography (solvent; chloroform / methanol = 100/0 to 90/10) to give the title compound. 348 mg was obtained as a colorless powder (yield 60%).
MS (APCI) m / z; 561 [M + H] ^< +>.

Example 137
[2- [4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- 3-Fluorophenyl] -oxazol-4-yl] methanol

2- [4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3 -Fluoro-phenyl] -oxazole-4-carboxylic acid methyl ester (the compound obtained in Example 136) To a solution of 112 mg of 6 ml of tetrahydrofuran was added 15 mg of lithium aluminum hydride, and the mixture was stirred overnight at room temperature and then heated to reflux for 50 minutes. did. Further, 30 mg of lithium aluminum hydride was added, and the mixture was heated to reflux for 15 minutes. To the reaction mixture, 45 μL of water, 90 μL of 2N aqueous sodium hydroxide solution and 90 μL of water were sequentially added, and insoluble matters were filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel chromatography (solvent; hexane / ethyl acetate = 80/20 to 20/80) to give 42 mg of the title compound as a colorless powder (yield 39 %).
MS (APCI) m / z; 533 [M + H] ^< +>.

Example 138
[4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl]-((R) -2-hydroxymethylpiperidin-1-yl) methanone (Compound 138A) and [(R) -1- [4- [7- [1- (5-ethylpyrimidin-2-yl) Preparation of piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluorobenzyl] piperidin-2-yl] methanol (Compound 138B)

(R) -1- [4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidine-4- [Ilamino] -3-fluorobenzoyl] -piperidine-2-carboxylic acid methyl ester (compound obtained in Example 98) 135 mg of tetrahydrofuran 4.5 mL solution was added 25 mg of lithium aluminum hydride and stirred at room temperature for 1 hour. . To the reaction mixture, 25 μL of water, 50 μL of 2N aqueous sodium hydroxide solution and 50 μL of water were sequentially added, and insoluble matters were filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by NH silica gel chromatography (Chromatorex; Fuji Silysia Chemical, solvent; hexane / ethyl acetate = 50/50 to 0/100) to give the title compound (Compound 138A / 27 mg (powder, yield: 21%) and Compound 138B / 27 mg (powder, yield: 21%)) were obtained.
Compound 138A: MS (APCI) m / z; 577 [M + H] ⁺
Compound 138B: MS (APCI) m / z; 563 [M + H] ⁺ .

Example 139
[4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl] ((S) -3-hydroxymethylpiperidin-1-yl) methanone

The corresponding starting material compound was treated in the same manner as in Example 138 to give the title compound as a powder (yield: 54%).
MS (APCI) m / z; 577 [M + H] ^< +>.

Example 140
2- [4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3 -Fluorophenyl] oxazole-4-carboxamide

2- [4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3 -Fluorophenyl] oxazole-4-carboxylic acid methyl ester (the compound obtained in Example 136) To a solution of 95 mg of tetrahydrofuran in 3.4 mL was added 2N aqueous sodium hydroxide solution (847 μL), and the mixture was stirred at room temperature for 19 hours. After adding 847 μL of 2N hydrochloric acid to the reaction mixture, the solvent was concentrated under reduced pressure. After adding 5 mL of dimethylformamide, 45 mg of ammonium chloride, 39 mg of N-hydroxybenzotriazole monohydrate (HOBt · H ₂ O), 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (WSC · HCl) 49 mg and triethylamine 236 μL were added and the mixture was stirred at 60 ° C. overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was triturated successively with dichloromethane-diethyl ether and methanol to give 30 mg of the title compound as a colorless powder (yield 32%).
MS (APCI) m / z; 546 [M + H] ^< +>.

Example 141
1- [4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3 -Fluorophenyl] carbonylpiperidine-3-carboxamide

The corresponding starting material compound was treated in the same manner as in Example 140 to give the title compound as a powder (yield: 27%).
MS (APCI) m / z; 590 [M + H] ^< +>.

Example 142
4- [7- [trans-1- (5-ethylpyrimidin-2-yl) -3-hydroxypiperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino Production of 3-fluoro-N, N-dimethylbenzamide (racemic)

Benzoic acid trans-4- (4-Chloro-5-fluoropyrrolo [2,3-d] pyrimidin-7-yl) -1- (5-ethylpyrimidin-2-yl) piperidin-3-yl ester (reference example) Compound obtained in 77; 144 mg), 4-amino-3-fluoro-N, N-dimethylbenzamide (compound obtained in Reference Example 2; 82 mg), [1,1-bis (diphenylphosphino) ferrocene] A solution of 25 mg of dichloropalladium (II) and 74 mg of tert-butoxy sodium in 3 mL of dioxane was stirred at 80 ° C. for 10 minutes. After cooling to room temperature with ice, the reaction mixture was poured into an aqueous ammonium chloride solution and extracted with ethyl acetate. The organic layer was evaporated. The residue was purified by silica gel column chromatography (ethyl acetate: hexane = 60: 40 → 100: 0) to give 4- [7- [trans-1- (5-ethylpyrimidin-2-yl) -3- Hydroxypiperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro-N, N-dimethylbenzamide (27 mg) was obtained as a powder. (Yield 17%)
MS (APCI) m / z: 523 [M + 1] ^< +>.

Example 143
(1,1-Dioxo-1λ ⁶ -thiazolidin-3-yl) [4- [7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [ 2,3-d] Pyrimidin-4-ylamino] -3-fluorophenyl] methanone

[4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro 24 μL of methanesulfonic acid and 43 mg of m-chloroperbenzoic acid were added to a solution of 34 mg of phenyl] (thiazolidin-3-yl) methanone (the compound obtained in Reference Example 78) in 1 mL of dichloromethane under ice cooling, and the mixture was stirred at room temperature. Stir for 2 hours. 24 μL of methanesulfonic acid and 43 mg of m-chloroperbenzoic acid were added, and the mixture was stirred overnight at room temperature. A sodium thiosulfate aqueous solution and a saturated sodium hydrogen carbonate aqueous solution were added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was concentrated, and the obtained residue was purified by silica gel chromatography (solvent; chloroform / methanol = 100/0 to 95/5) to give 3.3 mg of the title compound as a powder (yield 9%). ).
MS (APCI) m / z; 583 [M + H] ^< +>.

Example 144
4- [3-Fluoro-4- [5-fluoro-7- [1- (5-propylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine-4- Of [Ilamino] benzoylamino] butyric acid

4- [3-Fluoro-4- [5-fluoro-7- [1- (5-propylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine-4- [Ilamino] benzoylamino] butyric acid methyl ester (compound obtained in Example 39) 77 mL of tetrahydrofuran 1.5 mL was added 1.5 N of 1N aqueous sodium hydroxide solution, and the mixture was stirred at room temperature overnight. The reaction mixture was neutralized with 1N aqueous hydrochloric acid and extracted three times with ethyl acetate. The organic layer was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (solvent; chloroform / methanol = 100/0 to 80/20) to give 63.9 mg of the title compound as a white solid (yield) 85%).
MS (APCI) m / z; 579 [M + H] ^< +>.

Example 145
((R) -3-Aminopyrrolidin-1-yl) [4- [5-chloro-7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2, Preparation of 3-d] pyrimidin-4-ylamino] -3-fluorophenyl] methanone

[(R) -1- [4- [5-Chloro-7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine-4 -Ilamino] -3-fluorobenzoyl] pyrrolidin-3-yl] carbamic acid tert-butyl ester (compound obtained in Reference Example 55) (92 mg) was added with 4N hydrochloric acid-dioxane solution (1.5 mL), and the mixture was allowed to stand at room temperature overnight. Stir. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by NH silica gel chromatography (Chromatorex; Fuji Silysia Chemical, solvent; chloroform / methanol = 100/0 to 90/10) to give 68.2 mg of the title compound as white. Obtained as a solid (81% yield).
MS (APCI) m / z; 564/566 [M + H] ^< +>.

Example 146
[[3-Fluoro-4- [5-fluoro-7- [1- (5-propylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino ] Production of benzoyl] methylamino] acetic acid

[[3-Fluoro-4- [5-fluoro-7- [1- (5-propylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino 2 mL of 4N hydrochloric acid-dioxane solution was added to 73 mg of] -benzoyl] methylamino] acetic acid tert-butyl ester (compound obtained in Example 34), and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel chromatography (solvent; chloroform / methanol = 95/5 to 80/20) to give 45.1 mg of the title compound as a yellow solid (yield) 73%).
MS (APCI) m / z; 565 [M + H] ^< +>.

Examples 147-153
The corresponding starting materials were treated in the same manner as in Example 1 to obtain the compounds shown in Table 18 below.

Example 154
[7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-yl]-(2-fluoro-4 -Methylsulfinylphenyl) amine production

[7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-yl]-(2-fluoro-4 -Methylthio-phenyl) amine (the compound obtained in Example 147) To a solution of 96 mg of dichloromethane in 4 mL was added 51 mg of m-chloroperbenzoic acid under ice cooling, and the mixture was stirred at room temperature for 5 minutes. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer is concentrated, and the obtained residue is purified by NH silica gel chromatography (Chromatorex; Fuji Silysia Chemical, solvent; hexane / ethyl acetate = 70/30 to 25/75) to obtain 80 mg of the title compound as a powder. (Yield 80%).
MS (APCI) m / z; 498 [M + H] ^< +>.

Examples 155 to 156
The corresponding starting material compound was treated in the same manner as in Example 144, to give compounds as shown in Table 19 below.

Examples 157 to 161
The corresponding starting material compound was treated in the same manner as in Example 145 to give the compounds shown in Table 20 below.

Examples 162-163
The corresponding starting materials were treated in the same manner as in Example 2 to obtain the compounds shown in Table 21 below.

Example 164
Preparation of 3- [4- (4-Dimethylcarbamoyl-2-fluorophenylamino) -5-fluoropyrrolo [2,3-d] pyrimidin-7-ylmethyl] pyrrolidine-1-carboxylic acid tert-butyl ester

3- (4-Chloro-5-fluoro-pyrrolo [2,3-d] pyrimidin-7-ylmethyl) -pyrrolidine-1-carboxylic acid tert-butyl ester (the compound obtained in Reference Example 113) 250 mg of 1, To 7 mL of 4-dioxane, 128 mg of 4-amino-3-fluoro-N, N-dimethylbenzamide (the compound obtained in Reference Example 2) and 169 mg of sodium tert-butoxide were added, and the mixture was stirred at 100 ° C. for 1 hour. . Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was concentrated under reduced pressure, and the resulting residue was purified by silica gel chromatography (solvent; hexane / ethyl acetate = 20/80 to 0/100) to give 124 mg of the title compound as a powder (yield 35% ).
MS (APCI) m / z; 501 [M + H] ^< +>.

Example 165
[7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-yl]-(1-methanesulfonylpiperidine -4-yl) amine production

4-chloro-5-fluoro-7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine (the compound obtained in Reference Example 17) ) 30 mg of 4-amino-1-methanesulfonylpiperidine and 48 μL of diisopropylethylamine were added to a solution of 50 mg of ethanol in 1 mL, and the mixture was stirred at 140 ° C. for 2 hours in a microwave reactor (Initiator, manufactured by Biotage). Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and the resulting residue was purified by silica gel chromatography (solvent; chloroform / methanol = 100/0 to 95/5) to give 40 mg of the title compound as a powder (yield 57%). .
MS (APCI) m / z; 503 [M + H] ^< +>.

Example 166
Preparation of 4- [4- (4-Dimethylcarbamoyl-2-fluorophenylamino) -5-fluoro-pyrrolo [2,3-d] pyrimidin-7-yl] azepan-1-carboxylic acid isopropyl ester

4-[(7-Azepan-4-yl) -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro-N, N-dimethylbenzamide dihydrochloride (Reference Example) Compound obtained in 125) 37 μL of isopropyl chloroformate and 158 μL of triethylamine were added to a solution of 100 mg of dichloromethane in 1 mL, and the mixture was stirred at room temperature for 24 hours. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was concentrated under reduced pressure, and the obtained residue was purified by NH silica gel chromatography (Chromatorex; Fuji Silysia Chemical, solvent; hexane / ethyl acetate = 70/30 to 40/60) to give 76 mg of the title compound as a powder. Obtained (yield 94%).
MS (APCI) m / z; 501 [M + H] ^< +>.

Example 167
4- [7- [4- (5-Ethylpyrimidin-2-yl) morpholin-2-ylmethyl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro- Production of N, N-dimethylbenzamide

3-Fluoro-4- [5-fluoro-7- (morpholin-2-ylmethyl) -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -N, N-dimethylbenzamide dihydrochloride (Reference Example) The compound obtained in 129) 136 mg and diisopropylethylamine 388 mg in ethanol solution 5 mL was added 2-chloro-5-ethylpyrimidine 214 mg, and the mixture was stirred at 90 ° C. for 3 days. The reaction mixture was cooled to room temperature, poured into a saturated aqueous sodium hydrogen carbonate solution, and extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform: methanol = 100: 0 to 95: 5) to give 153 mg of the title compound as a viscous oil. (Yield 98%)
MS (APCI) m / z: 523 [M + H] ^< +>.

Example 168
3-Fluoro-4- [5-fluoro-7- [trans-4- (2-isopropyl-2H-tetrazol-5-yl) -cyclohexyl-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -Production of N, N-dimethylbenzamide

3-Fluoro-4- [5-fluoro-7- [trans-4- (2H-tetrazol-5-yl) cyclohexyl-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -N, N- 14 μL of isopropyl iodide and 32 mg of potassium carbonate were added to a solution of 54 mg of dimethylbenzamide (compound obtained in Reference Example 131) in 1 mL of dimethylformamide, and the mixture was stirred at room temperature for 1.5 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and the resulting residue was purified by silica gel chromatography (solvent; chloroform / methanol = 99/1 to 95/5) to give 18 mg of the title compound as a powder (yield 30%). .
MS (APCI) m / z; 510 [M + H] ^< +>.

Example 169
3-Fluoro-4- [5-fluoro-7- [trans-4- (5-isopropyl- [1,2,4] oxadiazol-3-yl) cyclohexyl-7H-pyrrolo [2,3-d] Preparation of pyrimidin-4-ylamino] -N, N-dimethylbenzamide

3-Fluoro-4- [5-fluoro-7- [trans-4- (N-hydroxycarbamimidoyl) cyclohexyl-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -N, N- To a solution of 89 mg of dimethylbenzamide (the compound obtained in Reference Example 141) in 1.5 mL of toluene was added 33 μL of triethylamine and 20 μL of isobutyryl chloride under ice-cooling, and the mixture was stirred at room temperature for 10 minutes and further stirred at 120 ° C. for 4 hours. did. The reaction mixture was cooled to room temperature, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with ethyl acetate and chloroform. The organic layer was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (solvent; hexane / ethyl acetate = 60 / 40-0 / 100) to give 69 mg of the title compound as a powder (yield 69%). ).
MS (APCI) m / z; 510 [M + H] ^< +>.

Example 170
3-Fluoro-4- [5-fluoro-7- [1- (5-trifluoromethyl- [1,2,4] oxadiazol-3-yl) azepan-4-yl] -7H-pyrrolo [2 , 3-d] pyrimidin-4-ylamino] -N, N-dimethylbenzamide

4- [7- (1-cyanoazepan-4-yl) -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro-N, N-dimethylbenzamide (Reference Example 143 Compound obtained in 1) 69 μL of 50% aqueous hydroxylamine solution was added to a solution of 114 mg of isopropanol in 2.6 mL, and the mixture was stirred at 90 ° C. for 2 hours. To the residue obtained by evaporating the solvent under reduced pressure, 4 mL of toluene was added, 108 μL of triethylamine and 72 μL of trifluoroacetic anhydride were added, and the mixture was stirred at 100 ° C. for 4 hours. An additional 108 μL of triethylamine and 72 μL of trifluoroacetic anhydride were added to the reaction mixture and the mixture was stirred at 100 ° C. for 18 hours. The reaction mixture was cooled to room temperature, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with chloroform. The organic layer was concentrated under reduced pressure, and the obtained residue was purified by NH silica gel chromatography (Chromatorex; Fuji Silysia Chemical, solvent; hexane / ethyl acetate = 80/20 to 30/70) to give 40 mg of the title compound as a powder. Obtained (yield 28%).
MS (APCI) m / z; 551 [M + H] ^< +>.

Example 171
3-Fluoro-4- [5-fluoro-7-[(R) -1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) pyrrolidin-3-ylmethyl] -7H-pyrrolo Preparation of [2,3-d] pyrimidin-4-ylamino] -N, N-dimethylbenzamide

4- [7-((R) -1-cyanopyrrolidin-3-ylmethyl) -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro-N, N-dimethyl 97 mg of N-hydroxyisobutylamidine, 18 mg of p-toluenesulfonic acid monohydrate and 13 mg of zinc chloride were added to a solution of benzamide (compound obtained in Reference Example 142) in 101 mL of dimethylformamide in 3 mL, and the mixture was added at 80 ° C. for 4 hours. Stir. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by NH silica gel chromatography (Chromatorex; Fuji Silysia Chemical, solvent; hexane / ethyl acetate = 80/20 to 30/70) to obtain 90 mg of the title compound as a powder (yield 74% ).
MS (APCI) m / z; 511 [M + H] ^< +>.

Example 172
4- [7- [trans-1- (5-ethylpyrimidin-2-yl) -3-fluoropiperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino Preparation of 3-fluoro-N- (2-hydroxyethyl) -N-methylbenzamide (racemate)

N- [2- (tert-butyldimethylsilanyloxy) ethyl] -4- [7- [trans-1- (5-ethylpyrimidin-2-yl) -3-fluoropiperidin-4-yl] -5 Fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro-N-methylbenzamide (the compound obtained in Reference Example 150) in a solution of 107 mg of tetrahydrofuran and 1N tetra-n-butyl After dropwise addition of 0.18 mL of ammonium fluoride-tetrahydrofuran solution at room temperature, the mixture was stirred for 3 hours. The reaction solution was poured into water, extracted with ethyl acetate, and the organic layer was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform: methanol = 100: 0 to 95: 5) to give 80 mg of the title compound as a powder. (Yield 91%)
MS (APCI) m / z: 555 [M + H] ^< +>.

Example 173
4- [7-[(R) -1- (5-ethylpyrimidin-2-yl) pyrrolidin-3-ylmethyl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- Production of 3-fluoro-N, N-dimethylbenzamide

(R) -3- [4- (4-Dimethylcarbamoyl-2-fluorophenylamino) -5-fluoro-pyrrolo [2,3-d] pyrimidin-7-ylmethyl] -pyrrolidine-1-carboxylate tert-butyl To a solution of 100 mg of the ester (compound obtained in Example 184 described later) in 3 mL of dichloromethane was added 500 μL of 4N hydrochloric acid-dioxane solution, and the mixture was stirred at room temperature for 17 hours. After adding 86 mg of 2-chloro-5-ethylpyrimidine, 4 mL of acetonitrile and 207 μL of diisopropylethylamine to the reaction mixture, the mixture was heated to reflux for 22 hours. The reaction mixture was cooled to room temperature, water was added, and the mixture was extracted with chloroform. The organic layer was concentrated under reduced pressure, and the obtained residue was purified by NH silica gel chromatography (Chromatorex; Fuji Silysia Chemical, solvent; hexane / ethyl acetate = 70/30 to 20/80) to give 66 mg of the title compound as a powder. Obtained (yield 65%).
MS (APCI) m / z; 507 [M + H] ^< +>.

Examples 174-180
The corresponding starting materials were treated in the same manner as in Example 1 to obtain the compounds shown in Table 22 below.

Examples 181 to 191
The corresponding starting materials were treated in the same manner as in Example 164, to give compounds as shown in Tables 23 and 24 below.

Examples 192 to 197
The corresponding starting material compound was treated in the same manner as in Example 4 to obtain the compounds shown in Table 25 below.

Examples 198-202
The corresponding starting materials were treated in the same manner as in Example 167, to give compounds as shown in Table 26 below.

Examples 203-215
The corresponding starting materials were treated in the same manner as in Example 173, to give compounds as shown in Tables 27 to 28 below.

Examples 216-280
The corresponding starting materials were treated in the same manner as in Example 5 to give the compounds shown in Tables 29 to 37 below.

Examples 281 to 282
The corresponding starting materials were treated in the same manner as in Example 170 to give the compounds as shown in Table 38 below.

Example 283
The corresponding starting compounds were treated in the same manner as in Example 146 to give the compounds as shown in Table 39 below.

Examples 284-285
The corresponding starting material compound was treated in the same manner as in Example 147 to give the compounds shown in Table 40 below.

Examples 286-287
The corresponding starting material compound was treated in the same manner as in Example 171 to give the compounds shown in Table 41 below.

Examples 288-289
The corresponding starting materials were treated in the same manner as in Example 172 to give the compounds as shown in Table 42 below.

Example 290
3-Fluoro-4- [5-fluoro-7- [4- (5-trifluoromethyl- [1,2,4] oxadiazol-3-yl) -trans-cyclohexyl] -7H-pyrrolo [2, Preparation of 3-d] pyrimidin-4-ylamino] -N, N-dimethylbenzamide

4-chloro-5-fluoro-7- [trans-4- (5-trifluoromethyl- [1,2,4] oxadiazol-3-yl) cyclohexyl] -7H-pyrrolo [2,3-d] Pyrimidine (compound obtained in Reference Example 124) 50 mg of isopropanol 1 mL solution was added 4-amino-3-fluoro-N, N-dimethylbenzamide (Compound obtained in Reference Example 2) 23 mg, 4N hydrochloric acid-dioxane solution 5 μL. In addition, the mixture was stirred at 80 ° C. for 17 hours. The reaction mixture was cooled to room temperature, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with chloroform. The organic layer was concentrated under reduced pressure, and the obtained residue was purified by NH silica gel chromatography (Chromatorex; Fuji Silysia Chemical, solvent; hexane / ethyl acetate = 80/20 to 55/45) to give 52 mg of the title compound as a powder. Obtained (yield 75%).
MS (APCI) m / z; 536 [M + H] ^< +>.

Example 291
4- [7-[(3S, 4R) -1- (5-ethylpyrimidin-2-yl) -3-methylpiperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidine -4-ylamino] -3-fluoro-N, N-dimethylbenzamide and 4- [7-[(3R, 4S) -1- (5-ethylpyrimidin-2-yl) -3-methylpiperidin-4-yl ] -5-Fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro-N, N-dimethylbenzamide

4- [7- [rac-cis-1- (5-ethylpyrimidin-2-yl) -3-methylpiperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidine-4 -Ilamino] -3-fluoro-N, N-dimethylbenzamide (compound obtained in Example 256) (107 mg) was dissolved in 6 mL of ethanol / chloroform mixed solution (1/1) and then subjected to the following conditions using a chiral column. Optical resolution (× 6) was performed to obtain the title compounds Compound A: 47 mg and Compound B: 49 mg as white powders (43% and 45% yield), respectively.
Compound A: MS (APCI) m / z; 521 [M + H] ⁺
Compound B: MS (APCI) m / z; 521 [M + H] ⁺
(Optical splitting conditions)
Column: CHIRALPAK IC (20mmΦ × 250mm) (Daicel Chemical)
Mobile phase: hexane / ethanol / diethylamine (50/50 / 0.1)
Flow rate: 5.0 mL / min.
Detection wavelength: 340 nm (Waters 302 (600E system) (Waters)
Example 292
(S) -1- (4- [7-[(3S, 4R) -1- (5-ethylpyrimidin-2-yl) -3-methylpiperidin-4-yl] -5-fluoro-7H-pyrrolo [ 2,3-d] pyrimidin-4-ylamino] -3-fluorobenzoyl) -pyrrolidine-2-carboxylic acid amide and (S) -1- (4- [7-[(3R, 4S) -1- (5 -Ethylpyrimidin-2-yl) -3-methylpiperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluorobenzoyl) -pyrrolidin-2- Production of carboxamide

138 mg of the compound obtained in Example 258 was dissolved in 6 mL of ethanol, and optical resolution (x6 times) was performed using a chiral column under the following conditions, whereby the title compounds Compound A: 56 mg and Compound B: 55 mg were respectively white powder. (Yield 41%, 41%).
Compound A: MS (APCI) m / z; 590 [M + H] ⁺
Compound B: MS (APCI) m / z; 590 [M + H] ⁺
(Optical splitting conditions)
Column: CHIRALPAK IB (Daicel Chemical, 20mmΦ × 250mm)
Mobile phase: hexane / ethanol / diethylamine (70/30 / 0.1)
Flow rate: 8.0 mL / min.
Detection wavelength: 280 nm (Senshu Scientific, SSC-8200).

Example 293
3-Fluoro-4- [5-fluoro-7-[(R) -1- [5- (1-fluoro-1-methylethyl)-[1,2,4] oxadiazol-3-yl] pyrrolidine Preparation of -3-ylmethyl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -N, N-dimethylbenzamide

4- [7-((R) -1-cyanopyrrolidin-3-ylmethyl) -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro-N, N-dimethyl 116 μL of 50% aqueous hydroxylamine solution was added to a solution of benzamide (the compound obtained in Reference Example 142) 150 mg in isopropanol 3.5 mL, and the mixture was stirred at 90 ° C. for 18 hours. The reaction mixture was concentrated under reduced pressure, 3.5 mL of toluene, 184 μL of diisopropylethylamine, and 95 mg of 2-fluoro-2-methyl-propionic acid ethyl ester were added, and the mixture was stirred at 100 ° C. for 6 hours. The reaction mixture was cooled to room temperature, 2 mL of tetrahydrofuran and 28 mg of sodium hydride were added, and the mixture was stirred at 70 ° C. for 18 hours. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was concentrated, and the resulting residue was purified by NH silica gel chromatography (solvent; hexane / ethyl acetate = 80/20 to 30/70) to give 17 mg of the title compound as a colorless powder (yield 9 %).
MS (APCI) m / z; 529 [M + H] ^< +>.

Example 294
4- [7-[(R) -1- [5- (1,1-difluoroethyl)-[1,2,4] oxadiazol-3-yl] pyrrolidin-3-ylmethyl] -5-fluoro- Preparation of 7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro-N, N-dimethylbenzamide

4- [7-((R) -1-cyanopyrrolidin-3-ylmethyl) -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro-N, N-dimethyl Benzamide (the compound obtained in Reference Example 142) 340 μL of 50% aqueous hydroxylamine solution was added to 340 mg of an isopropanol 8 mL solution, and the mixture was stirred at 90 ° C. for 22 hours. The reaction solution was concentrated under reduced pressure, and O- (7-azabenzotriazol-1-yl) -N ′, N ′, N ′, N′-tetramethyluronium hexafluorophosphate (HATU) 608 mg, 2,2-difluoro 106 mg of propionic acid, 8 mL of dimethylformamide and 557 μL of diisopropylethylamine were added, and the mixture was stirred at 100 ° C. for 6 hours. The reaction mixture was cooled to room temperature, tetrahydrofuran (2 mL) and sodium hydride (28 mg) were added, and the mixture was stirred at room temperature for 24 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer is dried over magnesium sulfate and concentrated under reduced pressure. The resulting residue is purified by NH silica gel chromatography (solvent; hexane / ethyl acetate = 80/20 to 30/70) to give 36 mg of the title compound as a colorless powder. (Yield 8%).
MS (APCI) m / z; 533 [M + H] ^< +>.

Example 295
3-Fluoro-4- [5-fluoro-7-[(R) -1- (5-trifluoromethyl- [1,2,4] oxadiazol-3-yl) pyrrolidin-3-ylmethyl] -7H Preparation of pyrrolo [2,3-d] pyrimidin-4-ylamino] -N- (2-hydroxyethyl) -N-methylbenzamide

3-Fluoro-4- [5-fluoro-7-[(R) -1- (5-trifluoromethyl- [1,2,4] oxadiazol-3-yl) pyrrolidin-3-ylmethyl] -7H -Pyrrolo [2,3-d] pyrimidin-4-ylamino] benzoic acid hydrochloride (the compound obtained in Reference Example 155) 109 mg, 2-methylaminoethanol 28 mg, 4- (4,6-dimethoxy [1, 3,5] Triazin-2-yl) -4-methylmorpholinium chloride (83 mg) in tetrahydrofuran (4 mL) was added with N-methylmorpholine (66 μL), and the mixture was stirred at room temperature for 3 hours. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The obtained residue was purified by NH silica gel chromatography (solvent; hexane / ethyl acetate = 50 / 50-0 / 100) to give 34 mg of the title compound as a colorless powder (yield 30%).
MS (APCI) m / z; 567 [M + H] ^< +>.

Examples 296-308
The corresponding starting materials were treated in the same manner as in Example 5 to give the compounds shown in Tables 43 to 44 below.

Examples 309-310
The corresponding starting materials were treated in the same manner as in Example 295 to give the compounds as shown in Table 45 below.

Reference example 1
Preparation of 4- (4-chloro-5-fluoropyrrolo [2,3-d] pyrimidin-7-yl) piperidine-1-carboxylic acid tert-butyl ester

(1) 20 mL of acetic acid and N-fluoro-N ′-(chloromethyl) triethylenediaminebis (tetrafluoroborate) 6 in a 100 mL acetonitrile solution of 2.00 g of 4-chloro-7H-pyrrolo [2,3-d] pyrimidine .92 g was added and the mixture was stirred at 70 ° C. for 18 hours under a nitrogen atmosphere. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. Methylene chloride / ethyl acetate (1/1) was added to the residue, and the solution was passed through a column packed with 100 mL of silica gel and extracted with methylene chloride / ethyl acetate = 1/1 (2 L). The extract was concentrated, and the resulting residue was purified by silica gel chromatography (hexane / ethyl acetate = 70/30 to 35/65) to give 4-chloro-5-fluoro-7H-pyrrolo [2,3- d] 1.30 g of pyrimidine was obtained as a powder (yield 58%).
MS (APCI) m / z; 172/174 [M + H] ^< +>.

(2) A toluene solution of 1.20 g of the compound obtained in (1) above in 215 mL of tetrahydrofuran, 3.52 g of 1-tert-butoxycarbonyl-4-hydroxypiperidine, 7.33 g of triphenylphosphine and diethyl azodicarboxylate 12 .7 mL was added and the mixture was stirred for 1 hour at room temperature under nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (solvent: hexane / ethyl acetate = 80 / 20-60 / 40) to give 1.47 g of the title compound as a powder (yield) 59%).
MS (APCI) m / z; 355/357 [M + H] ^< +>.

Reference example 2
Preparation of 4-amino-3-fluoro-N, N-dimethylbenzamide

(1) To a solution of 4.99 g of 3-fluoro-4-nitrobenzoic acid in 50 mL of methylene chloride was added 2.5 mL of oxalyl chloride and 1 drop of dimethylformamide under ice cooling, and the mixture was stirred at room temperature for 4 hours. The reaction mixture was concentrated under reduced pressure, 100 mL of methylene chloride was added to the obtained residue, and a solution of 1.98 g of dimethylamine hydrochloride and 11.27 mL of triethylamine in 40 mL of methylene chloride was added dropwise under ice cooling, and the mixture was stirred for 1 hour. . Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was washed with saturated brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (solvent; hexane: ethyl acetate = 67/33 to 0/100) to give 3-fluoro-4-nitro-N, N-dimethyl. 4.45 g of benzamide was obtained as a powder (yield 78%).
MS (APCI) m / z; 213 [M + H] ^< +>.

(2) To a mixture of 4.45 g of the compound obtained in the above (1), ethanol 80 mL, tetrahydrofuran 80 mL and water 16 mL, ammonium chloride 4.49 g and iron 4.69 g were added, and the mixture was stirred at 90 ° C. for 1 hour. . The reaction mixture was cooled to room temperature and filtered through celite. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (solvent: hexane / ethyl acetate = 50 / 50-0 / 100) to give 3.71 g of the title compound as a powder (yield) 97%).
MS (APCI) m / z; 183 [M + H] ^< +>.

Reference example 3
Preparation of 4-amino-3-fluoro-N-methylbenzamide

The corresponding starting material compound was treated in the same manner as in Reference Example 2 to give the title compound (yield 26%).
MS (APCI) m / z; 169 [M + H] ^< +>.

Reference example 4
Preparation of 3-fluoro-4- [5-fluoro-7- (piperidin-4-yl) -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -N, N-dimethylbenzamide hydrochloride

To a solution of the compound 482 mg obtained in Example 1 in 4 mL of 1,4-dioxane, 4 mL of 4N hydrochloric acid-dioxane solution was added, and the mixture was stirred at room temperature for 1 hour. After adding 2 mL of methanol to the reaction mixture, the mixture was further stirred for 30 minutes. The reaction mixture was concentrated under reduced pressure, diethyl ether was added to the resulting residue, and the precipitate was collected by filtration to give 540 mg of the title compound as a powder (yield 100%).
MS (APCI) m / z; 401 [M + H] ^< +>.

Reference Example 5
Production of 3-pentyl 4-nitrophenyl carbonate

To a solution of 3-pentanol (210 mg) in methylene chloride (5 mL) were added triethylamine (490 μL) and 4-nitrophenyl chloroformate (472 mg), and the mixture was stirred at room temperature for 14 hours. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was concentrated, and the obtained residue was purified by silica gel chromatography (solvent; hexane / ethyl acetate = 95/5 to 70/30) to give 251 mg of the title compound as a colorless liquid (yield 42% ).
MS (APCI) m / z; 254 [M + H] ^< +>.

Reference Example 6
Production of (2-cyanoprop-2-yl) 4-nitrophenyl carbonate

The corresponding starting material compound was treated in the same manner as in Reference Example 5 to obtain the title compound (yield 42%).

Reference Example 7
Production of (1,3-difluoroprop-2-yl) 4-nitrophenyl carbonate

The corresponding starting material compound was treated in the same manner as in Reference Example 5 to give the title compound (yield 58%).
MS (APCI) m / z; 262 [M + H] ^< +>.

Reference Example 8
Preparation of 4- (5-bromo-4-chloropyrrolo [2,3-d] pyrimidin-7-yl) piperidine-1-carboxylic acid tert-butyl ester

(1) To a solution of 3.00 g of 4-chloro-7H-pyrrolo [2,3-d] pyrimidine in 85 mL of chloroform was added 3.55 g of N-bromosuccinimide, and the mixture was heated to reflux for 1 hour. After cooling the reaction mixture to room temperature, the precipitate is collected by filtration and purified by silica gel chromatography (solvent; hexane / ethyl acetate = 70/30 to 20/80) to give 5-bromo-4-chloro-7H— 3.83 g of pyrrolo [2,3-d] pyrimidine was obtained as a colorless powder (yield 84%).
MS (APCI) m / z; 232/234 [M + H] ^< +>.

(2) By treating 450 mg of the compound obtained in (1) above in the same manner as in Reference Example 1 (2), 684 mg of the title compound was obtained as a colorless powder (yield 85%).
MS (APCI) m / z; 415/417 [M + H] ^< +>.

Reference Example 9
Preparation of 3-fluoro-4-hydroxy-N, N-dimethylbenzamide

To a solution of 1.00 g of 3-fluoro-4-hydroxybenzoic acid, 1.57 g of dimethylamine hydrochloride, 2.68 mL of triethylamine and 1.47 g of N-hydroxybenzotriazole monohydrate in a 20 mL solution of methylene chloride, 1-ethyl-3- 1.83 g of (3-dimethylaminopropyl) carbodiimide hydrochloride was added and the mixture was stirred at room temperature overnight. Dilute aqueous hydrochloric acid was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was washed with saturated aqueous sodium hydrogen carbonate solution and concentrated under reduced pressure, and the resulting residue was purified by silica gel chromatography (solvent; chloroform / methanol = 100/0 to 89/11) to give 515 mg of the title compound as colorless. Obtained as a solid (44% yield).
MS (APCI) m / z; 184 [M + H] ^< +>.

Reference Example 10
Preparation of 2-fluoro-4-hydroxy-N, N-dimethylbenzamide

The corresponding starting material compound was treated in the same manner as in Reference Example 9 to give the title compound (yield 47%).
MS (APCI) m / z; 184 [M + H] ^< +>.

Reference Example 11
Preparation of 3-chloro-4-hydroxy-N, N-dimethylbenzamide

The corresponding starting material compound was treated in the same manner as in Reference Example 9 to give the title compound (yield 47%).
MS (APCI) m / z; 200/202 [M + H] ^< +>.

Reference Example 12
Preparation of 4-amino-3-chloro-N, N-dimethylbenzamide

The corresponding starting material compound was treated in the same manner as in Reference Example 9 to give the title compound (yield 53%).
MS (APCI) m / z; 199/201 [M + H] ^< +>.

Reference Example 13
Preparation of 1- (3-isopropyl-1,2,4-oxadiazol-5-yl) piperidin-4-ol

(1) To a solution of 8.00 g of 4-hydroxypiperidine in 160 mL of ethanol was added 8.38 g of cyanogen bromide and 20.2 g of sodium bicarbonate under ice cooling, and the mixture was stirred at room temperature overnight. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel chromatography (solvent; ethyl acetate) to obtain 9.59 g of 4-hydroxypiperidine-1-carbonitrile as a pale yellow liquid (yield 96%).
MS (APCI) m / z; 127 [M + H] ^< +>.

(2) After adding 9.79 g of N-hydroxyisobutylamidine to a solution of 9.59 g of the compound obtained in (1) above in 350 mL of ethyl acetate, 92 mL of 1.0 M zinc chloride-diethyl ether solution was added dropwise, The mixture was stirred at room temperature for 1 hour. Diethyl ether was added to the reaction mixture, and the precipitated solid was collected by filtration. Ethanol (80 mL) and concentrated hydrochloric acid (40 mL) were added to the obtained solid, and the mixture was stirred at 95 ° C. for 1 hour. The reaction mixture was allowed to cool to room temperature, and the reaction mixture was neutralized with an aqueous sodium hydrogen carbonate solution and extracted with methylene chloride. The organic layer was washed successively with water and saturated brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain 8.76 g of the title compound as a pale yellow liquid (yield 54%).
MS (APCI) m / z; 212 [M + H] ^< +>.

Reference Example 14
Preparation of 1- (3-tert-butyl-1,2,4-oxadiazol-5-yl) piperidin-4-ol

The corresponding starting material compound was treated in the same manner as in Reference Example 13 to give the title compound (yield 26%).
MS (APCI) m / z; 226 [M + H] ^< +>.

Reference Example 15
4-Chloro-5-fluoro-7- [1- (3-isopropyl-1,2,4-oxadiazol-5-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine Manufacturing of

300 mg of 4-chloro-5-fluoro-7H-pyrrolo [2,3-d] pyrimidine (the compound obtained in Reference Example 1 (1)) and 0.92 g of the compound obtained in Reference Example 13 were used in Reference Example 1 ( By treating in the same manner as in 2), 220 mg of the title compound was obtained as a colorless powder (yield 34%).
MS (APCI) m / z; 365/367 [M + H] ⁺

Reference Example 16
4-Chloro-5-fluoro-7- [1- (3-tert-butyl-1,2,4-oxadiazol-5-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d Production of pyrimidine

The title compound was obtained by treating the compound (500 mg) obtained in Reference Example 1 (1) and the compound (1.05 g) obtained in Reference Example 14 in the same manner as in Reference Example 1 (2). Rate 55%).
MS (APCI) m / z; 379/381 [M + H] ^< +>.

Reference Example 17
Preparation of 4-chloro-5-fluoro-7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine

(1) To a solution of 710 mg of 4-hydroxypiperidine in 5 mL of ethanol was added 425 μL of 5-ethyl-2-chloropyrimidine and the mixture was stirred at 80 ° C. overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (solvent: chloroform / methanol = 100/0 to 90/10) to give 1- (5-ethylpyrimidin-2-yl) piperidine- 699 mg of 4-ol was obtained as a colorless solid (yield 96%).
MS (APCI) m / z; 208 [M + H] ^< +>.

(2) The compound (903 mg) obtained in Reference Example 1 (1) and the compound (2.18 g) obtained in (1) above were treated in the same manner as in Reference Example 1 (2) to give the title compound ( 1.17 g) was obtained (62% yield).
MS (APCI) m / z; 361/363 [M + H] ^< +>.

Reference Example 18
Preparation of 4-chloro-5-fluoro-7- [5-isopropyl- (1,2,4-oxadiazol-3-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine

(1) 4-hydroxypiperidine-1-carbonitrile (compound obtained in Reference Example 13 (1)) 2.00 g of methylene chloride in 40 mL solution under ice-cooling, diisopropylethylamine 5.5 mL and methoxymethyl chloride 1.80 mL And the mixture was stirred at room temperature for 19 hours. After further adding 2.75 mL diisopropylethylamine and 0.60 mL methoxymethyl chloride to the reaction mixture, the mixture was stirred for 4.5 hours. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was washed with saturated brine, dried over magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography (solvent; hexane / ethyl acetate = 70/30 to 40/60) to obtain 2.31 g of 4-methoxymethoxypiperidine-1-carbonitrile as a colorless liquid ( Yield 86%).
MS (APCI) m / z; 171 [M + H] ^< +>.

(2) To a solution of 2.31 g of the compound obtained in (1) above in 2 mL of 2-propanol was added 1.79 g of 50% aqueous hydroxylamine solution in 3 mL of 2-propanol, and the mixture was stirred at 90 ° C. for 5 hours. The reaction mixture was allowed to cool to room temperature, diluted with ethyl acetate, dried over magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain 2.93 g of N-hydroxy-4-methoxymethoxypiperidine-1-carboxamidine as a colorless liquid (yield 100%).
MS (APCI) m / z; 204 [M + H] ^< +>.

(3) To 2.93 g of the compound obtained in (2) above and 1.89 mL of triethylamine in 30 mL of toluene was added dropwise a solution of isobutyryl chloride 1.42 mL in 10 mL of toluene, and the mixture was added at 130 ° C. Stir for hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (solvent; hexane / ethyl acetate = 95/5 to 80/20) to give 1- (5-isopropyl-1,2,4- 1.86 g of oxadiazol-3-yl) -4-methoxymethoxypiperidine was obtained as a colorless liquid (yield 54%).
MS (APCI) m / z; 256 [M + H] ^< +>.

(4) To a solution of 1.86 g of the compound obtained in (3) above in 10 mL of 1,4-dioxane, 5 mL of 4N hydrochloric acid-dioxane was added, and the mixture was stirred at room temperature for 3 hours. 4N Hydrochloric acid-dioxane (1 mL) was further added to the reaction mixture, and the mixture was stirred for 1 hr. The reaction mixture was concentrated under reduced pressure, saturated aqueous sodium hydrogen carbonate solution was added to the resulting residue, and the mixture was extracted with chloroform. The organic layer is dried over magnesium sulfate and filtered, and the filtrate is concentrated under reduced pressure to give 1.60 g of 1- (5-isopropyl-1,2,4-oxadiazol-3-yl) piperidin-4-ol. Was obtained as a colorless liquid (yield 100%).
MS (APCI) m / z; 212 [M + H] ^< +>.

(5) By treating the compound (500 mg) obtained in Reference Example 1 (1) and the compound (1.60 g) obtained in (4) above in the same manner as in Reference Example 1 (2), the title compound ( 505 mg) (yield 48%).
MS (APCI) m / z; 365/367 [M + H] ^< +>.

Reference Example 19
Preparation of 4-chloro-5-fluoro-7- [1- (5-methylpyridin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine

(1) To a solution of 1.42 g of 4-hydroxypiperidine in 12 mL of N-methylpyrrolidone, 1.20 g of 2-bromo-5-methylpyridine and 3.67 mL of diisopropylethylamine were added, and the mixture was added to a microwave reactor (Initiator, Biotage). The mixture was stirred at 200 ° C. for 1 hour. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (solvent: chloroform / methanol = 100/0 to 93/7) to give 1- (5-methylpyridin-2-yl) piperidine- 0.81 g of 4-ol was obtained as a light brown solid (yield 60%).
MS (APCI) m / z; 193 [M + H] ^< +>.

(2) The title compound (363 mg) was obtained by treating the compound (250 mg) obtained in Reference Example 1 (1) and the compound (476 mg) obtained in (2) above in the same manner as in Reference Example 1 (2). (Yield 72%).
MS (APCI) m / z; 346/348 [M + H] ^< +>.

Reference Example 20
Preparation of 4-chloro-5-fluoro-7- [1- (5-ethyl-1,3,4-thiadiazol-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine

(1) To a solution of 1.00 g of 2-amino-5-ethyl-1,3,4-thiadiazole in 20 mL of acetonitrile / 20 mL of dimethylacetamide, 2.07 g of cupric bromide and 1.40 mL of n-amyl nitrite were added, The mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure, saturated aqueous ammonium chloride solution was added to the residue, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel chromatography (solvent; hexane / ethyl acetate = 95/5 to 80/20) to give 2-bromo-5-ethyl-1,3,4. -0.75 g of thiadiazole was obtained as a colorless liquid (yield 50%).
MS (APCI) m / z; 193/195 [M + H] ⁺ .

(2) 671 mg of 4-hydroxypiperidine was added to a solution of 640 mg of the compound obtained in (1) above in 5 mL of ethanol, and the mixture was stirred at 140 ° C. for 1 hour in a microwave reactor (Initiator, manufactured by Biotage). . The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (solvent: chloroform / methanol = 100/0 to 93/7) to give 1- (5-ethyl-1,3,4-thiadiazole). -2-yl) piperidin-4-ol 707 mg was obtained as a colorless liquid (yield 100%).
MS (APCI) m / z; 214 [M + H] ^< +>.

(3) The title compound (86 mg) was obtained by treating the compound (200 mg) obtained in Reference Example 1 (1) and the compound (373 mg) obtained in (2) above in the same manner as in Reference Example 1 (2). (Yield 20%).
MS (APCI) m / z; 367/369 [M + H] ^< +>.

Reference Example 21
Production of 2-chloro-5-ethoxypyrimidine

To a solution of 1.00 g of 2-chloro-5-hydroxypyrimidine in 15 mL of dimethylformamide were added 1.59 g of potassium carbonate and 1.84 mL of ethyl iodide, and the mixture was stirred at 50 ° C. for 1 hour. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (solvent; hexane / ethyl acetate = 99/1 to 78/22) to give 1.07 g of the title compound as a colorless solid (yield). 88%).
MS (APCI) m / z; 159/161 [M + H] ^< +>.

Reference Example 22
Production of 2-chloro-5-isopropyloxypyrimidine

The corresponding starting material compound was treated in the same manner as in Reference Example 21 to give the title compound (yield 89%).
MS (APCI) m / z; 173/175 [M + H] ^< +>.

Reference Example 23
Preparation of 4-amino-3-fluorobenzoic acid tert-butyl ester

(1) To a solution of 2.00 g of 3-fluoro-4-nitrobenzoic acid in 32 mL of methylene chloride was added 4.2 mL of tert-butanol, 198 mg of 4-dimethylaminopyridine and 1-ethyl-3- (3-dimethyl) under ice cooling. 2.47 g of aminopropyl) carbodiimide hydrochloride was added and the mixture was stirred at room temperature for 16 hours. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was distilled off under reduced pressure, and the resulting residue was purified by silica gel chromatography (solvent; hexane / ethyl acetate = 99/1 to 92/8) to give tert-butyl 3-fluoro-4-nitrobenzoate. 1.94 g of ester was obtained as a pale yellow powder (yield 75%).

(2) By treating 1.74 g of the compound obtained in the above (1) in the same manner as in Reference Example 2 (2), 1.42 g of the title compound was obtained as a colorless powder (yield 88%).
MS (APCI) m / z; 212 [M + H] ^< +>.

Reference Example 24
4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluorobenzoic acid Production of acid dihydrochloride

(1) By treating 400 mg of the compound obtained in Reference Example 17 and 4-amino-3-fluorobenzoic acid tert-butyl ester (258 mg) in the same manner as in Example 1, 4- [7- [1- ( 286 mg of 5-ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluorobenzoic acid tert-butyl ester as colorless powder (Yield 48%).
MS (APCI) m / z; 536 [M + H] ^< +>.

(2) To a solution of 300 mg of the compound obtained in (1) above in 4 mL of methylene chloride was added 3 mL of 4N hydrochloric acid-dioxane, and the mixture was stirred at room temperature for 18 hours. 4N Hydrochloric acid-dioxane (2 mL) was further added to the reaction mixture, and the mixture was stirred for 7 hr. The reaction mixture was concentrated under reduced pressure to give 340 mg of the title compound as a crude product.
MS (APCI) m / z; 480 [M + H] ^< +>.

Reference Example 25
Preparation of 4- (4-chloro-3-cyano-2-formimidoylaminopyrrol-1-yl) piperidine-1-carboxylic acid isopropyl ester

(1) To a solution of 4-piperidone hydrochloride monohydrate (5.00 g) in methylene chloride (100 mL) was added dropwise triethylamine (11.3 mL) and isopropyl chlorocarbonate (6.1 mL) under ice cooling, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water and the mixture was extracted with chloroform. The extract was dried over magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (solvent: ethyl acetate / hexane = 50/50 → 33/67) to obtain 3.05 g of 4-oxopiperidine-1-carboxylic acid isopropyl ester as a liquid. (Yield 50%).
MS (APCI) m / z; 186 [M + H] ^< +>.

(2) To a solution of 3.05 g of the compound obtained in (1) above in 200 mL of methylene chloride, 2.74 g of aminoacetaldehyde diethyl acetal and 1.2 mL of acetic acid were added at room temperature, and the mixture was stirred at the same temperature for 1 hour. To the reaction mixture was added 4.36 g of sodium triacetoxyborohydride and the mixture was stirred at room temperature overnight. The reaction mixture was poured into saturated aqueous sodium hydrogen carbonate solution and the mixture was extracted with chloroform. The extract was dried over magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure to obtain 6.35 g of 4- (2,2-diethoxyethylamino) piperidine-1-carboxylic acid isopropyl ester as a liquid.
MS (APCI) m / z; 303 [M + H] ^< +>.

(3) To a solution of 6.35 g of the compound obtained in (2) above in 150 mL of methylene chloride were added 2.17 g of malononitrile and 6.26 g of p-toluenesulfonic acid monohydrate at room temperature, and the mixture was stirred overnight at room temperature. The reaction solution was poured into a saturated aqueous sodium hydrogen carbonate solution and extracted with chloroform. The extract was dried over magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (solvent; ethyl acetate / hexane = 50/50 → 67/33) to give 4- (2-amino-3-cyanopyrrol-1-yl) piperidine-1 -2.30 g of carboxylic acid isopropyl ester was obtained as a solid (total yield of steps (2) to (3): 50%).
MS (APCI) m / z; 277 [M + H] ^< +>.

(4) To a solution of 0.50 g of the compound obtained in (3) above in 3 mL of acetonitrile, 0.80 g of triethyl orthoformate and 0.11 g of acetic acid were added at room temperature, and the mixture was stirred at 80 ° C. for 2 hours. The reaction mixture is cooled to room temperature and concentrated under reduced pressure. The resulting residue is purified by silica gel column chromatography (solvent; ethyl acetate / hexane = 50/50 → 67/33) to give 4- (3-cyano- 641 mg of 2-ethoxymethyleneaminopyrrol-1-yl) piperidine-1-carboxylic acid isopropyl ester was obtained as an oil.
MS (APCI) m / z; 333 [M + H] ^< +>.

(5) To a solution of 641 mg of the compound obtained in (4) above in 2.5 mL of methanol was added 7N ammonia-methanol solution at room temperature, and the mixture was stirred at the same temperature overnight. The precipitate was collected by filtration and dried to obtain 220 mg of 4- (3-cyano-2-formimidoylaminopyrrol-1-yl) piperidine-1-carboxylic acid isopropyl ester as a solid (step (4)). (Total yield of (5): 38%).
MS (APCI) m / z; 304 [M + H] ^< +>.

(6) To a solution of 303 mg of the compound obtained in (5) above in 10 mL of acetonitrile, 161 mg of N-chlorosuccinimide was added at room temperature, and the mixture was stirred overnight. The reaction mixture was poured into saturated aqueous sodium bicarbonate solution and the mixture was extracted three times with ethyl acetate. The organic layer was dried over magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (solvent; ethyl acetate / hexane = 35/65 → 55/45) to give 197 mg of the title compound as a powder (yield 58%).
MS (APCI) m / z; 308 [M + H] ^< +>.

Reference Example 26
Production of 5-ethyl-2-fluoropyridine

To a solution of 5.00 g of 5-bromo-2-fluoropyridine in 75 mL of dimethylformamide was added 43 mL of 1.0 M triethylborane-tetrahydrofuran solution, 15.70 g of potassium carbonate and 1.64 g of tetrakistriphenylphosphine palladium, and the mixture was added under a nitrogen atmosphere. , And stirred at 85 ° C. for 4 hours. Water was added to the reaction mixture, followed by extraction with hexane. The organic layer was washed successively with water and saturated brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (solvent; hexane / methylene chloride = 1/1) to give 1.89 g of the title compound as a pale yellow liquid (yield 53%). ).
MS (APCI) m / z; 126 [M + H] ^< +>.

Reference Example 27
Preparation of 4-chloro-5-fluoro-7- [1- (5-ethylpyridin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine

The title compound was obtained by treating the compound obtained in Reference Example 26 in the same manner as in Reference Example 19.
MS (APCI) m / z; 360/362 [M + H] ^< +>.

Reference Example 28
Preparation of 1- (3-propyl-1,2,4-oxadiazol-5-yl) piperidin-4-ol

The corresponding starting material compound was treated in the same manner as in Reference Example 13 to give the title compound (yield 47%).
MS (APCI) m / z; 212 [M + H] ^< +>.

Reference Example 29
4-Chloro-5-fluoro-7- [1- (3-propyl-1,2,4-oxadiazol-5-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine Manufacturing of

The title compound was obtained by treating the compound obtained in Reference Example 1 (1) (640 mg) and the compound obtained in Reference Example 28 (1.57 g) in the same manner as in Reference Example 1 (2). 44%).
MS (APCI) m / z; 365/367 [M + H] ^< +>.

Reference Example 30
Preparation of 1- (5-isopropenylpyrimidin-2-yl) piperidin-4-ol

(1) By treating 5.8 g of 5-bromo-2-chloropyrimidine in the same manner as in Reference Example 17 (1), 7.8 g of 1- (5-bromopyrimidin-2-yl) piperidin-4-ol was obtained. Obtained as a powder (yield 100%).
MS (APCI) m / z; 258/260 [M + H] ^< +>.

(2) In a mixed solution of 160 g of 1,4-dioxane of 4 g of the compound obtained in (1) above and 40 mL of water, 10.1 g of cesium carbonate, 3.5 mL of isopropenylboronic acid pinacol ester and 895 mg of tetrakistriphenylphosphine palladium And the mixture was stirred at 80 ° C. for 5 hours. The reaction mixture was poured into water and the mixture was extracted three times with ethyl acetate. The organic layer is dried over magnesium sulfate and concentrated. The obtained residue is purified by silica gel chromatography (solvent; hexane / ethyl acetate = 70/30 to 10/90) to give 3.4 g of the title compound as a powder. Obtained (yield 100%).
MS (APCI) m / z; 220 [M + H] ^< +>.

Reference Example 31
Preparation of 4-chloro-5-fluoro-7- [1- (5-isopropylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine

(1) A mixture of the compound obtained in Reference Example 30 (1.5 g), 10% palladium carbon and methanol (70 mL) was stirred at room temperature for 20 hours in a nitrogen atmosphere. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain 1.6 g of 1- (5-isopropylpyrimidin-2-yl) piperidin-4-ol as a crude product.

(2) By treating 1.6 g of the compound obtained in (1) above in the same manner as in Reference Example 1 (2), 1.24 g of the title compound was obtained as a powder (yield 48%).
MS (APCI) m / z; 375/377 [M + H] ^< +>.

Reference Example 32
Preparation of 1- (5-cyclopropylpyrimidin-2-yl) piperidin-4-ol

By treating 2 g of the compound obtained in Reference Example 30 (1) and 1.56 g of cyclopropylboronic acid pinacol ester in the same manner as in Reference Example 30 (2), 377 mg of the title compound was obtained (yield 22%).
MS (APCI) m / z; 220 [M + H] ^< +>.

Reference Example 33
Preparation of 4-chloro-7- [1- (5-cyclopropylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidine

The compound (570 mg) obtained in Reference Example 1 (1) and the compound (800 mg) obtained in Reference Example 32 were treated in the same manner as in Reference Example 1 (2) to obtain 770 mg of the title compound (yield) 57%).
MS (APCI) m / z; 375/377 [M + H] ^< +>.

Reference Example 34
Production of 2-fluoro-4-methylthiophenylamine

(1) To a solution of 25.0 g of 4-bromo-2-fluorobenzoic acid in 1.25 L of tetrahydrofuran was added dropwise 68.5 mL of 1.0 M dibutyl magnesium-heptane solution at 0 ° C., and the mixture was stirred for 30 minutes. To the reaction mixture, 52.2 mL of a 2.62 M butyllithium-hexane solution was added dropwise at −78 ° C., and the mixture was stirred for 1 hour. After 13.4 mL of dimethyl disulfide was added dropwise to the reaction mixture, the mixture was stirred at room temperature for 2 hours. The reaction mixture was acidified with 2N aqueous hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, hexane was added to the resulting residue, and the mixture was filtered to obtain 15.09 g of 2-fluoro-4-methylthiobenzoic acid as a pale yellow liquid (yield 71% ).
MS (APCI) m / z; 185 [M−H] ⁻ .

(2) To a solution of 2.20 g of the compound obtained in (1) above in 22 mL of tert-butanol was added 1.76 mL of triethylamine and 2.69 mL of diphenylphosphoryl azide, and the mixture was stirred at 60 ° C. for 1 hour, and then further 100 ° For 2 hours. The reaction mixture was cooled to room temperature, water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel chromatography (solvent; hexane / ethyl acetate = 95/5 to 90/10) to give (2-fluoro-4-methylthiophenyl) carbamic acid tert -1.22 g of butyl ester was obtained as a powder (yield 40%).
MS (APCI) m / z; 258 [M + H] ^< +>.

(3) To a solution of 579 mg of the compound obtained in (2) above in 10 mL of methylene chloride was added 2.8 mL of 4N hydrochloric acid-dioxane, and the mixture was stirred at room temperature for 15 hours. The reaction mixture was concentrated under reduced pressure, saturated aqueous sodium hydrogen carbonate solution was added to the residue, and the mixture was extracted with chloroform. The organic layer is dried over magnesium sulfate and filtered. The filtrate is concentrated under reduced pressure, and the resulting residue is purified by silica gel chromatography (solvent; hexane / ethyl acetate = 95/5 to 75/25) to give the title. 315 mg of compound was obtained (89% yield).
MS (APCI) m / z; 158 [M + H] ^< +>.

Reference Example 35
Preparation of 4-chloro-7- [1- (5-chloropyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidine

The corresponding starting material compound was treated in the same manner as in Reference Example 17 to give the title compound (yield 68%).
MS (APCI) m / z; 367/369 [M + H] ^< +>.

Reference Example 36
Preparation of (4-amino-3-fluoro-phenyl) (1,1-dioxo-1λ ⁶ -thiazolidin-3-yl) methanone

(1) 535 mg of thiazoline, 919 mg of N-hydroxybenzotriazole monohydrate (HOBt · H ₂ O) and 1-ethyl-3- (3-dimethyl) in a solution of 926 mg of 3-fluoro-4-nitrobenzoic acid in 25 mL of dichloromethane Aminopropyl) carbodiimide hydrochloride (WSC.HCl) 1.15 g was added and the mixture was stirred at room temperature for 20 hours. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was concentrated, and the resulting residue was purified by silica gel column chromatography (solvent: hexane / ethyl acetate = 70/30 → 50/50) to give (3-fluoro-4-nitrophenyl) (thiazolidine- 1.07 g of 3-yl) methanone was obtained (84% yield).
MS (APCI) m / z; 257 [M + H] ^< +>.

(2) 2.69 g of m-chloroperbenzoic acid was added to a solution of 1 g of the compound obtained in (1) above in 40 mL of dichloromethane, and the mixture was stirred at room temperature for 19 hours. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with chloroform / methanol = 9/1. The organic layer is concentrated and the resulting residue is triturated with dichloromethane / diethyl ether to give (1,1-dioxo-1λ ⁶ -thiazolidin-3-yl) (3-fluoro-4-nitrophenyl) methanone. 1.03 g was obtained (yield 92%).
MS (APCI) m / z; 288 [M + H] ⁻ .

(3) 742 mg of ammonium chloride and 775 mg of iron were added to a mixture of 1 g of the compound obtained in (2) above, 10 mL of ethanol, 10 mL of tetrahydrofuran and 2 mL of water, and the mixture was stirred at 90 ° C. for 17 hours. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was concentrated, and the obtained residue was purified by silica gel chromatography (solvent; hexane / ethyl acetate = 70/30 to 20/80) to give 780 mg of the title compound (yield 87%).
MS (APCI) m / z; 259 [M + H] ^< +>.

Reference Example 37
Preparation of 4- (4-chloro-5-fluoropyrrolo [2,3-d] pyrimidin-7-yl) piperidine-1-carboxylic acid isopropyl ester

The corresponding starting material compound was treated in the same manner as in Reference Example 1 (2) to give the title compound (yield 45%).
MS (APCI) m / z; 341/343 [M + H] ^< +>.

Reference Example 38
Preparation of (R) -N- (1,1-dioxotetrahydro-1λ ⁶ -thiophen-3-yl) amine hydrochloride

(1) A mixture of 4.95 g of (R) -methioninol, 8.3 mL of benzonitrile and 250 mg of zinc bromide was stirred at 120 ° C. for 90 hours under a nitrogen atmosphere. The reaction solution was cooled to room temperature and then filtered. The filtrate was washed successively with water and brine, dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (solvent; hexane / ethyl acetate = 5/1 to 3/1) to give (R) -4- (2-methylthioethyl) -2-Phenyl-4,5-dihydrooxazole (3.94 g, yield 48.6%) was obtained as a colorless oil.
MS (APCI) m / z; 222 [M + H] ^< +>.

(2) To a solution of 3.94 g of the compound obtained in (1) above in 65 mL of acetic acid was added 7.7 mL of concentrated hydrochloric acid, and the mixture was heated to reflux overnight. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. To the residue, 50 mL of an aqueous sodium hydroxide solution and 100 mL of chloroform were added and stirred, and then the organic layer was separated. Magnesium sulfate and silica gel were added thereto and stirred, followed by filtration. The filtrate was concentrated under reduced pressure, and the resulting residue was washed with isopropyl ether and dried to give (R) -N- (tetrahydrothiophen-3-yl) benzamide (2.80 g, yield 76%) colorless. Obtained as a solid.
MS (APCI) m / z; 208 [M + H] ^< +>.

(3) To 70 mL of methylene chloride of 3.59 g of the compound obtained in (2) above, 10 g of 3-chloroperbenzoic acid (75%) was gradually added under ice cooling, and the mixture was stirred at room temperature overnight. To the reaction mixture, 35 mL of water, 3.5 g of sodium sulfite and 100 mL of saturated aqueous sodium hydrogen carbonate solution were added, and the mixture was stirred for 30 minutes. The reaction mixture was extracted with chloroform, and the organic layer was washed with an aqueous sodium hydrogen carbonate solution, dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was washed with ethyl acetate to give (R) -N- (1,1-dioxotetrahydro-1λ ⁶ -thiophen-3-yl) benzamide (3.5 g, Yield 85%) was obtained as a colorless solid.
MS (APCI) m / z; 240 [M + H] ^< +>.

(4) To a solution of 3.51 g of the compound obtained in (3) above in 13 mL of ethanol was added 52 mL of 6N aqueous hydrochloric acid, and the mixture was heated to reflux for 1 day. The reaction mixture was cooled to room temperature, and the aqueous layer was washed with ethyl acetate and concentrated under reduced pressure. The precipitate is washed with ethanol / diethyl ether, filtered, and further washed with diethyl ether to give (R) -N- (1,1-dioxotetrahydro-1λ ⁶ -thiophen-3-yl) amine hydrochloride The salt (2.52 g, 100% yield) was obtained as a colorless solid.
MS (APCI) m / z; 136 [M + H] ^< +>.

Reference Example 39
Preparation of (S) -N- (1,1-dioxotetrahydro-1λ ⁶ -thiophen-3-yl) amine hydrochloride

(S) -Methioninol (4.83 g) was treated in the same manner as in Reference Example 38 to give the title compound (3.86 g) as a colorless solid.
MS (APCI) m / z; 136 [M + H] ^< +>.

Reference Example 40
Preparation of 4,5-dichloro-7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine

The corresponding starting material compound was treated in the same manner as in Reference Example 1 (2) to give the title compound (yield 62%).
MS (APCI) m / z; 377/379 [M + H] ^< +>.

Reference Example 41
4- [5-Chloro-7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluorobenzoic acid Production of acid dihydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield 35%).
MS (APCI) m / z; 552/554 [M + H] ^< +>.

Reference Example 42
3-Fluoro-4- [5-fluoro-7- [1- (5-isopropyl- [1,2,4] oxadiazol-3-yl) piperidin-4-yl] -7H-pyrrolo [2,3 -D] Preparation of pyrimidin-4-ylamino] benzoic acid hydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield 35%).
MS (APCI) m / z; 484 [M + H] ^< +>.

Reference Example 43
3-Fluoro-4- [5-fluoro-7- [1- (5-propylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] benzoate Production of acid dihydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield 60%).
MS (APCI) m / z; 494 [M + H] ^< +>.

Reference Example 44
3-Fluoro-4- [5-fluoro-7- [1- (5-isopropylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] benzoate Production of acid dihydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield 64%).
MS (APCI) m / z; 494 [M + H] ^< +>.

Reference Example 45
4- [7- [1- (5-Cyclopropylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Production of benzoic acid dihydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield 54%).
MS (APCI) m / z; 492 [M + H] ^< +>.

Reference Example 46
4- [7- [1- (5-Chloropyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluorobenzoic acid Production of acid dihydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield 32%).
MS (APCI) m / z; 486/488 [M + H] ^< +>.

Reference Example 47
3-Fluoro-4- [5-fluoro-7- [1- (5-fluoropyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] benzoate Production of acid dihydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield 49%).
MS (APCI) m / z; 470 [M + H] ^< +>.

Reference Example 48
3-Fluoro-4- [5-fluoro-7- [1- (3-isopropyl- [1,2,4] oxadiazol-5-yl) piperidin-4-yl] -7H-pyrrolo [2,3 -D] Preparation of pyrimidin-4-ylamino] benzoic acid hydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield 91%).
MS (APCI) m / z; 484 [M + H] ^< +>.

Reference Example 49
Preparation of 4- [4- (4-carboxy-2-fluorophenylamino) -5-fluoropyrrolo [2,3-d] pyrimidin-7-yl] piperidine-1-carboxylic acid isopropyl ester hydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield 80%).
MS (APCI) m / z; 460 [M + H] ^< +>.

Reference Example 50
3-Fluoro-4- [5-fluoro-7- [1- (5-isopropoxypyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] Production of benzoic acid dihydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield 53%).
MS (APCI) m / z; 510 [M + H] ^< +>.

Reference Example 51
3-Fluoro-4- [5-fluoro-7- [1- (3-propyl- [1,2,4] oxadiazol-5-yl) piperidin-4-yl] -7H-pyrrolo [2,3 -D] Preparation of pyrimidin-4-ylamino] benzoic acid hydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield 34%).
MS (APCI) m / z; 484 [M + H] ^< +>.

Reference Example 52
Preparation of ((2S, 4R) -4-fluoropyrrolidin-2-yl) methanol hydrochloride

(1) 2.45 g of N-tert-butoxycarbonyl-cis-4-hydroxy-L-proline methyl ester was added to a solution of 3.22 g of N, N-diethylaminosulfur trifluoride (DAST) in 30 mL of methylene chloride at −60 ° C. After dropwise addition of methylene chloride solution, the mixture was stirred at room temperature for 3 days. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (solvent; hexane / ethyl acetate = 90/10 to 65/35) to give N-tert-butoxycarbonyl-trans-4-fluoro- 2.31 g of L-proline methyl ester was obtained as a pale yellow liquid (yield 93%).
MS (APCI) m / z; 248 [M + H] ^< +>.

(2) To a solution of calcium chloride (888 mg) in tetrahydrofuran (30 mL) was added sodium borohydride (605 mg), and the mixture was stirred at room temperature for 1 hour. To the mixture was added dropwise a solution of 989 mg of the compound obtained in (1) above in 6 mL of tetrahydrofuran, and the mixture was stirred overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The resulting residue is purified by silica gel chromatography (solvent; hexane / ethyl acetate = 85/15 to 40/60) to give (2S, 4R) -4-fluoro-2-hydroxymethylpyrrolidine-1-carboxylic acid 959 mg of tert-butyl ester was obtained as a colorless liquid (yield 100%).
MS (APCI) m / z; 164 [M + 2H-Bu] ⁺ .

(3) To a solution of 832 mg of the compound obtained in (2) above in 4 mL of 1,4-dioxane, 9 mL of 4N hydrochloric acid-dioxane solution was added, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated, diethyl ether was added to the residue, and the precipitate was collected by filtration to give 486 mg of the title compound (yield 82%).
MS (APCI) m / z; 120 [M + H] ^< +>.

Reference Example 53
Preparation of 4-chloro-5-fluoro-7- [1- (5-propylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine

The corresponding starting material compound was treated in the same manner as in Reference Example 1 (2) to give the title compound (yield 60%).
MS (APCI) m / z; 375/377 [M + H] ^< +>.

Reference Example 54
Preparation of 4-chloro-5-fluoro-7- [1- (5-fluoropyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine

The corresponding starting material compound was treated in the same manner as in Reference Example 17 to give the title compound (yield 41%).
MS (APCI) m / z; 351/353 [M + H] ^< +>.

Reference Example 55
[(R) -1- [4- [5-Chloro-7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine-4 Preparation of -ylamino] -3-fluorobenzoyl] pyrrolidin-3-yl] carbamic acid tert-butyl ester

The corresponding starting material compound was treated in the same manner as in Example 5 to obtain the title compound (yield 47%).
MS (APCI) m / z; 664/666 [M + H] ^< +>.

Reference Example 56
[2- [4- [5-Chloro-7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- Preparation of 3-fluorobenzoylamino] ethyl] carbamic acid tert-butyl ester

The corresponding starting material compound was treated in the same manner as in Example 5 to obtain the title compound (yield 51%).
MS (APCI) m / z; 638/640 [M + H] ^< +>.

Reference Example 57
[2- [3-Fluoro-4- [5-fluoro-7- [1- (5-propylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine-4 -Ilamino] -benzoylamino] ethyl] carbamic acid tert-butyl ester

The corresponding starting material compound was treated in the same manner as in Example 5 to obtain the title compound (yield 85%).
MS (APCI) m / z; 636 [M + H] ^< +>.

Reference Example 58
Preparation of 2-fluoro-4- (5-methyl- [1,3,4] oxadiazol-2-yl) -phenol

To a solution of 170 mg of 3-fluoro-4-hydroxy-benzoic acid methyl ester in 5 mL of methanol was added 620 μL of hydrazine-hydrate (80%), and the mixture was heated to reflux for 21 hours. 3 mL of triethyl orthoacetate was added to the residue obtained by concentrating the reaction mixture under reduced pressure, and the mixture was heated to reflux for 19 hours. The residue obtained by concentrating the reaction mixture under reduced pressure was purified by silica gel column chromatography (hexane: ethyl acetate = 90: 10-0: 100) to give 116 mg of the title compound (yield 60%).
MS (APCI) m / z; 195 [M + H] ^< +>.

Reference Example 59
Production of 2-chloro-5-difluoromethoxypyrimidine

To a solution of 4.13 g of 2-chloro-5-hydroxypyrimidine in 40 mL of DMF, 12.83 g of ethyl 2-bromo-2,2-difluoroacetate and 20.59 g of cesium carbonate were added and reacted at 80 ° C. overnight. After cooling to room temperature, it was poured into water and extracted three times with ethyl acetate. The obtained organic layer was dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane: ethyl acetate = 80: 20-60: 40) to give 2.16 g of the title compound as a colorless liquid (yield 38%).

Reference Example 60
Preparation of 1- (5-difluoromethoxypyrimidin-2-yl) piperidin-4-ol

The corresponding starting material compound was treated in the same manner as in Reference Example 17 (1) to give the title compound (yield 100%).
MS (APCI) m / z: 246 [M + H] ^< +>.

Reference Example 61
Preparation of 4-chloro-7- [1- (5-difluoromethoxypyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidine

The corresponding starting material compound was treated in the same manner as in Reference Example 1 (2) to give the title compound (yield 63%).
MS (APCI) m / z: 399/401 [M + H] ^< +>.

Reference Example 62
4- [7- [1- (5-Ditrifluoromethoxypyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3- Production of fluorobenzoic acid dihydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield 62%).
MS (APCI) m / z; 518 [M + H] ^< +>.

Reference Example 63
(3R, 5R) -5-Hydroxymethylpyrrolidin-3-ol hydrochloride

(1) (2R, 4R) -4-Hydroxypyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 1220 mg of tetrahydrofuran 10 mL of lithium borohydride (2M / tetrahydrofuran) 10 mL under ice-cooling Was added. The mixture was stirred at room temperature overnight. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer is concentrated, and the obtained residue is purified by silica gel column chromatography (solvent: hexane / ethyl acetate = 50/50 → 20/80) to give (2R, 4R) -4-hydroxy-2-hydroxy. 1000 mg of methyl-1-carboxylic acid tert-butyl ester was obtained (yield 92%).
MS (APCI) m / z; 218 [M + H] ^< +>.

(2) To a solution of 900 mg of the compound obtained in (1) above in 10 mL of dichloromethane was added 10.4 mL of 4N hydrochloric acid-dioxane solution, and the mixture was stirred at room temperature for 20 hours. Thereafter, the reaction solution was concentrated to obtain 622 mg of the title compound (yield 98%).
MS (APCI) m / z; 118 [M + H] ^< +>.

Reference Example 64
(3S, 5S) -5-Hydroxymethylpyrrolidin-3-ol hydrochloride

The corresponding starting material compound (1220 mg) was treated in the same manner as in Reference Example 63 to give the title compound (748 mg, yield 98%).
MS (APCI) m / z; 118 [M + H] ^< +>.

Reference Example 65
(3S, 5R) -5-Hydroxymethylpyrrolidin-3-ol hydrochloride

(1) (2R, 4R) -4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 1.22 g of 2-methyl ester, 1.7 g of benzoic acid, 672 mg of triphenylphosphine in 20 mL of tetrahydrofuran Under cooling, 2.95 mL of a toluene solution of diethyl azodicarboxylate was added. The mixture was warmed to room temperature and stirred for 18 hours. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (solvent; hexane / ethyl acetate = 95/5 to 70/30) to give (2R, 4S) -4-benzoyloxypyrrolidine-1 , 2-dicarboxylic acid 1-tert-butyl ester 1.75 g of 2-methyl ester was obtained (yield: 100%).
MS (APCI) m / z; 350 [M + H] ^< +>.

(2) 15 mL of lithium borohydride (2M / tetrahydrofuran) was added to a solution of 1.74 g of the compound obtained in (1) above in 15 mL of tetrahydrofuran under ice cooling, and the mixture was stirred at room temperature for 18 hours. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer is concentrated, and the obtained residue is purified by silica gel column chromatography (solvent: hexane / ethyl acetate = 50/50 → 20/80) to give (2R, 4S) -4-hydroxy-2-hydroxy. 1.08 g of methyl-1-carboxylic acid tert-butyl ester was obtained (yield 98%).

(3) To a solution of 1.08 g of the compound obtained in (2) above in 12.5 mL of dichloromethane was added 12.5 mL of 4N hydrochloric acid-dioxane solution, and the mixture was stirred overnight at room temperature. Thereafter, the reaction solution was concentrated to obtain 748 mg of the title compound (yield 100%).
MS (APCI) m / z; 118 [M + H] ^< +>.

Reference Example 66
(2S, 4R) -4-Hydroxypyrrolidine-2-carboxamide hydrochloride

(1) To a solution of 1.0 g of (2S, 4R) -4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester in 17 mL of tetrahydrofuran was added 663 μL of triethylamine and 455 μL of ethyl chloroformate under ice cooling, and the mixture Was stirred for 30 minutes. To the reaction mixture, 28% aqueous ammonia was added at the same temperature, and the mixture was stirred at room temperature for 18 hours. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was concentrated, and the resulting residue was purified by silica gel column chromatography (solvent: chloroform / methanol = 95/5 → 80/20) to give (2S, 4R) -2-carbamoyl-4-hydroxypyrrolidine. 216 mg of -1-carboxylic acid tert-butyl ester was obtained (22% yield).

(2) 2.35 mL of 4N hydrochloric acid-dioxane solution was added to a mixed solution of 216 mg of the compound obtained in (1) above and 2.5 mL of dichloromethane-2.5 mL of tetrahydrofuran, and the mixture was stirred at room temperature for 19 hours. The reaction mixture was concentrated to give 164 mg of the title compound (yield 100%).
MS (APCI) m / z; 131 [M + H] ^< +>.

Reference Example 67
(2S, 4S) -4-Hydroxypyrrolidine-2-carboxamide hydrochloride

The corresponding starting material compound (500 mg) was treated in the same manner as in Reference Example 66 to give the title compound (200 mg) (yield 49%).
MS (APCI) m / z; 131 [M + H] ^< +>.

Reference Example 68
(R) -piperidine-2-carboxamide hydrochloride

(1) (R) -piperidine-1,2-carboxylic acid 1-tert-butyl ester 800 mg, ammonium chloride 933 mg, N-hydroxybenzotriazole monohydrate (HOBt · H ₂ O) 695 mg, and 1-ethyl 3.4 mL of triethylamine was added to a solution of 869 mg of -3-mg of 3- (3-dimethylaminopropyl) carbodiimide hydrochloride (WSC · HCl) in dimethylformamide, and the mixture was stirred at room temperature for 22 hours. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (solvent; hexane / ethyl acetate = 50/50 → 0/100) to give (R) -2-carbamoylpiperidine-1-carboxylic acid. 605 mg of acid tert-butyl ester was obtained (76% yield).
MS (APCI) m / z; 229 [M + H] ^< +>.

(2) To a solution of 600 mg of the compound obtained in (1) above in 6.6 mL of dichloromethane was added 6.6 mL of 4N hydrochloric acid-dioxane solution, and the mixture was stirred at room temperature for 26 hours. The reaction mixture was concentrated to give 432 mg of the title compound (yield 100%).
MS (APCI) m / z; 129 [M + H] ^< +>.

Reference Example 69
(S) -Pyrrolidine-3-carboxamide hydrochloride

The corresponding starting material compound (240 mg) was treated in the same manner as in Reference Example 68 to give the title compound 91 mg (yield 54%).
MS (APCI) m / z; 115 [M + H] ^< +>.

Reference Example 70
(R) -1- (Pyrrolidin-3-yl) methanol / hydrochloride

15 mL of 4N hydrochloric acid-dioxane solution was added to 15 mL of dichloromethane in 1.2 g of (R) -3-hydroxymethylpyrrolidine-1-carboxylic acid tert-butyl ester, and the mixture was stirred at room temperature for 22 hours. The reaction mixture was concentrated to give 826 mg of the title compound (yield 100%).
MS (APCI) m / z; 102 [M + H] ^< +>.

Reference Example 71
(2S, 4R) -4-Hydroxypyrrolidine-2-carbonitrile hydrochloride

(2S, 4R) -2-Carbamoyl-4-hydroxypyrrolidine-1-carboxylic acid tert-butyl ester (compound obtained in Reference Example 66 (1)) To a solution of 1.15 g of pyridine in 12 mL of trifluoroacetic anhydride 1.77 mL was added at −20 ° C. and the mixture was stirred at room temperature for 21 hours. Water and ethyl acetate were added to the reaction mixture, the pH was adjusted to 3-5 with 2N hydrochloric acid, and the mixture was washed successively with 2N aqueous sodium hydroxide solution and saturated brine. The organic layer was separated, dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain (2S, 4R) -2-cyano-4-hydroxypyrrolidine-1-carboxylic acid tert-butyl ester as a crude product. The compound was dissolved in 9 mL of dichloromethane, and 8.9 mL of 4N hydrochloric acid-dioxane solution was added thereto, followed by stirring at room temperature for 1 hour. Hexane was added to the reaction mixture, and the precipitate was collected by filtration and dried under reduced pressure to give 460 mg of the title compound (yield 62%).
MS (APCI) m / z; 113 [M + H] ^< +>.

Reference Example 72
(S) -2-tert-butoxycarbonylamino-3- [4- [7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2, 3-d] pyrimidin-4-ylamino] -3-fluorobenzoylamino] propionic acid methyl ester

The corresponding starting material compound was treated in the same manner as in Example 5 to obtain the title compound (yield 79%).
MS (APCI) m / z; 680 [M + H] ^< +>.

Reference Example 73
[(S) -1-carbamoyl-2- [4- [7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d ] Pyrimidin-4-ylamino] -3-fluorobenzoylamino] ethyl] carbamic acid tert-butyl ester

(S) -2-tert-butoxycarbonylamino-3- [4- [7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2, To 150 mg of 3-d] pyrimidin-4-ylamino] -3-fluorobenzoylamino] propionic acid methyl ester (the compound obtained in Reference Example 72), 5 mL of 7N ammonia-methanol solution was added and stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure to give 146 mg of the title compound (yield 99%).
MS (APCI) m / z; 665 [M + H] ^< +>.

Reference Example 74
Preparation of 2- (3,6-dihydro-2H-pyridin-1-yl) -5-ethylpyrimidine

A solution of 5.00 g of 1,2,3,6-tetrahydropyridine and 8.58 g of 2-chloro-5-ethylpyrimidine in 100 mL of ethanol was heated to reflux overnight. The reaction mixture is cooled to room temperature and concentrated under reduced pressure, and the resulting residue is purified by silica gel column chromatography (ethyl acetate: hexane = 5: 95 → 15: 85) to give 2- (3,6-dihydro -44H of -2H-pyridin-1-yl) -5-ethylpyrimidine was obtained as a liquid. (Yield 39%)
MS (APCI) m / z: 190 [M + H] ^< +>.

Reference Example 75
Production of cis-1- (5-ethylpyrimidin-2-yl) piperidine-3,4-diol (racemate)

A mixture of 4.44 g of 2- (3,6-dihydro-2H-pyridin-1-yl) -5-ethylpyrimidine, 5.51 g of N-methylmorpholine oxide in 40 mL of acetonitrile, and 8 mL of water at room temperature, 0.5% 8.62 g of an osmium tetroxide-tert-butanol solution was added and the mixture was stirred for 2 days. The reaction mixture was poured into water and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform: methanol = 100: 0 → 89: 11) to obtain cis-1- (5-ethylpyrimidin-2-yl) piperidine-3,4-diol 3 Obtained .65 g as a solid. (Yield 70%)
MS (APCI) m / z: 224 [M + H] ^< +>.

Reference Example 76
Benzoic acid cis-1- (5-ethylpyrimidin-2-yl) -4-hydroxypiperidin-3-yl ester (racemate) and benzoic acid cis-1- (5-ethylpyrimidin-2-yl) -3- Production of hydroxypiperidin-4-yl ester

To a solution of cis-1- (5-ethylpyrimidin-2-yl) piperidin-3,4-diol 3.57 g, dibutyltin dichloride 486 mg, potassium carbonate 3.32 g in tetrahydrofuran 100 mL was added benzoyl chloride 2.23 mL under ice-cooling. The mixture was added dropwise and the mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into saturated aqueous sodium hydrogen carbonate solution and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (ethyl acetate: hexane = 20: 80 → 40: 60) to give cis-1- (5-ethylpyrimidin-2-yl) -4-hydroxybenzoate. 1.08 g of piperidin-3-yl ester and 2.88 g of benzoic acid cis-1- (5-ethylpyrimidin-2-yl) -3-hydroxypiperidin-4-yl ester were obtained as viscous oils, respectively. (Yield 21%, 55%)
MS (APCI) m / z: 328 [M + H] ^< +>.
MS (APCI) m / z: 328 [M + H] ^< +>.

Reference Example 77
Benzoic acid trans-4- (4-Chloro-5-fluoro-pyrrolo [2,3-d] pyrimidin-7-yl) -1- (5-ethylpyrimidin-2-yl) piperidin-3-yl ester (racemic) Body)

Benzoic acid cis-1- (5-ethylpyrimidin-2-yl) -4-hydroxypiperidin-3-yl ester 1.08 g, 4-chloro-5-fluoro-7H-pyrrolo [2,3-d] pyrimidine 0 A solution of diethyl azodicarboxylate-toluene (2.2 mol / L, 2.25 mL) was added dropwise to a solution of .62 g and 1.30 g of triphenylphosphine in 50 mL of tetrahydrofuran under ice-cooling, and the mixture was stirred overnight at room temperature. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (ethyl acetate: hexane = 20: 80 → 35: 65) to give benzoic acid trans-4- (4-chloro-5-fluoropyrrolo [2,3-d Pyrimidin-7-yl) -1- (5-ethylpyrimidin-2-yl) piperidin-3-yl ester 907 mg was obtained as a powder. (Yield 57%)
MS (APCI) m / z: 481/483 [M + H] ^< +>.

Reference Example 78
[4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Of phenyl] (thiazolidin-3-yl) methanone

The corresponding starting material compound was treated in the same manner as in Example 5 to obtain the title compound as a powder (yield: 74%).
MS (APCI) m / z: 551 [M + H] ^< +>.

Reference Example 79
Preparation of 4-amino-2,5-difluorobenzoic acid tert-butyl ester

The corresponding starting material compound was treated in the same manner as in Reference Example 23 to give the title compound (yield: 48%).
MS (APCI) m / z; 230 [M + H] ^< +>.

Reference Example 80
Preparation of 4-amino-3-trifluoromethylbenzoic acid tert-butyl ester

The corresponding starting material compound was treated in the same manner as in Reference Example 23 to obtain the title compound (yield: 54%).

Reference Example 81
4- [7- [1- (5-Ethylpyrimidin-2-yl) -piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -2,5 -Production of difluorobenzoic acid dihydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield: 30%).
MS (APCI) m / z; 498 [M + H] ^< +>.

Reference Example 82
4- [7- [1- (5-Ethylpyrimidin-2-yl) -piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-tri Production of fluoromethylbenzoic acid dihydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield: 18%).
MS (APCI) m / z; 530 [M + H] ^< +>.

Reference Example 83
Preparation of 4-chloro-5-fluoro-7- [1- (5-pentyl-pyrimidin-2-yl) -piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine

The corresponding starting material compound was treated in the same manner as in Reference Example 1 (2) to give the title compound (yield: 55%).
MS (APCI) m / z; 403/405 [M + H] ^< +>.

Reference Example 84
3-Fluoro-4- [5-fluoro-7- [1- (5-pentylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] benzoate Production of acid dihydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield: 33%).
MS (APCI) m / z; 522 [M + H] ^< +>.

Reference Example 85
4-Chloro-5-fluoro-7- [1- (5-trifluoromethyl- [1,2,4] oxadiazol-3-yl) piperidin-4-yl] -7H-pyrrolo [2,3- d] Production of pyrimidines

The corresponding starting material compound was treated in the same manner as in Reference Example 18 to give the title compound.
MS (APCI) m / z; 391/393 [M + H] ^< +>.

Reference Example 86
Preparation of 2-methylsulfanyl-5-trifluoromethylpyrimidine

(1) A solution of 6.4 g of 3,3,3-trifluoropropionic acid in 50 mL of N, N-dimethylformamide was heated to 60 ° C., and 14 mL of phosphorus oxychloride was added dropwise over 2 hours (internal temperature of 70 ° C. or less). ) And then stirred at 70 ° C for 1 hour. After cooling the reaction mixture to room temperature, this and 28 mL of 5N aqueous sodium hydroxide solution were added dropwise over 30 minutes to a mixed solution of 60 mL of ice-cooled water, 15 mL of 5N aqueous sodium hydroxide solution and 13 g of 60% hexafluorophosphoric acid. The mixture was stirred at the same temperature for 1.5 hours. The precipitate was collected by filtration, washed with water, and dried at 40 ° C. to obtain 7.04 g of 3-dimethylamino-2-trifluoromethylallylidine) dimethylammonium hexafluorophosphate as a powder. (Yield 41%)
MS (APCI) m / z: 195 [M-F6P] ^<+> .

(2) To a solution of 2.35 g of the compound obtained in (1) in 20 mL of dimethyl sulfoxide were added 1.14 g of 2-methyl-isothiourea 1/2 sulfate and 2.8 mL of triethylamine, and the mixture was stirred at room temperature for 3 hours. did. Water was added to the reaction mixture, followed by stirring for 15 minutes under ice cooling. The precipitate was collected by filtration, washed with water, and dried under reduced pressure to give 1.04 g of the title compound. (Yield 78%)
MS (APCI) m / z: 195 [M + H] ^< +>.

Reference Example 87
Preparation of 1- (5-trifluoromethylpyrimidin-2-yl) piperidin-4-ol

To a solution of 0.97 g of 2-methylsulfanyl-5-trifluoromethylpyrimidine (the compound obtained in Reference Example 86) in 25 mL of methylene chloride was added 2.30 g of metachloroperbenzoic acid (containing 25% water) under ice-cooling, After stirring the mixture at room temperature for 1 hour, 1.01 g of 4-hydroxypiperidine and 2.02 g of triethylamine were added to the reaction solution, and the mixture was further stirred at room temperature overnight. The reaction solution was poured into a saturated aqueous sodium hydrogen carbonate solution, and the organic layer was separated. The aqueous layer was extracted twice with chloroform, the organic layer was dried over magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography to obtain 0.93 g of the title compound. (Yield 75%)
MS (APCI) m / z: 248 [M + H] ^< +>.

Reference Example 88
Preparation of 4-chloro-5-fluoro-7- [1- (5-trifluoromethylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine

The corresponding starting material compound was treated in the same manner as in Reference Example 1 (2) to give the title compound (yield 23%).
MS (APCI) m / z: 401/403 [M + H] ^< +>.

Reference Example 89
3-Chloro-4- [7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] benzoate Acid production

4-chloro-5-fluoro-7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine (the compound obtained in Reference Example 17) ) 890 mg, 4-amino-3-chlorobenzoic acid tert-butyl ester (the compound obtained in Reference Example 91), 563 mg, [1,1′-bis (diphenylphosphino) ferrocene] palladium (II) dichloride dichloromethane complex ( 1: 1) To a solution of 101 mg of 1,4-dioxane in 25 mL was added 594 mg of tert-butoxy sodium, and the mixture was stirred at 100 ° C. for 1 hour. Water was added to the reaction mixture and washed with ethyl acetate. The aqueous layer was adjusted to pH 6-7 with 1N HCl and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was triturated with dichloromethane-hexane to give 473 mg of the title compound as a powder (yield 39%).
MS (APCI) m / z; 496/498 [M + H] ^< +>.

Reference Example 90
3-Fluoro-4- [5-fluoro-7- [1- (5-trifluoromethyl- [1,2,4] oxadiazol-3-yl) piperidin-4-yl] -7H-pyrrolo [2 , 3-d] pyrimidin-4-ylamino] benzoic acid hydrochloride

(1) To 952 mg of the compound obtained in Reference Example 85 and 1.03 g of 4-amino-3-fluorobenzoic acid tert-butyl ester (the compound obtained in Reference Example 23) in 19 mL of 2-propanol, 4N hydrochloric acid Add 61 μL of dioxane solution and stir at 80 ° C. for 17 hours. The reaction mixture was cooled to room temperature, saturated aqueous sodium hydrogen carbonate solution was added, and the mixture was extracted with ethyl acetate. The organic layer was concentrated under reduced pressure, and the resulting residue was purified by NH silica gel column chromatography (Chromatorex; Fuji Silysia Chemical, solvent; chloroform / methanol = 100/0 to 92/8), and then gel permeation chromatography (JAIGEL). -1H, 2H; Nippon Analytical Industries, Mobile Phase; Chloroform) to give 3-fluoro-4- [5-fluoro-7- [1- (5-trifluoromethyl- [1,2,4] 594 mg of oxadiazol-3-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] benzoic acid tert-butyl ester was obtained (43% yield).
MS (APCI) m / z; 566 [M + H] ^< +>.

(2) By treating 653 mg of the compound obtained in (1) above in the same manner as in Reference Example 24 (2), 595 mg of the title compound was obtained (yield 95%).
MS (APCI) m / z; 510 [M + H] ^< +>.

Reference Example 91
Preparation of 4-amino-3-chlorobenzoic acid tert-butyl ester

The corresponding starting material compound was treated in the same manner as in Reference Example 23 to give the title compound.
MS (APCI) m / z; 228/230 [M + H] ^< +>.

Reference Example 92
Preparation of 4-amino-2-fluorobenzoic acid tert-butyl ester

The corresponding starting material compound was treated in the same manner as in Reference Example 23 to give the title compound.
MS (APCI) m / z; 212 [M + H] ^< +>.

Reference Example 93
Preparation of 4-amino-2-chlorobenzoic acid tert-butyl ester

The corresponding starting material compound was treated in the same manner as in Reference Example 23 to give the title compound.
MS (APCI) m / z; 228/230 [M + H] ^< +>.

Reference Example 94
2-Chloro-4- [7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] benzoate Production of acid dihydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield 63%).
MS (APCI) m / z; 496/498 [M + H] ^< +>.

Reference Example 95
2-Fluoro-4- [7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] benzoate Production of acid dihydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield 40%).
MS (APCI) m / z; 480 [M + H] ^< +>.

Reference Example 96
3-Fluoro-4- [5-fluoro-7- [1- (5-trifluoromethylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino ] Production of benzoic acid dihydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield 20%).
MS (APCI) m / z; 520 [M + H] ^< +>.

Reference Example 97
Preparation of 4- [4- (4-carboxy-2-chlorophenylamino) -5-fluoro-pyrrolo [2,3-d] pyrimidin-7-yl] piperidine-1-carboxylic acid isopropyl ester hydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield 26%).
MS (APCI) m / z; 476/478 [M + H] ^< +>.

Reference Example 98
3-methyl-4- [5-fluoro-7- [1- (5-trifluoromethyl- [1,2,4] oxadiazol-3-yl) piperidin-4-yl] -7H-pyrrolo [2 , 3-d] pyrimidin-4-ylamino] benzoic acid hydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 90 to give the title compound (yield 55%).
MS (APCI) m / z; 506 [M + H] ^< +>.

Reference Example 99
Production of (S) -3-methylaminopropane-1,2-diol

To 860 mL of 40% methylamine aqueous solution, 14.24 g of (R) -glycidol was dropped (liquid temperature of 20 ° C. or lower) and stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure, and the obtained residue was distilled (122 ° C., 5-6 mmHg) to obtain 17.5 g of (S) -3-methylaminopropane-1,2-diol as a liquid (yield). 83%).
MS (APCI) m / z; 106 [M + H] ^< +>.

Reference Example 100
Production of (R) -3-methylaminopropane-1,2-diol

The corresponding compound was treated in the same manner as in Reference Example 99 to give the title compound (yield 60%).
MS (APCI) m / z; 106 [M + H] ^< +>.

Reference Example 101
Preparation of 4-amino-3-methylbenzoic acid tert-butyl ester

The corresponding compound was treated in the same manner as in Reference Example 23 to give the title compound (yield 53%).
MS (APCI) m / z; 208 [M + H] ^< +>.

Reference Example 102
4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-methylbenzoate Acid production

The corresponding compound was treated in the same manner as in Reference Example 89 to give the title compound (yield 21%).
MS (APCI) m / z; 476 [M + H] ^< +>.

Reference Example 103
[2- [4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- Preparation of 3-fluorobenzoylamino] ethyl] carbamic acid tert-butyl ester

The corresponding starting material compound was treated in the same manner as in Example 5 to obtain the title compound (yield 90%).
MS (APCI) m / z; 622 [M + H] ^< +>.

Reference Example 104
[2-[[4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] Preparation of -3-fluorobenzoyl] methylamino] ethyl] carbamic acid tert-butyl ester

The corresponding starting material compound was treated in the same manner as in Example 5 to obtain the title compound (yield 60%).
MS (APCI) m / z; 636 [M + H] ^< +>.

Reference Example 105
Preparation of 3- (4-chloro-5-fluoropyrrolo [2,3-d] pyrimidin-7-yl) piperidine-1-carboxylic acid tert-butyl ester

The corresponding starting material compound was treated in the same manner as in Reference Example 1 to give the title compound (yield 14%).
MS (APCI) m / z; 355/357 [M + H] ^< +>.

Reference Example 106
(1R, 3S, 5S) -3- (4-Chloro-5-fluoropyrrolo [2,3-d] pyrimidin-7-yl) -8-azabicyclo [3.2.1] octane-8-carboxylic acid tert -Production of butyl esters

(1) To 150 mL of toluene of 14.12 g of tropine and 1.38 g of potassium carbonate, 23.30 g of 2,2,2-trichloroethyl chloroformate was gradually added at room temperature, and the mixture was stirred at 120 ° C. for 5 hours. The reaction mixture was cooled, poured into water, and the mixture was extracted with ethyl acetate. The organic layer is dried over magnesium sulfate and filtered, and the filtrate is concentrated under reduced pressure to give (1R, 3R, 5S) -3-hydroxy-8-azabicyclo [3.2.1] octane-8-carboxylic acid 2 , 2,2-triethyl ester 30.8 g was obtained (crude yield 100%).
MS (APCI) m / z; 302/304 [M + H] ^< +>.

(2) To a solution of 30.8 g of the compound obtained in (1) in 200 mL of acetic acid, 65.0 g of powdered zinc was gradually added at room temperature, and the mixture was stirred at 80 ° C. for 4 hours. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to obtain 22.88 g of (1R, 3R, 5S) -8-azabicyclo [3.2.1] octan-3-ol (crude yield 100 %).
MS (APCI) m / z; 128 [M + H] ⁺

(3) To 100 mL of a 1N aqueous sodium hydroxide solution of 6.36 g of the compound obtained in (2) above, 13.1 g of ditert-butyl dicarbonate was gradually added under ice cooling, and the mixture was stirred at room temperature overnight. . The reaction mixture was extracted with ethyl acetate, and the organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by silica gel chromatography (ethyl acetate: hexane = 10: 90 → 40: 60) to give (1S, 3R, 5R) -3-hydroxy-8-azabicyclo. [3.2.1] 1.83 g of octane-8-carboxylic acid tert-butyl ester was obtained (yield 16%).
MS (APCI) m / z; 228 [M + H] ⁺

(4) The title compound was obtained by treating the compound obtained in (3) above in the same manner as in Reference Example 1 (yield 66%).
MS (APCI) m / z; 381/383 [M + H] ^< +>.

Reference Example 107
Preparation of 3- (4-chloro-5-fluoropyrrolo [2,3-d] pyrimidin-7-ylmethyl) azetidine-1-carboxylic acid tert-butyl ester

The corresponding starting material compound was treated in the same manner as in Reference Example 1 to give the title compound (yield 86%).
MS (APCI) m / z; 341/343 [M + H] ^< +>.

Reference Example 108
Preparation of 6-methanesulfonyl-4-methylpyridin-3-ylamine

(1) A dimethyl sulfoxide solution (3.0 mL) containing 2-chloro-4-methyl-5-nitropyridine (600 mg) and sodium methanesulfinate (355 mg) was stirred at room temperature for one day. The reaction mixture was poured into 100 mL of ice water, and the precipitate was collected by filtration and dried to obtain 519 mg of 2-methanesulfonyl-4-methyl-5-nitropyridine as a brown solid (yield 69%).
MS (APCI) m / z; 217 [M + H] ⁺

(2) To a mixture of 772 mg of zinc powder and 4.72 mL of 3M ammonium chloride solution was added 5.1 mL of an ethyl acetate solution of 510 mg of the compound obtained in (1) above at 0 ° C., and the mixture was stirred at room temperature for 1 day. The reaction mixture was filtered through celite, water and ethyl acetate were added to the filtrate, the organic layer was separated, and the aqueous layer was extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated, and the resulting residue was dissolved in a small amount of chloroform. Diisopropyl ether was added to the solution, and the precipitate was collected by filtration and dried to obtain 280 mg of the title compound (yield: 64%). ).
MS (APCI) m / z; 187 [M + H] +

Reference Example 109
Preparation of 6-methanesulfonyl-2-methyl-pyridin-3-ylamine

(1) By treating 3.0 mL of a dimethyl sulfoxide solution of 600 mg of 6-chloro-2-methyl-3-nitropyridine and 355 mg of sodium methanesulfinate in the same manner as in Reference Example 108 (1), 6-methanesulfonyl-2 520 mg of methyl-3-nitropyridine were obtained (yield 79%).
MS (APCI) m / z; 217 [M + H] ⁺

(2) To a mixture of 877 mg of zinc powder and 5.37 mL of 3M ammonium chloride solution, 5.8 mL of an ethyl acetate solution of 580 mg of the compound obtained in (1) above was added at 0 ° C., and the mixture was referred to as Reference Example 108 (2 ) To give 374 mg of the title compound as a pale yellow solid (yield 75%).
MS (APCI) m / z; 187 [M + H] ^< +>.

Reference Example 110
2-Methyl-6- [1,2,4] triazol-1-ylpyridin-3-ylamine

(1) 6-chloro-2-methyl-3-nitropyridine (500 mg), 1H-1,2,4-triazole (200 mg) and potassium carbonate (400 mg) in 2.5 mL of a dimethyl sulfoxide solution were stirred at room temperature for 1 day. The reaction mixture was poured into 100 mL of ice water, and the precipitate was collected by filtration and dried to obtain 366 mg of 2-methyl-3-nitro-6- [1,2,4] triazol-1-ylpyridine ( Yield 62%).
MS (APCI) m / z; 205 [M + H] +

(2) To a mixture of 558 mg of zinc powder and 2M ammonium chloride solution, 5.3 mL of an ethyl acetate solution of 350 mg of the compound obtained in (1) above was added at 0 ° C., and the mixture was stirred at room temperature for 1 day. The reaction mixture was filtered through celite, water and ethyl acetate were added to the filtrate, the aqueous layer was separated, and extracted with ethyl acetate. The organic layer was washed successively with water and saturated brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated, and the obtained residue was purified by NH-silica gel column chromatography (Chromatorex (Fuji Silysia Chemical Ltd.); n-hexane / ethyl acetate = 60/40 → 40/60) to give the title compound. 186 mg was obtained (62% yield).
MS (APCI) m / z; 176 [M + H] +

Reference Examples 111-119
The corresponding compound was treated in the same manner as in Reference Example 1 to obtain the following compound.

(Reference Example 111) 4- (4-Chloro-5-fluoropyrrolo [2,3-d] pyrimidin-7-yl) azepan-1-carboxylic acid tert-butyl ester

MS (APCI) m / z; 369/371 [M + H] ^< +>.

(Reference Example 112) 4- (4-Chloro-5-fluoropyrrolo [2,3-d] pyrimidin-7-ylmethyl) piperidine-1-carboxylic acid tert-butyl ester

MS (APCI) m / z; 369/371 [M + H] ^< +>.

(Reference Example 113) 3- (4-Chloro-5-fluoropyrrolo [2,3-d] pyrimidin-7-ylmethyl) pyrrolidine-1-carboxylic acid tert-butyl ester

MS (APCI) m / z; 355/357 [M + H] ^< +>.

(Reference Example 114) 3- (4-Chloro-5-fluoropyrrolo [2,3-d] pyrimidin-7-ylmethyl) piperidine-1-carboxylic acid tert-butyl ester

MS (APCI) m / z; 369/371 [M + H] ^< +>.

(Reference Example 115) (S) -3- (4-Chloro-5-fluoropyrrolo [2,3-d] pyrimidin-7-ylmethyl) pyrrolidine-1-carboxylic acid tert-butyl ester

MS (APCI) m / z; 355/357 [M + H] ^< +>.

(Reference Example 116) (R) -3- (4-Chloro-5-fluoropyrrolo [2,3-d] pyrimidin-7-ylmethyl) pyrrolidine-1-carboxylic acid tert-butyl ester

MS (APCI) m / z; 355/357 [M + H] ^< +>.

(Reference Example 117) (R) -3- (4-Chloro-5-fluoropyrrolo [2,3-d] pyrimidin-7-ylmethyl) piperidine-1-carboxylic acid tert-butyl ester

MS (APCI) m / z; 369/371 [M + H] ^< +>.

(Reference Example 118) (S) -3- (4-Chloro-5-fluoropyrrolo [2,3-d] pyrimidin-7-ylmethyl) piperidine-1-carboxylic acid tert-butyl ester

MS (APCI) m / z; 369/371 [M + H] ^< +>.

(Reference Example 119) [3- (4-Chloro-5-fluoropyrrolo [2,3-d] pyrimidin-7-yl) propyl] -methylcarbamic acid tert-butyl ester

MS (APCI) m / z; 343/345 [M + H] ^< +>.

Reference examples 120-122
The corresponding compound was treated in the same manner as in Reference Example 17 to obtain the following compound.

Reference Example 120 4-Chloro-7-[(R) -1- (5-ethylpyrimidin-2-yl) pyrrolidin-3-ylmethyl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidine

MS (APCI) m / z; 361/363 [M + H] ^< +>.

(Reference Example 121) 4-chloro-7-[(R) -1- (5-trifluoromethylpyrimidin-2-yl) pyrrolidin-3-ylmethyl] -5-fluoro-7H-pyrrolo [2,3-d Pyrimidine

MS (APCI) m / z; 401/403 [M + H] ^< +>.

(Reference Example 122) 4-Chloro-7-[(R) -1- (5-ethylpyrimidin-2-yl) piperidin-3-ylmethyl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidine

MS (APCI) m / z; 375/377 [M + H] ^< +>.

Reference Example 123
Production of cis-4-methoxymethoxycyclohexanecarbonitrile

(1) To 3.57 g of 4-hydroxy-1-cyclohexanecarboxylic acid δ-lactone was added 40 mL of 28% aqueous ammonia, and the mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure, and the residue was recrystallized from acetonitrile to obtain 3.33 g of cis-4-hydroxycyclohexanecarboxamide as a colorless solid (yield 82%).
MS (APCI) m / z; 144 [M + H] ^< +>.

(2) To a solution of 3.33 g of the compound obtained in (1) above in 50 mL of methylene chloride, 8.10 mL of diisopropylethylamine and 2.65 mL of methoxymethyl chloride were added under ice cooling, and the mixture was stirred at room temperature for 5 hours. Water was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was washed with saturated brine, dried over magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel chromatography (solvent; chloroform / methanol = 100/0 to 90/10) to obtain 1.68 g of cis-4-methoxymethoxycyclohexanecarboxamide as a colorless solid (yield 39 %).
MS (APCI) m / z; 188 [M + H] ^< +>.

(3) 1.88 mL of 1,8-diazabicyclo [5,4,0] undec-7-ene was added to a solution of 1.48 g of the compound obtained in (2) above in 35 mL of methylene chloride. After the addition of 1.88 mL of lodrochloridate, the mixture was stirred at room temperature for 2.5 hours. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was washed with saturated brine, dried over magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (solvent; hexane / ethyl acetate = 75 / 25-60 / 40) to give 1.25 g of the title compound as a colorless liquid (yield). 94%).
MS (APCI) m / z; 170 [M + H] ^< +>.

Reference Example 124
4-chloro-5-fluoro-7- [trans-4- (5-trifluoromethyl- [1,2,4] oxadiazol-3-yl) cyclohexyl] -7H-pyrrolo [2,3-d] Pyrimidine production

The corresponding starting material compound was treated in the same manner as in Reference Examples 18 (2) to (5) to give the title compound (yield 19%).
MS (APCI) m / z; 390/392 [M + H] ^< +>.

Reference Example 125
Preparation of 4-[(7-azepan-4-yl) -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro-N, N-dimethylbenzamide dihydrochloride

The title compound was obtained by treating the compound obtained in Example 180 in the same manner as in Reference Example 4 (yield 100%).
MS (APCI) m / z; 415 [M + H] ^< +>.

Reference examples 126 to 127
By treating the compound obtained in Example 175 or Example 180 in the same manner as in Reference Example 4, the following compound was obtained.

(Reference Example 126) ((1S, 3S, 5R) -7- (8-azabicyclo [3.2.1] oct-3-yl) -5-fluoro-7H-pyrrolo [2,3-d] pyrimidine- 4-yl) (2-fluoro-4-methanesulfonylphenyl) amine hydrochloride

MS (APCI) m / z; 434 [M + H] ^< +>.

(Reference Example 127) 4-((1S, 3S, 5R) -7- (8-azabicyclo [3.2.1] oct-3-yl) -5-fluoro-7H-pyrrolo [2,3-d] Pyrimidin-4-ylamino) -3-fluoro-N, N-dimethylbenzamide hydrochloride

MS (APCI) m / z; 427 [M + H] ^< +>.

Reference Example 128
Preparation of 2- [4- (4-Dimethylcarbamoyl-2-fluorophenylamino) -5-fluoropyrrolo [2,3-d] pyrimidin-7-ylmethyl] morpholine-4-carboxylic acid tert-butyl ester

The corresponding starting material compound was treated in the same manner as in Example 1 to obtain the title compound (yield 92%).
MS (APCI) m / z; 517 [M + H] ^< +>.

Reference Example 129
Preparation of 3-fluoro-4- (5-fluoro-7-morpholin-2-ylmethyl-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino) -N, N-dimethylbenzamide dihydrochloride

The title compound was obtained by treating the compound obtained in Reference Example 128 in the same manner as in Reference Example 4.
MS (APCI) m / z; 417 [M + H] ^< +>.

Reference Example 130
Preparation of 3-fluoro-4- (5-fluoro-7- (S) -1-pyrrolidin-3-ylmethyl-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino) -N, N-dimethylbenzamide

The compound obtained in Example 183 was treated in the same manner as in Reference Example 4, and then the obtained compound was treated with a saturated aqueous sodium hydrogen carbonate solution to obtain the title compound.
MS (APCI) m / z; 401 [M + H] ^< +>.

Reference Example 131
3-Fluoro-4- [5-fluoro-7- [trans-4- (2H-tetrazol-5-yl) cyclohexyl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -N, N -Production of dimethylbenzamide

(1) 1.00 g of 4-chloro-5-fluoro-7H-pyrrolo [2,3-d] pyrimidine (the compound obtained in Reference Example 1 (1)) and cis-4-hydroxycyclohexanecarboxamide (Reference Example 123) The compound obtained in (1)) is treated in the same manner as in Reference Example 1 (2) to give trans-4- (4-chloro-5-fluoropyrrolo [2,3-d] pyrimidin-7-yl). 578 mg of cyclohexanecarboxamide was obtained (33% yield).
MS (APCI) m / z; 297/299 [M + H] ^< +>.

(2) By treating 474 mg of the compound obtained in (1) above in the same manner as in Reference Example 123 (3), trans-4- (4-chloro-5-fluoro-pyrrolo [2,3-d] pyrimidine -7-yl) cyclohexanecarbonitrile was obtained as a colorless solid (82% yield).
MS (APCI) m / z; 279/281 [M + H] ^< +>.

(3) By treating 366 mg of the compound obtained in (2) above in the same manner as in Example 164, 4- [7- (trans-4-cyanocyclohexyl) -5-fluoro-7H-pyrrolo [2,3 -D] Pyrimidin-4-ylamino] -3-fluoro-N, N-dimethylbenzamide was obtained as a colorless solid (69% yield).
MS (APCI) m / z; 425 [M + H] ^< +>.

(4) To a solution of 100 mg of the compound obtained in (3) above in 1 mL of dimethylformamide was added 38 mg of sodium azide and 34 mg of ammonium chloride, and the mixture was stirred at 100 ° C. for 24 hours. After further adding 38 mg of sodium azide and 34 mg of ammonium chloride to the reaction mixture, the mixture was stirred at 100 ° C. for 17 hours. A citric acid aqueous solution was added to the reaction mixture, followed by extraction with chloroform. The organic layer was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (solvent; chloroform / methanol = 99/1 to 88/12) to give 54.7 mg of the title compound as a light brown solid (yield). Rate 50%).
MS (APCI) m / z; 468 [M + H] ^< +>.

Reference Example 132
Preparation of [3- [4- (4-Dimethylcarbamoyl-2-fluorophenylamino) -5-fluoropyrrolo [2,3-d] pyrimidin-7-yl] propyl] methylcarbamic acid tert-butyl ester

The corresponding starting material compound was treated in the same manner as in Example 1 to obtain the title compound (yield 27%).
MS (APCI) m / z; 489 [M + H] ^< +>.

Reference Example 133
(1S, 3S, 5R) -3- [4- (4-Carboxy-2-fluorophenylamino) -5-fluoropyrrolo [2,3-d] pyrimidin-7-yl] -8-azabicyclo [3.2 .1] Preparation of octane-8-carboxylic acid isopropyl ester hydrochloride

(1) To 100 mL of a 1N sodium hydroxide aqueous solution of 11.44 g of the compound obtained in Reference Example 106 (2), 6.6 mL of isopropyl chloroformate was added dropwise under ice cooling, and the mixture was stirred at room temperature overnight. The reaction mixture was extracted three times with ethyl acetate, the organic layer was dried over magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give (1S, 3R, 5R) -3-hydroxy-8-azabicyclo [3. 2.1] 4.05 g of octane-8-carboxylic acid isopropyl ester was obtained (yield 38%).
MS (APCI) m / z; 214 [M + H] ^< +>.

(2) The compound obtained in (1) above is treated in the same manner as in Example 1 to give (1S, 3S, 5R) -3- (4-chloro-5-fluoro-pyrrolo [2,3-d Pyrimidin-7-yl) -8-azabicyclo [3.2.1] octane-8-carboxylic acid isopropyl ester (1.86 g, yield 34%) was obtained.
MS (APCI) m / z; 367/369 [M + H] ^< +>.

(3) The title compound was obtained by treating the product obtained in (2) above in the same manner as in Reference Example 24 (yield 87%).
MS (APCI) m / z; 486 [M + H] ^< +>.

Reference Example 134
4- [7-[(R) -1- (5-ethylpyrimidin-2-yl) pyrrolidin-3-yl] methyl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino ] Production of 3-fluorobenzoic acid

The corresponding starting material compound was treated in the same manner as in Reference Example 89 to give the title compound (yield 47%).
MS (APCI) m / z; 480 [M + H] ^< +>.

Reference Example 135
4- [7-[(R) -1- (5-ethylpyrimidin-2-yl) piperidin-3-ylmethyl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- Production of 3-fluorobenzoic acid dihydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield 100%).
MS (APCI) m / z; 494 [M + H] ^< +>.

Reference Example 136
4- [7- [1- (5-trifluoromethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3- Production of methylbenzoic acid dihydrochloride

(1) The corresponding starting material compound was treated in the same manner as in Reference Example 24 (1) to give 4- [7- [1- (5-trifluoromethylpyrimidin-2-yl) piperidin-4-yl] -5- 346 mg of fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-methylbenzoic acid tert-butyl ester was obtained (43% yield).
MS (APCI) m / z; 572 [M + H] ^< +>.

(2) To 340 mg of the compound obtained in (1) above, 5 mL of trifluoroacetic acid was added, and the mixture was stirred at room temperature for 2 days. The reaction mixture was concentrated under reduced pressure, 10 mL of 4N hydrochloric acid-dioxane solution was added to the residue, and the mixture was concentrated under reduced pressure to obtain 259 mg of the title compound as a crude product (yield 78%).
MS (APCI) m / z; 516 [M + H] ^< +>.

Reference Example 137
4- [7- [1- (5-Ethylpyrimidin-2-yl) -cis-3-methylpiperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino ] Preparation of 3-fluorobenzoic acid dihydrochloride

(1) A methanol / water 30 mL / 70 mL mixed solution of 10.3 g of 1-benzyl-3-methyl-4-piperidone and 5.84 g of 85% phosphoric acid was cooled to −15 ° C., and 3.83 g of sodium borohydride was added. Gradually added (internal temperature -5 ° C. or lower), and the mixture was stirred at room temperature overnight. A 5N aqueous sodium hydroxide solution was added to the reaction mixture under ice-cooling, and the mixture was extracted 3 times with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methanol: chloroform = 2: 98 → 10: 90) to obtain 9.39 g of 1-benzyl-trans-3-methylpiperidin-4-ol (yield 90%). ).
MS (APCI) m / z; 206 [M + H] ^< +>.

(2) A mixed solution of 9.35 g of the compound obtained in (1), 2.3 g of 10% Pd / C (containing 50% water) and 90 mL of ethanol was stirred for 7 hours under an atmospheric hydrogen atmosphere. The reaction mixture was filtered through Celite, and 6.10 g of 2-chloro-5-ethylpyrimidine, 6.27 mL of triethylamine and 20 mL of ethanol were added to the filtrate, and the mixture was stirred at 80 ° C. overnight. The reaction mixture was cooled and concentrated under reduced pressure. To the residue was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate: hexane = 10: 90 → 100: 0) to give 1- (5-ethylpyrimidin-2-yl) -trans-3-methylpiperidin-4-ol 7 .3 g was obtained (73% yield).
MS (APCI) m / z; 222 [M + H] ^< +>.

(3) By treating the compound obtained in (2) in the same manner as in Reference Example 1 (2), 4-chloro-7- [1- (5-ethylpyrimidin-2-yl) -cis-3- 9.13 g of methylpiperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidine was obtained (84% yield).
MS (APCI) m / z; 375/377 [M + H] ^< +>.

(4) The compound obtained in (3) was treated in the same manner as in Reference Example 24 to give 3.6 g of the title compound (yield 64%).
MS (APCI) m / z; 494 [M + H] ^< +>.

Reference Example 138
4- [7- [1- (5-Ethylpyrimidin-2-yl) -trans-3-methylpiperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino ] Preparation of 3-fluorobenzoic acid dihydrochloride

(1) 18.6 g of 1M L-selectride was added dropwise to a solution of 15.0 g of 1-benzyl-3-methyl-4-piperidone in 300 mL of tetrahydrofuran under ice-cooling (internal temperature of 5 ° C. or less), and the mixture was stirred at room temperature. Stir for 1.5 hours. The reaction mixture was poured into water and extracted three times with ethyl acetate. The organic layer was washed with saturated brine, dried over sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methanol: chloroform = 0: 100 → 10: 90) to obtain 10.5 g of 1-benzyl-cis-3-methylpiperidin-4-ol (yield 69%) ).
MS (APCI) m / z; 206 [M + H] ^< +>.

(2) By treating the product obtained in (1) in the same manner as in Reference Example 137 (2), 1- (5-ethylpyrimidin-2-yl) -cis-3-methylpiperidin-4-ol 8.5 g was obtained (75% yield).
MS (APCI) m / z; 222 [M + H] ^< +>.

(3) By treating the product obtained in (2) in the same manner as in Reference Example 137 (3), 4-chloro-7- [1- (5-ethylpyrimidin-2-yl) -trans-3 -Methylpiperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidine (3.54 g, yield 29%) was obtained.
MS (APCI) m / z; 375/377 [M + H] ^< +>.

(4) By treating the product obtained in (3) in the same manner as in Reference Example 137 (4), 2.5 g of the title compound was obtained (yield 42%).
MS (APCI) m / z; 494 [M + H] ^< +>.

Reference Example 139
4- [7-[(R) -1- (5-trifluoromethylpyrimidin-2-yl) pyrrolidin-3-ylmethyl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino ] Preparation of 3-fluorobenzoic acid dihydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give the title compound (yield 42%).

Reference Example 140
Production of (3S, 4S) -pyrrolidine-3,4-diol

To a solution of 522 mg of (3S, 4S) -1-benzylpyrrolidine-3,4-diol in 15 mL of ethanol was added 100 mg of 10% palladium carbon and 10 mL of acetic acid, and the mixture was stirred at room temperature for 7 hours under hydrogen pressure (40 psi). The reaction mixture was filtered through celite, and the filtrate was concentrated under reduced pressure. A 4N hydrochloric acid-dioxane solution was added to the resulting residue, followed by concentration under reduced pressure to obtain 373 mg of the title compound as a yellow solid (yield 99%).
MS (APCI) m / z; 104 [M + H] ^< +>.

Reference Example 141
3-Fluoro-4- [5-fluoro-7- [trans-4- (N-hydroxycarbamimidoyl) cyclohexyl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -N, N -Production of dimethylbenzamide

(1) 4- [7- (trans-4-cyanocyclohexyl) -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro-N, N-dimethylbenzamide (reference The title compound (89 mg) was obtained by treating 100 mg of the compound obtained in Example 131 (3) in the same manner as in Reference Example 18 (2) (yield 82%).
MS (APCI) m / z; 458 [M + H] ^< +>.

Reference Example 142
4- [7-((R) -1-cyanopyrrolidin-3-ylmethyl) -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro-N, N-dimethyl Production of benzamide

(R) -3- [4- (4-Dimethylcarbamoyl-2-fluorophenylamino) -5-fluoropyrrolo [2,3-d] pyrimidin-7-ylmethyl] pyrrolidine-1-carboxylic acid tert-butyl ester ( Compound obtained in Example 183) 1.25 mL of 4N hydrochloric acid-dioxane solution was added to a solution of 250 mg of dichloromethane in 4 mL, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure, 4 mL of ethanol and 2 mL of tetrahydrofuran were added to the residue, 79 mg of cyanogen bromide and 210 mg of sodium bicarbonate were added thereto, and the mixture was stirred at room temperature for 23 hours. The reaction mixture was diluted with dichloromethane and filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was triturated with hexane to give the title compound (205 mg) as a colorless powder. (Yield 96%).
MS (APCI) m / z; 426 [M + H] ^< +>.

Reference Example 143
Preparation of 4- [7- (1-cyanoazepan-4-yl) -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro-N, N-dimethylbenzamide

The corresponding starting material compound was treated in the same manner as in Reference Example 142 to give the title compound (yield 95%).
MS (APCI) m / z; 440 [M + H] ^< +>.

Reference Example 144
4- [7-((R) -1-cyanopiperidin-3-ylmethyl) -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro-N, N-dimethyl Production of benzamide

The corresponding starting material compound was treated in the same manner as in Reference Example 142 to give the title compound (yield 93%).
MS (APCI) m / z; 440 [M + H] ^< +>.

Reference Example 145
[5- (4- [7- [1- (5-Ethylpyrimidin-2-yl) -piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] Preparation of -3-fluorophenyl) -1- (2-hydroxyethyl) -1H- [1,2,4] triazol-3-yl] carbamic acid tert-butyl ester

(1) 21.82 g of di-tert-butyl dicarbonate was added to a mixed solution of 15.31 g of 2-methylisothiourea 1/2 sulfate and 21.82 g of potassium carbonate in 300 mL of tetrahydrofuran and 100 mL of water under ice cooling, The mixture was stirred at room temperature overnight. The reaction mixture was extracted with ethyl acetate, and the organic layer was dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to obtain 18.85 g of 1-tert-butoxycarbonyl-2-methylisothiourea (yield). Rate 99%).
MS (APCI) m / z; 191 [M + H] ^< +>.

(2) 4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3 1-tert-Butoxycarbonyl-3 was treated in the same manner as in Example 5 by treating 365 mg of fluorobenzoic acid dihydrochloride (compound obtained in Reference Example 24) and 188 mg of the compound obtained in (1) above. -(4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3- 322 mg of fluorobenzoyl) -2-methylisothiourea was obtained (yield 75%).
MS (APCI) m / z; 652 [M + H] ^< +>.

(3) 76 mg of 2-hydrazinoethanol was added to a 5 mL ethanol solution of the compound obtained in (1) above in 130 mg, and the mixture was stirred at 80 ° C. overnight. The reaction mixture was cooled to room temperature, poured into water, and the mixture was extracted with ethyl acetate. The organic layer was concentrated, and the obtained residue was purified by silica gel chromatography (chloroform: methanol = 100: 0 → 95: 5) to give 72 mg of the title compound as a white powder (yield 55%).
MS (APCI) m / z; 662 [M + H] ^< +>.

Reference Example 146
[(3-Fluoro-4- [5-fluoro-7- [1- (5-trifluoromethylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidine-4 -Ilamino] benzoyl) methylamino] acetic acid Preparation of tert-butyl ester

The corresponding starting material compound was treated in the same manner as in Example 5 to obtain the title compound (yield 56%).
MS (APCI) m / z; 647 [M + H] ^< +>.

Reference Example 148
[(3-Fluoro-4- [5-fluoro-7- [1- (5-pentylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino ] Benzoyl) methylamino] acetic acid Preparation of tert-butyl ester

The corresponding starting material compound was treated in the same manner as in Example 5 to obtain the title compound (yield 47%).
MS (APCI) m / z; 649 [M + H] ^< +>.

Reference Example 149
Preparation of 4-amino-N- [2- (tert-butyldimethylsilanyloxy) ethyl] -3-fluoro-N-methylbenzamide

(1) N-hydroxybenzotriazole monohydrate (HOBt · H ₂ O) 4 in a solution of 3.10 g of 4-amino-3-fluorobenzoic acid and 1.80 g of N-methyl-2-aminoethanol in 200 mL of dichloromethane .59 g, 4.05 g triethylamine and 5.75 g 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (WSC.HCl) were added and the mixture was stirred at room temperature for 18 hours. A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer is concentrated, and the resulting residue is purified by silica gel chromatography (chloroform / methanol = 100/0 to 90/10) to give 4-amino-3-fluoro-N- (2-hydroxyethyl)- 2.55 g of N-methylbenzamide was obtained as a yellow powder (yield 60%).
MS (APCI) m / z; 213 [M + H] ^< +>.

(2) To a solution of 2.55 g of the compound obtained in (1) above and 1.94 g of triethylamine in 50 mL of dichloromethane was added 2.26 g of tert-butylchlorodimethylsilane at room temperature and stirred overnight. The reaction mixture was poured into saturated aqueous sodium hydrogen carbonate solution and extracted with chloroform. The organic layer was dried over magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography (ethyl acetate: hexane = 30: 70 → 58: 42) to give 3.92 g of the title compound as a yellow powder (yield 100%).
MS (APCI) m / z; 372 [M + H] ^< +>.

Reference Example 150
N- [2- (tert-butyldimethylsilanyloxy) -ethyl] -4- [7-trans-1- (5-ethylpyrimidin-2-yl) -3-fluoropiperidin-4-yl] -5 Preparation of fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro-N-methylbenzamide

(1) Diethylamino benzoic acid cis-1- (5-ethylpyrimidin-2-yl) -3-hydroxypiperidin-4-yl ester 2.88 g (compound of Reference Example 76) in 100 mL dichloromethane solution under ice-cooling Sulfur trifluoride (7.09 g) was added, and the mixture was stirred at room temperature for 3 days. The reaction solution was poured into a saturated aqueous sodium hydrogen carbonate solution and extracted with chloroform. The organic layer was dried over magnesium sulfate and filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (ethyl acetate: hexane = 10: 90 → 30: 70) to obtain benzoic acid cis-1- (5-ethylpyrimidin-2-yl) -3-fluoropiperidine-4- 354 mg of yl ester was obtained as a white powder (yield 12%).
MS (APCI) m / z; 330 [M + H] ^< +>.

(2) To a solution of 318 mg of the compound obtained in (1) above in 3 mL of tetrahydrofuran was added 3 mL of 1N aqueous sodium hydroxide at room temperature, and the mixture was stirred for 2 days. The reaction mixture was poured into an aqueous ammonium chloride solution and extracted with ethyl acetate. The organic layer was concentrated, and the residue was purified by silica gel chromatography (ethyl acetate: hexane = 40: 60 → 60: 40) to give cis-1- (5-ethylpyrimidin-2-yl) -3-fluoropyrimidine 162 mg of -4-ol was obtained as a white powder (yield 74%).
MS (APCI) m / z; 226 [M + H] ^< +>.

(3) By treating 160 mg of the compound obtained in (2) above in the same manner as in Reference Example 1, 4-chloro-7- [trans-1- (5-ethylpyrimidin-2-yl) -3-fluoro 147 mg of piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidine was obtained as a white powder (yield 55%).
MS (APCI) m / z; 379/381 [M + H] ^< +>.

(4) By treating 144 mg of the compound obtained in (3) above and 186 mg of the compound obtained in Reference Example 149 in the same manner as in Example 1, 107 mg of the title compound was obtained as a yellow powder (yield 42%) .
MS (APCI) m / z; 669 [M + H] ^< +>.

Reference Example 151
Preparation of 5-amino-6-methyl-2-carboxylic acid tert-butyl ester

The corresponding starting material compound was treated in the same manner as in Reference Example 23 to give 181 mg of the title compound. (Yield 16%)
MS (APCI) m / z; 212 [M + H] ^< +>.

Reference Example 152
5- [7- [1- (5-Ethylpyrimidin-2-yl) -piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -6-methyl Preparation of pyridine-2-carboxylic acid dihydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 24 to give 63 mg of the title compound (yield: 12%).
MS (APCI) m / z; 477 [M + H] ^< +>.

Reference Example 153
Production of (S) -3-hydroxy-2-methylaminopropionamide hydrochloride

(1) 1.096 g of (S) -2- (t-butoxycarbonyl-methyl-α-amino) -3-hydroxy-propionic acid, 995 mg of N-hydroxybenzotriazole monohydrate (HOBt · H ₂ O) Then, 4.88 mL of triethylamine was added to a 20 mL chloroform solution of 1.25 g of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (WSC · HCl) and 1.34 g of ammonium chloride, and the mixture was stirred at 50 ° C. for 22 hours. . A saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was concentrated, and the obtained residue was purified by silica gel chromatography (solvent: hexane / ethyl acetate = 50 / 50-0 / 100) to give ((S) -1-carbamoyl-2-hydroxyethyl) 309 mg of methylcarbamic acid t-butyl ester was obtained as a colorless powder (yield 28%).
MS (APCI) m / z; 219 [M + H] ^< +>.

(2) To a solution of 303 mg of the compound obtained in (1) above in 5 mL of dichloromethane was added 3.46 mL of 4N hydrochloric acid-dioxane solution, and the mixture was stirred at room temperature for 17 hours. The reaction mixture was concentrated under reduced pressure and triturated with dichloromethane-hexane to give 215 mg of the title compound as a colorless powder (yield 100%).
MS (APCI) m / z; 119 [M + H] ^< +>.

Reference Example 154
4-Chloro-7-[(R) -1- (5-trifluoro- [1,2,4] oxadiazol-3-yl) pyrrolidin-3-ylmethyl] -5-fluoro-7H-pyrrolo [2 , 3-d] pyrimidine production

(R) -3-Hydroxymethylpyrrolidine-1-carboxylic acid tert-butyl ester was treated in the same manner as in Reference Example 70, and then the resulting reaction product was treated in the same manner as in Reference Example 18 to give the title compound. Got.
MS (APCI) m / z; 391/393 [M + H] ^< +>.

Reference Example 155
3-Fluoro-4- [5-fluoro-7-[(R) -1- (5-trifluoromethyl- [1,2,4] oxadiazol-3-yl) pyrrolidin-3-ylmethyl] -7H -Preparation of pyrrolo [2,3-d] pyrimidin-4-ylamino] benzoic acid / hydrochloride

The corresponding starting material compound was treated in the same manner as in Reference Example 90 to give the title compound (yield 72%).
MS (APCI) m / z; 510 [M + H] ^< +>.

Experimental example 1
(Purpose of this experiment)
The purpose of this experiment is to evaluate the GPR119 agonist activity (in vitro) of these compounds by adding a sample compound to human GPR119-expressing CHO cells and measuring the amount of cAMP produced by the cells.

(Preparation of human GPR119-expressing CHO cells)
CHO cells expressing human GPR119 (L8-18) are luciferase expression vector pLG3-CRE6-CRE-VIP (in accordance with a known method (The Journal of Biological Chemistry Vol. 274 (34), pp. 23940-23947)). It was prepared by introducing the expression vector pMSF1-GPR119 (Geneticin resistance) carrying the human GPR119 gene into CHO cells (LM-3; Mock cells) into which Hygromycin B resistance) was introduced.

(Test method)
The cryopreserved L8-18 cells were thawed, suspended in 9 times the assay buffer, and centrifuged (1000 rpm, 5 minutes) at room temperature. After removing the supernatant, the precipitated cells were resuspended in 4 mL of assay buffer, and IBMX (Sigma, # 17018-1G) -containing assay buffer was added thereto to add 7.5 × 10 ⁴ cells / mL. Cell suspension was prepared. The cell suspension was allowed to stand at room temperature for 15 minutes, and then 20 μL of the cell suspension and 5 μL of the sample compound solution or AR231453 solution (25 μL / total) were added to each well of a 96 half well white plate (Corning, # 3693). well) (final concentration: 1500 cells / mL, 500 μM IBMX, 1% dimethyl sulfoxide). After incubating the mixture at 37 ° C. for 30 minutes, 20-fold dilutions (12.5 μL / well each) of cAMP-d2 and Anti cAMP-Cryptate from the HTRF cAMP kit (Cisbio, # 62AM4PEC) were added to each well. did. The mixture was stirred and allowed to stand for 1 hour in the dark, and fluorescence intensity was measured in a time-resolved fluorescence mode (Ex: 320 nm, Em: 665 nm, 620 nm) of a microplate reader (ARVO or SpectraMax M5e). . In the case of ARVO, the ratio of cAMP-d2 to Anti cAMP-Cryptate [Ratio = (665 nm / 620 nm) × 10 ⁴ )] was calculated from the obtained fluorescence intensity, and cAMP prepared using the Ratio value and GraphPad Prism. From the standard curve, the cAMP concentration in each well was calculated. In the case of SpectraMax M5e, the cAMP concentration in each well was calculated based on the obtained fluorescence intensity and the standard curve prepared by Sofmax pro.
The EC ₅₀ value of the sample compound was calculated using GraphPad Prism.

(result)
The results of this experiment (EC ₅₀ values for each analyte compound) are as shown in Tables 46 to 47 below. In the table, “++” and “++++” have the following meanings.
++: 3 μM> EC ₅₀ > 1 μM
+++: 1 μM> EC ₅₀

Experimental example 2
(Inhibition of blood glucose elevation of the compound of the present invention)
experimental method:
C57BL / 6N male mice were fasted for 21 hours (18 hours until grouping) and then stratified randomized allocation using SAS 9.1.3 (SAS Institute, Inc.) based on body weight (n = 8). The vehicle was orally administered with a vehicle (solvent: 0.1% Tween 80 / 0.5% hydroxypropylmethylcellulose) (control group) or a solution in which the sample compound was suspended in the vehicle (sample administration group), and the sample was administered for 1 hour. Later glucose loading (3 g / kg, po) was performed. Blood collection from the test mice is performed immediately before drug administration (−60 min), immediately before glucose load (0 min), 30 minutes after glucose load (30 min), 60 minutes (60 min), and 120 minutes (120 min). It was. The blood glucose level at each time point was measured using Glucose CII-Test Wako (manufactured by Wako Pure Chemical Industries), and AUC (0-120 min) in each administration group was calculated based on the measured value, and SAS 9.1. Tested with Student's t-Test using 3 (SAS Institute, Inc.).

result:
Table 48 below shows the blood glucose elevation-inhibiting action of each sample compound (value of the ratio of AUC (0-120 min) in the sample administration group when the AUC (0-120 min) in the control group is 100).
In the table, “*” and “**” have the following meanings.
*: P <0.05
**: P <0.01

Experimental example 3
(Inhibition of blood glucose increase by the compound of the present invention 2)
experimental method:
Zucker Fatty male rats were fasted for 21 hours (18 hours until grouping) and then stratified randomized assignment using SAS 9.1.3 (SAS Institute, Inc.) based on body weight (n = 7). A vehicle (solvent: 0.1% Tween 80 / 0.5% hydroxypropylmethylcellulose) (control group) or a solution in which a sample compound is suspended in the vehicle (sample administration group) is orally administered to the rat, and the sample is administered for 1 hour. Later, mixed sugar solution loading (3.5 g / kg, po) was carried out. Blood collection from the test mice is performed immediately before drug administration (−60 min), immediately before glucose load (0 min), 30 minutes after glucose load (30 min), 60 minutes (60 min), and 120 minutes (120 min). It was. The blood glucose level at each time point was measured using Glucose CII-Test Wako (manufactured by Wako Pure Chemical Industries), AUC (0-120 min) in each administration group was calculated based on the measured value, and SAS 9.1. 3 (SAS Institute, Inc.) was used for Student's t-test.

result:
The blood glucose elevation inhibitory action of each specimen compound (AUC (0-120 min) ratio value of AUC (0-120 min) when the control group is 100 with respect to AUC (0-120 min) based on the -60 min value)) Shown in the table.
In this table, “**” and “***” have the following meanings.
**: P <0.01
***: P <0.001

Since the compound [I] of the present invention or a pharmacologically acceptable salt thereof has an agonistic action on the GPR119 receptor, various diseases or conditions that can be expected to be improved by regulating the receptor activity, such as obesity Metabolic diseases including diseases such as hyperglycemia, diabetes and its complications, metabolic syndrome, impaired glucose tolerance, hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and lipid metabolism disorders, or It is useful as a medicament for the prevention and treatment of cardiovascular diseases such as arteriosclerosis, hypertension, coronary disease, myocardial infarction.

Claims (23)

1. The following general formula [I]:
   

   

   [Where,
   E represents a group represented by the formula: —NH— or —O—;
   Ring A has the following formula:
   

   

   A substituted benzene ring, a substituted pyridine ring or a substituted piperidine ring represented by
   R ^01A and R ^01B are the same or different and are a hydrogen atom, a halogen atom, an alkyl group or a trihalogenoalkyl group,
   R ⁰² is A) an alkylthio group,
   B) an alkylsulfinyl group,
   C) an alkylsulfonyl group,
   D) a saturated or unsaturated nitrogen-containing 5-membered heterocyclic group which may be substituted with 1 to 2 groups selected from an alkyl group, an alkoxycarbonyl group, a hydroxyalkyl group, an amino group, an oxo group and a carbamoyl group ( Here, the heterocyclic group may contain an oxygen atom as a hetero atom other than a nitrogen atom),
   E) a group represented by the formula: —CONR ^a R ^b (where R ^a is a hydrogen atom or an alkyl group, R ^b is a) an alkyl group, b) a mono- or dihydroxyalkyl group, c) an alkoxy group, d) alkoxy An alkyl group substituted with a carbonyl group (the alkyl group portion may be further substituted with a hydroxyl group), e) a carboxyalkyl group, f) an alkylsulfonylalkyl group, g) an aminoalkyl group, h) a carbamoylalkyl group ( The alkyl portion of the group may be further substituted with an amino group), i) a morpholinoalkyl group, j) a 5- to 6-membered aliphatic sulfur-containing heterocyclic group (the heterocyclic group is a hydroxyl group, an oxo group, and Optionally substituted with 1 to 3 groups selected from hydroxyalkyl groups) or k) an alkyl group substituted with a hydroxyl group and a carbamoyl group), or F) the following formula (B-iii):
   

   

   Wherein G is a group represented by the formula: —C (═O) — or —CH ₂ —, and ring B further contains a heteroatom selected from a nitrogen atom, a sulfur atom and an oxygen atom. A 4- to 6-membered hetero ring, wherein R ^A1 and R ^A2 are the same or different and are a hydrogen atom or a halogen atom, R ^A3 and R ^A4 are the same or different and are a) a hydrogen atom, b) a halogen atom, c) Cyano group, d) hydroxyl group, e) oxo group, f) alkyl group, g) hydroxyalkyl group, h) alkoxyalkyl group, i) alkoxycarbonyl group, j) carboxyl group, k) 1-2 alkyl groups An optionally substituted amino group or l) a carbamoyl group optionally substituted by 1 to 2 alkyl groups),
   R ⁰³ is a hydrogen atom, an alkyl group or an alkoxy group,
   R ⁰⁴ represents a hydrogen atom, an alkyl group, an alkoxy group, an alkylsulfonyl group, a carbamoyl group (this group may be substituted with 1 or 2 groups selected from an alkyl group and a hydroxyalkyl group), or 1 to 4 A 5-membered aromatic heterocyclic group containing the nitrogen atom of
   R ⁰⁵ is an alkylsulfonyl group,
   Q is a single bond or an alkylene group,
   R ⁰ is (a) the following formula:
   

   

   (B) a group represented by the formula: R ⁰⁰¹ —N (R ^k ) — (where R ⁰⁰¹ is a 6-membered heteroaryl group or alkoxycarbonyl optionally substituted with an alkyl group) Group, R ^k represents a hydrogen atom or an alkyl group),
   R ¹ is a) an acyl group represented by R ¹¹ OCO— (where R ¹¹ represents an alkyl group which may be substituted with 1 to 3 halogen atoms), or b) a nitrogen atom, an oxygen atom and 5- to 6-membered heteroaryl group containing the same or different 1 to 4 heteroatoms selected from the group consisting of sulfur atoms (the heteroaryl group is substituted with 1 to 3 halogen atoms). Optionally substituted with 1 to 3 groups selected from an alkyl group, a cycloalkyl group and an alkoxy group),
   R ² is a halogen atom,
   R ³ represents a hydrogen atom, a hydroxyl group, a halogen atom or an alkyl group.
   (However,
   Ring A is a substituted benzene ring represented by the formula (Ai), Q is a single bond, R ⁰ is a group represented by the formula (R-iii), R ³ is a hydrogen atom, and (a) R ⁰² is a group represented by the formula (B-iii);
   G is a group represented by the formula: —C (═O) —, and R ^A1 , R ^A2 , R ^A3 and R ^A4 are all hydrogen atoms; or (b) R ⁰² is represented by the formula: —CONR or when ^{(c) R 02} is an alkylsulfonyl group; a group represented by ^a R ^b, and R ^b is an alkyl or monohydroxyalkyl group;
   (D) R ⁰² is an unsubstituted nitrogen-containing 5-membered heterocyclic group; or (e) R ⁰² is a group represented by the formula (B-iii), and G is a group represented by the formula: —C (═O) —. And when R ^A3 and / or R ^A4 is a hydroxyl group, the group R ^01A on the substituted benzene ring ( ^Ai ) represents an alkyl group). ]
   Or a pharmaceutically acceptable salt thereof.
2. Ring A is represented by the following formula (Aia):
   

   

   [Wherein the symbols have the same meaning as described above. ]
   The compound according to claim 1, which is a substituted benzene ring represented by the formula: or a pharmaceutically acceptable salt thereof.
3. Ring A is represented by the following formula:
   

   

   [Wherein the symbols have the same meaning as described above. ]
   The compound or a pharmaceutically acceptable salt thereof according to claim 1, which is a substituted pyridine ring represented by the formula:
4. Ring A is represented by the following formula (A-iii-a):
   

   

   [Wherein the symbols have the same meaning as described above. ]
   The compound or a pharmaceutically acceptable salt thereof according to claim 1, which is a substituted piperidine ring represented by the formula:
5. In general formula [I], ring A is represented by the following formula (Aib):
   

   

   [Wherein the symbols have the same meaning as described above. ]
   The compound according to claim 1, which is a substituted benzene ring represented by the formula: or a pharmaceutically acceptable salt thereof.
6. In general formula [I], ring A is represented by the following formula:
   

   

   [Wherein the symbols have the same meaning as described above. ]
   The compound or a pharmaceutically acceptable salt thereof according to claim 3, which is a substituted pyridine ring represented by the formula:
7. R ⁰² is a saturated or unsaturated nitrogen-containing 5-membered heterocyclic group which may be substituted with 1 to 2 groups selected from an alkyl group, an alkoxycarbonyl group, a hydroxyalkyl group, an amino group and a carbamoyl group (here And the heterocyclic group may contain an oxygen atom as a hetero atom other than a nitrogen atom) or a pharmacologically acceptable salt thereof.
8. R ⁰² is the following formula:
   

   

   [In the formula, R ^X represents a hydroxyalkyl group, an alkoxycarbonyl group or a carbamoyl group, R ^Y represents an alkyl group, R ^Z represents a hydroxyalkyl group, R ^W represents an amino group, and a dotted line represents the presence or absence of a bond.]
   The compound according to claim 7 or a pharmaceutically acceptable salt thereof.
9. R ⁰² represents formula (B-iii):
   

   

   [Wherein the symbols have the same meaning as described above. ]
   The compound according to claim 2 or a pharmaceutically acceptable salt thereof.
10. The group represented by the formula (B-iii) is represented by the following formula:
    

    

    [Where,
    R ^A20 represents a hydrogen atom or a halogen atom,
    R ^A30 is a hydrogen atom, a halogen atom or a hydroxyl group,
    R ^A40 represents a hydrogen atom, a halogen atom, a cyano group, an amino group, a hydroxyl group, a hydroxyalkyl group, an alkoxyalkyl group, a carboxyl group, an alkoxycarbonyl group, or a carbamoyl group (the amino moiety of the carbamoyl group is 1 to 2 alkyl groups). May be substituted),
    R ^A11 , R ^A21 , R ^A32 and R ^A42 are the same or different halogen atoms,
    R ^A33 is a hydrogen atom or a hydroxyl group,
    R ^A43 represents an alkyl group, a hydroxyalkyl group, an alkoxycarbonyl group or a carbamoyl group,
    Z is an oxygen atom or a sulfur atom,
    R ^A44 represents a hydrogen atom or a hydroxyalkyl group,
    R ^A35 and R ^A45 are the same or different halogen atoms,
    R ^A36 represents a hydrogen atom, an alkyl group or a hydroxyalkyl group (provided that when the above substituents R ^A20 , R ^A30 and R ^A40 are both hydrogen atoms, they are on the substituted benzene ring represented by the formula (Ai)). The group R ^01A is an alkyl group). ]
    The compound or a pharmaceutically acceptable salt thereof according to claim 9, wherein G is a group represented by the formula: —C (═O) — or —CH ₂ —.
11. 11. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein G is a group represented by the formula: —C (═O) —.
12. R ⁰² is a group represented by the formula: —CONR ^a R ^b , and R ^b is a 5- to 6-membered aliphatic sulfur-containing heterocyclic group (the 5- to 6-membered aliphatic sulfur-containing heterocyclic group is 3. The compound according to claim 2 or a pharmaceutically acceptable salt thereof, which may be substituted with 1 to 3 groups selected from the same or different groups selected from a hydroxyl group, an oxo group and a hydroxyalkyl group.
13. A substituted benzene ring in which ring A is represented by formula (Ai),
    R ^01A is a hydrogen atom or a halogen atom,
    R ^01B is a hydrogen atom or a halogen atom,
    R ⁰² is (a) an alkylsulfinyl group;
    (B) an alkylsulfonyl group;
    (C) a group represented by the formula: —CONR ^a R ^b , wherein R ^a is a hydrogen atom or an alkyl group, R ^b is an alkyl group, a monohydroxyalkyl group, a dihydroxyalkyl group, an aminoalkyl group, or a carbamoylalkyl group;
    (D) The following formula:
    

    

    R ^A20 is a hydrogen atom or a halogen atom, R ^A30 is a hydrogen atom, a hydroxyl group or a halogen atom, R ^A40 is a hydrogen atom, a halogen atom, a cyano group, a hydroxyalkyl group or a carbamoyl group, R ^A11 , R ^A21 , R ^A32 and R ^A42 are the same or different halogen atoms, and R ^A35 and R ^A45 are the same or different halogen atoms; or (e) 5-membered unsaturation containing 1 to 4 nitrogen atoms as heteroatoms A heterocyclic group,
    The compound according to claim 1, wherein R ² is a halogen atom, and R ³ is a hydrogen atom or an alkyl group (provided that R ^A20 , R ^A30 and R ^A40 are all hydrogen atoms and Q is a single bond) , R ⁰ is a group represented by the formula (R-vii)) or a pharmaceutically acceptable salt thereof.
14. Ring A is represented by the following formula (Aia):
    

    

    [Wherein the symbols have the same meaning as in claim 13. ]
    A substituted benzene ring represented by
    R ¹ contains a) an alkoxycarbonyl group, or b) 1 to 3 heteroatoms selected from a nitrogen atom and an oxygen atom, and is substituted with a halogen atom, an alkyl group, a trihalogenoalkyl group or a cycloalkyl group The compound or a pharmaceutically acceptable salt thereof according to claim 13, which is a 5- to 6-membered heteroaryl group.
15. Ring A contains a substituted benzene ring represented by the above formula (Aia), R ¹ contains 1) to 3 heteroatoms selected from a) an alkoxycarbonyl group or b) a nitrogen atom and an oxygen atom, and The compound or a pharmaceutically acceptable salt thereof according to claim 14, which is a 5- to 6-membered heteroaryl group substituted with a halogen atom, an alkyl group, a trihalogenoalkyl group or a cycloalkyl group.
16. Ring A is a substituted pyridine ring represented by the above formula (A-ii), R ⁰³ is an alkyl group, R ⁰⁴ is an alkylsulfonyl group, Q is an alkylene group, and R ⁰ is the following formula:
    

    

    The compound or a pharmaceutically acceptable salt thereof according to claim ¹ , wherein R ¹ is a nitrogen-containing 6-membered heteroaryl group substituted with a trihalogenoalkyl group.
17. The following general formula [I-AA]:
    

    

    [Where,
    R ^A is 2- (hydroxyC _1-4 alkyl) -1-pyrrolidinyl group, 2-cyano-1-pyrrolidinyl group, 2-carbamoyl-1-pyrrolidinyl group, 4-hydroxy-2- (hydroxyC _1-4 alkyl) ) -1-pyrrolidinyl group, 3-halogeno-1-pyrrolidinyl group, 1,1-dioxothiomorpholino group, N- (dihydroxy C _1-4 alkyl) amino group, N—C _1-4 alkyl-N— ( Dihydroxy C _1-4 alkyl) amino group, N- (amino C _1-4 alkyl) amino group or N—C _1-4 alkyl-N- (carbamoyl-C _1-4 alkyl) amino group,
    R ^01C is a halogen atom,
    R ^01D is a hydrogen atom or a halogen atom,
    R ¹⁰ represents a C _1-4 alkoxycarbonyl group, a 5-halogenopyrimidin-2-yl group, a 5-C _1-4 alkylpyrimidin-2-yl group, or 5- (trihalogeno C _1-4 alkyl) -1,2 , 4-oxadiazol-3-yl group,
    R ²⁰ represents a halogen atom, and R ³¹ represents a hydrogen atom or an alkyl group. ]
    Or a pharmaceutically acceptable salt thereof.
18. [4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl] ((R) -2-hydroxymethylpyrrolidin-1-yl) methanone;
    [4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl] (1,1-dioxo-1λ ⁶ -thiomorpholin-4-yl) methanone;
    [4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl] ((S) -2-cyanopyrrolidin-1-yl) methanone;
    [4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl] ((S) -2-carbamoylpyrrolidin-1-yl) methanone;
    3-Fluoro-4- [5-fluoro-7- [1- (5-propylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- N- [2-hydroxy-1- (hydroxymethyl) ethyl] benzamide;
    [4- [7- [1- (5-Isopropylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl] ((S) -2-carbamoylpyrrolidin-1-yl) methanone;
    [4- [7- [1- (5-Isopropylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl] ((R) -2-hydroxymethylpyrrolidin-1-yl) methanone;
    [4- [7- [1- (5-Isopropylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl] ((R) -2-carbamoylpyrrolidin-1-yl) methanone;
    [4- [7- [1- (5-Chloropyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl] ((S) -2-carbamoylpyrrolidin-1-yl) methanone;
    3-Fluoro-4- [5-fluoro-7- [1- (5-propylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- N- [2-hydroxy-1- (hydroxymethyl) ethyl] -N-methylbenzamide;
    3-Fluoro-4- [5-fluoro-7- [1- (5-propylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- N- (2,3-dihydroxypropyl) -N-methylbenzamide;
    3-Fluoro-4- [5-fluoro-7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- N- (2,3-dihydroxypropyl) -N-methylbenzamide;
    [4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-fluoro Phenyl] ((2R, 4R) -4-hydroxy-2-hydroxymethylpyrrolidin-1-yl) methanone;
    4- [4- [4-((R) -3-fluoropyrrolidine-1-carbonyl) -2-fluorophenylamino] -5-fluoropyrrolo [2,3-d] pyrimidin-7-yl] piperidine-1 -Carboxylic acid isopropyl ester;
    [4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -2,5 -Difluorophenyl] ((2R, 4R) -4-hydroxy-2-hydroxymethylpyrrolidin-1-yl) methanone;
    3-Fluoro-4- [5-fluoro-7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- N- (2-aminoethyl) benzamide;
    [4- [7- [1- (5-trifluoromethyl-1,2,4-oxadiazol-3-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d ] Pyrimidin-4-ylamino] -3-fluorophenyl] ((2R, 4R) -4-hydroxy-2-hydroxymethylpyrrolidin-1-yl) methanone;
    [4- [7- [1- (5-Ethylpyrimidin-2-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -3-chlorophenyl ] ((R) -2-hydroxymethylpyrrolidin-1-yl) methanone;
    3-Fluoro-4- [5-fluoro-7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- N-methyl-N-((R) -2,3-dihydroxy) propyl] benzamide;
    3-Fluoro-4- [5-fluoro-7- [1- (5-propylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- N-methyl-N-((S) -2,3-dihydroxy) propyl] benzamide;
    3-Fluoro-4- [5-fluoro-7- [1- (5-chloropyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- N-methyl-N-((S) -2,3-dihydroxy) propyl] benzamide;
    3-Fluoro-4- [5-fluoro-7- [1- (5-isopropylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino]- N-methyl-N-((S) -2,3-dihydroxy) propyl] benzamide;
    2,5-difluoro-4- [5-fluoro-7- [1- (5-ethylpyrimidin-2-yl) piperidin-4-yl] -7H-pyrrolo [2,3-d] pyrimidin-4-ylamino ] -N-methyl-N-((S) -2,3-dihydroxy) propyl] benzamide;
    [4- [7-cis- [1- (5-Ethylpyrimidin-2-yl) -3-methylpiperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidine-4- Ylamino] -3-fluorophenyl] ((S) -2-carbamoylpyrrolidin-1-yl) methanone; and 3-fluoro- [4- [7- [1- (5-trifluoromethyl-1,2,4] -Oxadiazol-3-yl) piperidin-4-yl] -5-fluoro-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino] -N- (carbamoylmethyl) -N-methylbenzamide A compound selected from the group or a pharmaceutically acceptable salt thereof.
19. A pharmaceutical composition comprising the compound according to any one of claims 1 to 18 or a pharmacologically acceptable salt thereof as an active ingredient.
20. 20. The pharmaceutical composition according to claim 19, which is a prophylactic / therapeutic agent for metabolic diseases or cardiovascular diseases which can be treated by activation of GPR119.
21. The metabolic disease is obesity, hyperglycemia, diabetes and / or complications thereof, metabolic syndrome, impaired glucose tolerance, hyperinsulinemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia or dyslipidemia 21. A pharmaceutical composition according to claim 20.
22. The pharmaceutical composition according to claim 20, wherein the cardiovascular disease is arteriosclerosis, hypertension, coronary disease or myocardial infarction.
23. A modulator of GPR119 activity comprising the compound according to any one of claims 1 to 18 or a pharmaceutically acceptable salt thereof as an active ingredient.